










Low-frequency Raman (LFR) spectroscopy was used to probe a variety of phar-
maceutical systems within a framework of different analysis scenarios, including
macro and bulk analysis, in-situ monitoring of solid-state transformations upon
exposure to different environmental conditions (for example, temperature and/or
relative humidity) and during the dissolution process, and spatial analysis of solid
dosage forms. Better LFR data interpretation was facilitated by the use of chemo-
metrics and complimentary analysis using other commonly used techniques such
as powder X-ray diffractometry (PXRD), differential scanning calorimetry (DSC),
thermogravimetric analysis (TGA), dynamic vapor sorption (DVS) as well as com-
putational simulations employing molecular quantum mechanics.
The first chapter gives an in-depth background on the solid-state forms, including
their structural, thermodynamic and kinetic descriptors. An overview on the LFR
theory, instrumentation and (chemometric) data analysis employed in this thesis is
also provided together with additional details related to the other aforementioned
utilized complimentary analytical techniques.
In the second chapter a series of pharmaceutically relevant entities with increas-
ing molecular complexity were investigated using variable temperature LFR spec-
troscopy and computational simulations. The combination of these experimental
and theoretical approaches allowed to elucidate the nature of various low-energy
vibrational modes, and, ultimately, establish a protocol for the preliminary com-
putational analysis of LFR spectral features of similar pharmaceuticals.
In the third chapter celecoxib (a popular anti-inflammatory agent) was used as
a model compound to investigate compression-induced destabilization in melt-
quenched amorphous drugs. Destabilization was assessed via the physical stabil-
ity and dissolution performance of these phases using LFR spectroscopy among
other complimentary techniques. Stability studies in the glassy and supercooled
states as well as surface dissolution measurements allowed for the identification
of the combined impact of preparation method and compression parameters on
these properties. Most notably, although a slower cooling rate during the melt-
quenching process gave an amorphous phase with a higher intrinsic physical stabil-
ity, it also promoted increased sensitivity to compression-induced destabilization.
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The fourth chapter further explored the compression-induced destabilization phe-
nomenon in melt-quenched amorphous solid dispersions. Three different poly-
mers (hydroxypropyl methylcellulose (HPMC), polyvinylpyrrolidone (PVP), and
polyvinylpyrrolidone/vinyl acetate (PVP/VA)) in the concentration range of 1-
10% w/w were used to formulate amorphous celecoxib systems with varied inter-
molecular interactions between the drug and polymer moieties. Dynamic LFR
and DSC measurements in the supercooled state revealed the differences in the
crystallization behavior. Polymer loading was found to significantly reduce the
sensitivity to compression-induced destabilization within these samples with min-
imal differences observed between different polymer types.
In the fifth chapter development of a new Raman subtechnique - spatially/micro-
spatially offset low-frequency Raman spectroscopy (SOLFRS/micro-SOLFRS) is
described with its main applications aimed toward the nondestructive spatial
analysis of solid dosage forms. The capabilities of this technique was tested us-
ing several model formulations comprised of celecoxib and several excipients of
crystalline and amorphous nature forming a variety of different (multi-layer/multi-
component) tablets. In all of the explored scenarios, the LFR spectral domain
was superior to more commonly used mid-frequency Raman (MFR) or fingerprint
region, where it enhanced or enabled the determination of different layer (i.e.,
coating) thicknesses as well as the spatial analysis of solid-state form transforma-
tions.
Lastly, the final chapter gives a brief overview of the main findings as well as
provides insight into potential future directions for the application of them in
relation to both research and industry based pharmaceutical settings.
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Clulow, S. Beilles, K. C. Gordon, B. Boyd; Application of Low-Frequency
Raman Scattering Spectroscopy to Probe in Situ Drug Solubilization in Milk
During Digestion. Journal of Physical Chemistry Letters 2019, 10 (9), 2258-
2263.
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Note: Parts of the discussion and images pertaining to the low-frequency Raman spectroscopy,
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man Spectroscopy for Pharmaceutical Applications. International Journal of Pharmaceutics
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This thesis explored the application of low-frequency Raman (LFR) spectroscopy (also called
low-wavenumber or THz Raman spectroscopy) for the analysis of a variety of pharmaceutical
systems, and included development of a new Raman sub technique - spatially/micro-spatially
offset low-frequency Raman spectroscopy (SOLFRS/micro-SOLFRS). These spectroscopic
techniques (complemented by variety of other typically used analytical methods) were uti-
lized to probe solid-state structural properties and extract both qualitative and quantitative
information. The obtained insight revealed intrinsic characteristics (for example, the temper-
ature dependence of low-energy vibrational modes) as well as solid-state form composition
and their transformations upon exposure to different environmental factors (for example,
temperature and relative humidity) or external physical stresses such as compression (includ-
ing their combined effect). The use of computational and multivariate data analysis tools are
also discussed in detail.
1.1 Solid-state forms
Active pharmaceutical ingredients (APIs) can exist in many different phases, including poly-
morphs (crystalline entities of the same compound with different arrangement and/or con-
formation of the molecules in the crystal lattice), solvates (crystalline forms where sol-
vent molecules are incorporated in the crystal structure, also known as pseudopolymorphs),
salts/co-crystals (multi-component solid forms composed of at least two ionic/neutral compo-
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CHAPTER 1. INTRODUCTION 2
nents) and amorphous phases that lack long-range molecular order and exhibit only certain
localized (short-range) structures, if any (Figure 1.1).1 Additionally, APIs can be specifically
formulated into mixed solid-state forms such as ionic cocrystals, where interactions of electro-
static nature are accompanied by hydrogen bonding, or (ternary) amorphous solid dispersions
in which molecular mixing between multiple chemical entities is achieved in the amorphous
state.1,2
Figure 1.1: Visual representation of the solid-state form landscape within
APIs (I, II, and III denote different types of conformational or packing
polymorphs, whereas A and B differentiate two solvate types, where sol-
vent molecules are either structurally incorporated or simply serve as void
fillers).
It is well known that these aforementioned phases can exhibit contrasting thermodynamic,
kinetic and mechanical properties that can affect the drug stability and dissolution perfor-
mance. Thus, in a pharmaceutical setting, it is important to ensure and control the use
of the correct solid-state form of API with desirable physicochemical properties. However,
it may not be a trivial task since solid-state forms can interchange under certain environ-
mental conditions (for example, temperature, pressure, relative humidity etc.) and external
physical stresses such as milling or compression.1,3,4 Under specific conditions, only a single
solid-state form can be considered as thermodynamically stable and is typically selected to
be used in the drug product. Nevertheless, there are many instances where the metastable
form is used due to kinetic considerations and/or superior characteristics such as chemical
stability, tabletability, solubility or even appearance or taste.5,6 This aspect also encourages
continuous discovery of new solid state forms and development of formulation strategies that
can not only provide valuable resources such as intellectual property, but also revitalize older
drugs as well as introduce completely new drug products.
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1.1.1 Thermodynamic stability of solid-state forms
As stated above, although an API can exist in number of different solid-state forms, only
a single crystalline configuration can be considered as thermodynamically stable at certain
conditions (i.e., the respective polymorph of anhydrous, solvated or multi-component sys-
tem).7–9 The rest of the phases can be divided into metastable and unstable forms, and their
relative stability can be defined by the free energy change (∆G, Equation 1.1), where ∆H
(enthalpy difference) is the lattice energy difference between two solid phases that originate
from distinct structural properties such as molecular conformation and/or intermolecular in-
teractions, whereas ∆S (entropy difference) results from different lattice vibrations and/or
structural disorder in the polymorphs. It is important to note that metastable phases can exist
outside their thermodynamic stability regions, where phase transition to the thermodynam-
ically stable form is typically slow or even inhibited.9 On the other hand, unstable systems
only correspond to an apparent equilibrium for a limited time followed by an irreversible
transition to a new unstable, metastable or thermodynamically stable state (Figure 1.2a).
∆G = ∆H − T∆S (1.1)
Figure 1.2b illustrates an energy-temperature diagram for a single crystalline phase at
isobaric conditions, where the enthalpy is depicted as increasing as the slope of the curve
represents the heat capacity (Cp) that is temperature-dependent.
10 Similarly, the entropy
term (TS) is also shown as increasing as governed by the Third law of thermodynamics. For
a two component system with theoretical polymorphs α and β of different thermodynamic
stability (i.e., one of the solid-state configurations is more stable at absolute zero) such
diagram would also reveal their transitions points, the existence of which below the melting
point of both polymorphs would elucidate their enantiotropic relationship. On the other hand,
if the free energy curves would converge above the melting point of each polymorph (i.e., form
a virtual transition point), α and β would represent a monotropic system. On a practical
level, each behavior governs the access to specific solid-state forms as certain pathways would
be thermodynamically prohibited. For example, it is impossible to obtain the metastable
crystalline phase from the thermal activation of the stable form, if both polymorphs share a
monotropic relationship.11 Additionally, the phase boundary point can be altered by other
factors such as the ratio of the actual to the saturation solvent vapor pressure (relative
humidity for water) that also governs the transitions between solvated/desolvated phases.12
In this thesis, a great deal of attention was given to investigating the stability of amor-
phous forms which have garnered an increased interest from the pharmaceutical industry as
well as research community in recent years.2 Such disordered phases are usually characterized
as thermodynamically unstable, but sometimes are also denoted as metastable, depending on
the relevant environmental conditions that ensure the existence of a certain energy barrier.13
The maximum stability is achieved when the storage temperature is equal or less than the
so-called Kauzmann temperature (Tk) at which the configurational entropy (Sc) is zero. This
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Figure 1.2: (a) Illustration of the definition of different states and (b)
energy-temperature diagram of a crystalline solid under isobaric condi-
tions. Adapted from Coquerel 8 and Lohani and Grant 9 with permission
from Wiley.
term is directly related to the molecular mobility that can be expressed as the reciprocal of
average molecular relaxation time (τ) from the Adam-Gibbs theory:13









where τ∞ is the average relaxation time at infinite temperature, s
∗
c/Sc is the critical size of
the cooperatively-rearranging subsystem, ∆µ is the potential energy barrier per molecule, k
is the Boltzmann constant and T is the temperature (K). From Equation 1.2, it is easy to
deduce that Tk denotes a point of zero molecular mobility (i.e., no molecular motions/static
dynamics). However, practically, it is almost impossible to exploit such conditions for the
storage of amorphous pharmaceutical products that are confined to ambient or refrigerated
temperatures. Here, the intrinsic glass transition temperature (Tg); a boundary point between
glassy and supercooled states that are dominated by local or global (cooperative) molecular
motions, respectively, becomes an important indicator for molecular mobility change, which
can contribute to the physical instability of the amorphous systems.14 For example, when
the temperature approaches the Tg region, τ typically starts to follow a non-Arrhenius tem-
perature dependence that may allow a large increase in molecular mobility with relatively
small rise in temperature in the region just above the Tg. The importance of secondary glass
transition temperature, so-called sub−Tg or Tgβ for the stability of amorphous materials has
also been highlighted, below which (certain) localized motions are believed to be strongly
inhibited contributing to an increased stability of the amorphous phases.15
These factors also affect the preparation of amorphous phases that can be achieved by
using different methods, the simplest of which is melt-quenching, where the melt of the
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Figure 1.3: Diagram illustrating the thermodynamic parameters as a func-
tion of temperature for an amorphous phase relative to its crystalline form.
Adapted from Zhou et al. 13 with permission from Wiley.
drug or drug mixture is quenched with a sufficient cooling-rate to avoid the formation of
an energetically favorable crystalline form (Figure 1.3).16 However, thermal degradation or
other considerations such as particle size etc. can prompt the use of other approaches, for
example freeze-drying, spray-drying, milling/cryomilling or desolvation.17,18 It is important
to note that the use of a specific preparation method and parameters will usually result
in procurement of an amorphous phase with specific properties that can also be altered by
changing the composition of the system (i.e., incorporating various excipients such as amino
acids,19 small organic acids,20 surfactants21 and, most notably, polymers22) encompassing
different intermolecular interactions. This strategy is often employed in order to reduce
the molecular mobility of the amorphous entities and enhance their physical stability and
ensure appropriate dissolution characteristics.23 Consequently, it can also help to reduce the
relaxation (aging or structural reordering) process that typically happens over time and is
directly governed by the molecular mobility.17
1.1.1.1 Nucleation and crystal growth
Nucleation and crystal growth is an important two-step process that encompasses self-assembly
of molecules and results in formation of the crystalline solid-state forms described previously.
Nucleation, specifically, is defined as the appearance of a small nuclei that can proceed into
a crystallization process if nucleation energy barrier(s) has/have been overcome.24 From a
classical nucleation theory, this process can be divided in multiple stages, which are visualized
in Figure 1.4.
The change in energy during a simple homogeneous nucleation process (∆Ghom) can be
expressed as the sum of the free energy due to the formation of new volume (∆GV ) and the
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Figure 1.4: Schematic diagram of the homogenous/heterogeneous nucle-
ation and growth process and the dependence of the Gibbs free energy
on the crystal size for classical nucleation theory. Below a critical radius
(r*), a reversible process occurs; for r>r* the process becomes irreversible.
Adapted from Thakore et al. 25 and Galwey and Laverty 24 with permission
from Wiley and Elsevier, respectively.
free energy which is required to create a new surface (∆GS):







where γ is the interfacial energy, ∆Hm is the enthalpy of fusion per unit volume, Tm is the
melting temperature and r is the radius of the nucleus. However, homogenous nucleation
occurs very rarely as nucleation typically proceeds in the vicinity of interfaces such as surface
impurities that grant a much smaller barrier toward the phase transition.25 More specifically,
the contact angle f(Θ) of heterogeneous nucleation promotes epitaxy between the nucleant
and the nucleus that significantly reduces the interfacial energy (γ) and, consequently, the
Gibbs energy change:




(2 + cosΘ)(1− cosΘ)2 < 1 (1.6)
Nevertheless, it is important to note that the so-called critical radius (r∗) for both types of
nucleation remains the same; this parameter defines a boundary point between reversible and





The initial stage I has been defined as formation of incipient nucleus - an activated
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nucleation site with enhanced probability of development that requires further change to
proceed. Stage II denotes the presence of a small and unstable germ nucleus characterized
by a slow growth until the conversion into growth nucleus (stage III). On a practical level, it
is difficult to obtain a direct experimental evidence for germ nucleus, whereas growth nucleus
can often be detected microscopically in suitable systems.24 Nevertheless, the use of typical
analytical methods for (bulk) characterization of solid-state forms (discussed in section 1.2)
usually disallow detection of nucleated phases within the solid-state matrix due to the limit of
detection. To address this, indirect approaches may be used by exposing the non-nucleated
and nucleated phases to specific conditions that would induce proceeding crystallization,
allowing for the characterization of the differences retrospectively.4
This aspect becomes especially important for pharmaceutically relevant amorphous phases,
where nucleation can be introduced by a number of unit operations used during the manu-
facture of drug products, and may falsely show no evidence of any potential danger due to
crystallization. Such processes include milling,26 compression4,27 and solvent granulation28
among others. Figure 1.5 highlights the temperature dependance of crystallization rate with
respect to the nucleation propensity in the amorphous state. It can be clearly seen that the
most intensive nucleation rate occurs near the Tg. This maximum is caused by the inter-
play of thermodynamic and kinetic factors, the last of which is correlated to aforementioned
changes in molecular mobility (i.e., viscosity/diffusion related processes) near this transition
point.29 The further increase in molecular mobility favors the occurrence of crystal growth,
governing the maximum overall crystallization rate to lie between the Tg and the melting
point (Tm).
Figure 1.5: Schematic depiction of the parameters controlling crystalliza-
tion from the amorphous state. Adapted from Hancock and Zografi 30 with
permission from Wiley.
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1.1.1.2 Qualitative and quantitative aspects of solid-state form transformations
Apart from thermodynamic considerations, the temporal dynamics or kinetics play a major
role in solid-state transformations that can be affected by number of different factors, includ-
ing geometrical shape of the particles and their size distribution, as well as their diffusion
characteristics in the solid-state.31 Thus, the use of standardized descriptors of solid-state
form transformations is important to enable complete characterization of the process that
can be compared between both similar and different chemical entities.
Solid-state reactions are unique in that concentration does not relate to reactivity as
they are typically initiated at the defects in the crystal lattice or crystal surfaces, edges,
or corners.31 Thus, the conversion degree, α (0 ≤ α ≤ 1) is used instead as a descriptor.




where k is the rate constant and f(α) is the differential reaction kinetic model or the rate
law. The integration of Equation 1.8 yields the integral reaction kinetic model g(α):32,33
g(α) = kt (1.9)
These expressions can be related to a range of kinetic models, the most common of which
are summarized in Table 1.1, and can be further categorized based on their underlying mech-
anism. These include, but are not limited to: (a) reaction order models, which are analogous
in their representation to homogenous kinetics as observed, for example, in solutions, and,
hence, are typically regarded as empirical in the solid-state; (b) nucleation models that are
related to dynamics described in the previous section and are usually separated in A and
P sub-models based on the relative rates of different nucleation stages; (c) diffusion models,
where the rate-limiting step is the diffusion of molecular entities into/away from the reac-
tion sites; and (d) geometrical contraction models, which define the rate-limiting step as the
spatial evolution of the product from the surface layer to the inner crystal domains.32–34
A complete quantification of the rate constant can be achieved by determining its tem-
perature dependence that is usually described via the Arrhenius equation:






where A is the Arrhenius pre-exponential factor, EA is the activation energy, and R is the
universal gas constant. The use of this fundamental expression for determining the kinetic
parameters can be divided into model fitting and model free methods, the first of which is
most commonly used for isothermal data35,36 and was also employed within this thesis. In
this approach, the kinetic model is determined/chosen from the best statistical fit and, ideally,
is supported by other complementary data. The corresponding EA values for isothermal data
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Table 1.1: Description of the most commonly used kinetic models (in-
cluding their differential f(α) and integral g(α) forms) for the analysis of
solid-state reactions.
Reaction model f(α) = (1/k)(dα/dt) g(α) = kt
n− th order (Fn) (n− 1)−1 − (1− α)1−n (1− α)n
Avrami-Erofeev (An) n(1− α) [−ln(1− α)](n−1)/n [−ln(1− α)]1/n
Power law (Pn) n(α)(n−1)/n α1/n
1D diffusion (D1) 1/2α α2
2D diffusion (D2) [−ln(1− α)]−1 (1− α)ln(1− α) + α








(1− α)−1/3 − 1
]−1
1− (2α/3)− (1− α)2/3
Contracting area (R2) 2(1− α)1/2 1− (1− α)1/2
Contracting volume (R3) 3(1− α)1/3 1− (1− α)1/3
are then determined from the Arrhenius plot. However, it is important to note that model-
fitting methods are designed to extract a single or averaged set of global Arrhenius parameters
for the whole process and, therefore, do not reflect changes in the mechanism and kinetics
with the temperature and the extent of conversion.35 These shortcomings can be addressed
with a use of more sophisticated and complex model free approaches. Nevertheless, since the
primary goal of the kinetic analysis described in Chapter 3 was only to extract secondary
kinetic parameters such as crystallization induction time (t0), the simplified approach of using
model-fitting methods was justified.
1.1.2 Molecular conformation, packing and intermolecular interactions
Arrangement of molecules in both crystalline and amorphous states can be characterized
by number of attributes that can govern their physicochemical properties and be used for
a comparison. However, they are much more easily accessible in crystalline systems via the
analysis of crystal structure,37 whereas similar analysis of disordered entities require use of
sophisticated experimental and theoretical approaches that often still provide only limited
information.38
Molecular conformation is, arguably, the easiest attribute to characterize and compare,
but also the least informative. A qualitative analysis of conformation can be carried out by
comparing any flexible dihedral or torsion angles that can also be visualized by overlaying
the conformers as shown in Figure 1.6a.39 The presented example also showcases the range of
conformers that can exist for different solid-state forms. Evidently, conformational flexibility
in multi-component systems can be affected by the presence of different components (in
this case, solvent molecules). Alternately, conformers can be compared quantitatively using
potential energy surface (PES) scans with respect to flexible torsion angles or by calculating
the respective energy differences.40 Such information, for example, can be used to rationalize
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the existence of certain polymorphs or adapted for their prediction.41
Figure 1.6: (a) Overlay of furosemide conformations presented in three
polymorphs of DMSO solvate (brown and orange - A and B conformers in
F(DMSO)-I, purple - conformer in F(DMSO)-II, burgundy - conformer in
F(DMSO)-III), and four polymorphs of DMF solvate (red and orange - A
and B conformers in F(DMF)-I, green - conformer in F(DMF)-II, magenta
- conformer in F(DMF)-III, dark and light blue - A and B conformers in
F(DMF)-IV); (b) visual representation of intermolecular interactions and
hydrogen bonding patterns in F(DMSO)-III. Adapted from Beloborodova
et al. 39 with permission from the American Chemical Society.
Differences in molecular conformation can further lead to formation of different inter-
molecular interactions in the solid-state that can range from weak dispersion (0.05-5 kJ
mol-1) and dipole-dipole (5-25 kJ mol-1) forces to relatively strong hydrogen-bonding (10-40
kJ mol-1) or even electrostatic (40-600 kJ mol-1) forces.42 The identification of such inter-
plays is conventionally used as a tool for characterization of crystal structures. A number
of software solutions are available that can help in visualization as well as the quantitative
analysis of interactions, for example, through the use of Hirshfeld surfaces43 that reflect the
electron density weighted boundary surface between the molecules in a crystal, and helps
to distinguish short and long (i.e., intramolecular and intermolecular) contacts. Hydrogen
bonding plays an important role in crystal structures and for characterization of (strong) hy-
drogen bonds, a graph set analysis is also often used. This method, as proposed by Margaret
C. Etter, categorizes hydrogen bonds in three intermolecular patterns: chains (C), rings (R),
and non-cyclic dimers and other finite hydrogen-bonded sets (D); and intramolecular or self-
associated hydrogen bonds (S).44 Additionally, the nomenclature can include subscript and
superscript denotations of the number of donors and acceptors, respectively, and the number
of involved atoms (in parenthesis) as shown in Figure 1.6b. This analysis is of particular
interest in crystal engineering, where presence of specific interactions can ensure desirable
physicochemical properties.45 The extent of these type of interactions can also affect the
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conformational flexibility of molecules in the amorphous state, and result in changes in their
respective molecular mobility. In fact, as stated above, engineering of specific drug-coformer
intermolecular interactions has recently emerged as a promising formulation strategy for de-
signing amorphous solid dispersions with improved physical stability.46
Lastly, packing reveals an extended representation of intermolecular interaction motifs
with respect to multiple or all molecules in the crystal structure. This attribute can be used
to compare coinciding patterns in the form of isolated units such as dimers (0D), rows (1D),
sheets (2D) or fully fledged frameworks (3D). Additionally, information about the contribu-
tions of different types of interactions can be extracted using specific software solutions, for
example, CrystalExplorer47 that was also employed for the analysis of crystalline compounds
explored in Chapter 2.
1.2 Experimental and theoretical characterization of solid-
state forms
1.2.1 Vibrational spectroscopy
Depending on the wavelength and intrinsic properties, light can interact with matter in a
number of different ways: it can be absorbed, transmitted, reflected, refracted, diffracted
or scattered. Vibrational spectroscopic techniques probe the vibrational energy levels or
vibrational modes that can reveal both chemical and structural information about the sample.
These methods, particularly infrared (IR) and Raman spectroscopy, have been increasingly
used for the analysis of pharmaceutically relevant entities,48 and were also exploited within
this work with predominant focus allocated to low-frequency Raman spectroscopy.
Intrinsically, IR spectroscopy is based on the measurement of changes to infrared radia-
tion absorption, whereas Raman spectroscopy is based on a photon scattering phenomenon
(Figure 1.7). Their complementary nature arises from the fact that both techniques probe
the same vibrational energy levels, but with different selection rules. For a strong IR transi-















From a practical standpoint, these factors determine the suitability of IR or Raman spec-
troscopy for the analysis of specific chemical systems. For example, IR spectroscopy is supe-
rior in probing hydroxyl (O-H) or carbonyl (C=O) related vibrational modes, whereas Raman
is better at detecting unsaturated alkyl chain motifs such as alkenes (C=C).52 Additionally,
while the aforementioned selection rules govern the vibrational intensities, the frequency or
wavenumber of the vibrational mode of a diatomic molecule can be approximated under the
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Figure 1.7: Energy-level diagram showing the states involved in Raman
and Rayleigh scattering as well as other possible interactions with light
related to rotational transitions, infrared (IR) and near-infrared (NIR)
absorption, and fluorescence. Reproduced from Bērziņš et al. 49 with per-
mission from Elsevier.
where ν̃j is the vibrational frequency, k is the force constant and µ is the reduced mass.
Nevertheless, the description of the vibrations of polyatomic molecules such as majority of
APIs becomes more complex as all the nuclei perform their own oscillations, and require
the use of different approximations/expressions, for example, superposition of a number of
“normal vibrations” that are independent of each other.53
1.2.1.1 Low-frequency Raman (LFR) spectroscopy
Inelastic or Raman scattering of light from a sample is a unique, low-probability phenomena,
which was first described by Raman and Krishnan in 1928.54 It occurs when the photon is
scattered with a lower or higher energy than the incident radiation source, corresponding to
Stokes and anti-Stokes Raman scattering, respectively (Figure 1.7). However, most of the
scattered light has no change in energy resulting in Rayleigh scattering (Figure 1.7).
This aspect, in particular, complicates the access to low-energy vibrations in the LFR
region as Rayleigh scattering needs to be filtered to avoid loss of information from otherwise
overlapping spectral profiles; due to its much higher intensity, Rayleigh scattering can over-
saturate the detector and/or suppress the Raman signals. Nevertheless, recent advancements
in narrow wavelength band filters such as volume Bragg gratings55 or iodine vapor filters56
as well as development of non-linear57 and filter-free time-domain58,59 Raman spectroscopic
techniques have made LFR measurements much more accessible and affordable. Further-
more, as this spectroscopic technique also shares many of the advantages with more com-
monly used mid-frequency Raman (MFR) spectroscopy (usually denoted from about 150-300
to 4000 cm-1) such as low-maintenance cost, flexible experimental setup, rapid measurement
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Figure 1.8: Research interest in LFR spectroscopy as measured by the
number of relevant research outputs (1965-2019) to chemical and pharma-
ceutical analysis. Presented data was gathered via SciFinder information
discovery tool, and manually examining the search results using three dif-
ferent keyword chains (low frequency Raman spectroscopy, low wavenum-
ber Raman spectroscopy and THz Raman spectroscopy). Reproduced from
Bērziņš et al. 49 with permission from Elsevier.
time and limited interference from water,60 it has experienced a great surge in popularity
as evidenced by its now broad application in many research fields, including pharmaceutical
analysis (Figure 1.8).61–63 The probed low-energy vibrational modes related to long-range or-
der (i.e., crystallinity) can grant access to qualitative62,64 and quantitative65–67 information
on solid-state forms (including intrinsic properties such as Tg of amorphous phases),
68,69 and
allow to monitor their (subtle) changes/transformations, even within solid dosage forms (for
example, tablets),70 or solubilization in complex dissolution media.71,72
This versatility primarily stems from the fact that LFR instrumental setup can be realized
in number of different ways by altering the laser irradiation geometry and using various
coupling options. Alongside in-house built setups,73 these include commercial probes74,75
and specialized modules for microscopes63,76 that can also allow for measurements to be
performed in both reflection and transmission mode.67,70 A typical dispersive LFR system
comprised of a laser source, amplified spontaneous emission (ASE) filters to clean up the laser
line, optics to focus on the sample, optics to collect the scattered light, volume Bragg gratings
(notch filters) to remove Rayleigh scattering, a spectrograph and charge coupled device (CCD)
as a highly sensitive photon detector has been illustrated in Figure 1.9. Furthermore, LFR
spectroscopy can be combined with other analytical methods to provide a unique insight into
chemical systems of interest.77
Interestingly, however, there has been no clear definition of LFR spectral range or the low-
frequency term in general as different wavenumber threshold values (from 150 to 400 cm-1)
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Figure 1.9: Visualization of a basic LFR experimental setup with a fiber-
optic coupling to the spectrograph allowing simultaneous access to Stokes
and anti-Stokes spectral regions. Adapted from Bērziņš et al. 49 with per-
mission from Elsevier.
have been used and suggested in the past. The associated challenge arises from the intrinsic
change in individual mode character for each chemical entity. In other words, the transi-
tion from inter- to mostly intramolecular motions (i.e., change in mixing between rotational,
translational and vibrational modes) can be observed in a broad wavenumber range.78,79
Figure 1.10 shows a typical representation of such motions using carbon dioxide as a simple
example that exhibits only one active Raman vibrational mode as the molecular vibrations
need to cause a change in polarizability of the molecule for them to manifest in the Ra-
man spectrum (see section 1.2.1). In the solid-state, translational motions also commonly
transition into collective torsion-type motions due to the presence of different intermolec-
ular interactions (see section 1.1.2), the complexity of which can govern their appearance
and mixing at different spectral ranges.77 These modes are unique in that they represent
the molecules breathing or rocking against each other (the bonds in the molecules do not
vibrate but the molecules move with respect to each other), so-called intermolecular modes
or phonon modes (Figure 1.10b). These are the Raman equivalent of the modes observed in
THz absorption spectroscopy that has also found utility in pharmaceutical analysis.80 For
the sake of simplicity, the LFR regime for pharmaceutical analysis has recently been pro-
posed to represent a spectral range from -300 to 300 cm-1, encompassing both anti-Stokes
and Stokes vibrations, as the majority of pharmaceutically relevant compounds are either
small organic/inorganic molecules or proteins.49
Figure 1.11 illustrates a number of key differences between low and mid-frequency Raman
spectra (alternatively denoted structural and chemical fingerprint regions, respectively) for




∂Ω ; a measure of probability of Raman scattering process) in the LFR
region are characterized by a much stronger signal response. One of the main reasons for
this phenomenon is that the Raman cross section for a vibrational mode j,
∂σj
∂Ω is strongly
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Figure 1.10: (a) Illustrative rotational, translational and vibrational mo-
tions of CO2, and (b) main phonon modes of its high-pressure (11.7 GPa;
room temperature) crystalline phase I based on the data by Sontising et.
al,81 where the molecules rock backwards and forwards with respect to
each other in an intermolecular fashion - however, no bond length or angle
changes occur. Reproduced from Bērziņš et al. 49 with permission from
Elsevier.


















where ν̃0 is the exciting or laser frequency and Sj represents Raman scattering activity.
82 The
Sj is related to the derivative terms of the mean polarizability (ᾱ
2
j ) as well as the anisotropy
(β2j ), and for a typical measurement of polarized Raman optical activity can be expressed








where gj is the degeneracy of the vibrational mode j. Nevertheless, it must be noted that
there are rare instances when solid-state forms of a particular API (for example, anhydrous
and hydrated forms of piroxicam) exhibit comparable Raman intensities between the LFR
and MFR spectral regions due to the intrinsic molecular properties.83
Another unique feature of the LFR spectral region is the comparable intensities between
the Stokes and anti-Stokes lines.85 The amplitude of these bands is governed by the population
of molecules in different vibrational states, which can be expressed as an energy difference
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Figure 1.11: Representative Raman spectra of (a) crystalline (form III)
and (b) amorphous celecoxib; full data and mid-frequency range (insets).
The laser line (Rayleigh scattering) is omitted for clarity. Adapted from
Bērziņš et al. 84 with permission from the American Chemical Society.









As the LFR region encompasses low-energy vibrations, the population ratio for these modes
remains closer to 1, whereas it greatly decreases for transitions observed at higher frequencies.
On a practical level, this can help to identify potential artifacts as Stokes and anti-Stokes
spectral features are essentially mirrored, and, thus, allows to distinguish any irregularities,
for example, cosmic spikes; high-intensity sharp features spanning 1-3 pixels that are gen-
erated upon collision of high energy particles with the CCD.86 Furthermore, intensities of
Stokes and anti-Stokes lines (i.e., their ratio) can be used to determine the ‘true‘ temperature
of the chemical entity (Equation 1.15).87 This phenomenon has been used for the development













Herein, IS and IaS represent the intensities of the respective Stokes and anti-Stokes bands
and ν̃j is the vibrational mode of interest.
Lastly, clear differences between the amorphous and crystalline LFR profiles can be ob-
served. While the mid-frequency domain (300-4000 cm-1) offers certain disparity in peak
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characteristics between both solid-state configurations for their identification and analysis,
the LFR region is far superior in this regard. In crystalline systems, the sharp phonon modes
(optic phonons) bear a unique signature of their structural properties, and are highly sensitive
to external factors (for example, temperature, pressure or relative humidity) that can also
promote internal processes such as phase transformations and/or composition changes.79,89
This set of conditions can also alter the LFR spectral features of disordered systems that are
less defined and are typically characterized by broad vibrational density of states (VDOS).
Although still debated, this type of signal response has been associated with the collective
motions of atoms within the intermediate range order, and is largely dominated by the so-
called Boson peak (excess in Debye density of states), but only at temperatures significantly
below the respective Tg.
90,91 In the vicinity of Tg, there is a significant contribution from
the quasi-elastic scattering that does not correspond to vibrational motions and can be in-
terpreted as an indicator for molecular mobility amongst other macroscopic properties.91,92
In the liquid state, identification of the Boson peak can only be achieved through specific
spectral pre-processing. Furthermore, such manipulations of spectra can also reveal other
VDOS components. For example, the reduced Raman intensity (Equation 1.16) can help to
observe very low-frequency scattering (<100 cm-1) related to anharmonic relaxational modes














Reduced Raman intensity can be further converted into Raman susceptibility (Equation 1.17)
that can reveal harmonic or quasi-harmonic vibrational spectrum, an explicit representation
of the structural organization of molecules (collective motions):
χ
′′
(ν̃j) = ν̃j(Ir(ν̃j)− Iq(ν̃j)) (1.17)
where Iq(ν̃j) is the intensity of the quasi-elastic scattering component that is usually deter-
mined by fitting procedures.94,95
1.2.1.2 Computational modeling of low-energy vibrational modes
With the continuous rapid advancement in computing power, computational chemistry meth-
ods have become more accessible. Many different tools have now been developed and are
readily available to assist with various theoretical simulations. Nonetheless, many of the
applications are non-trivial, including the modeling of LFR spectra.96 Computational meth-
ods for assigning bands in the low-frequency domain require more computationally heavy
approaches than the associated mid-frequency Raman counterpart. This is because the vi-
brations observed in the low-frequency region come about from both inter- and intramolecular
vibrations rather than the predominantly intramolecular vibrations observed in the higher
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frequency domain (see section 1.2.1.1). As such, calculations need to account for the pack-
ing of multiple molecules in a crystal lattice and the associated inter-molecular bonding
(see section 1.1.2) for LFR rather than a single molecule in vacuum as is often all that is
required for accurate mid-frequency Raman spectra simulations. This has been perfectly
illustrated by Yamamoto and his co-workers where the theoretical LFR spectrum of poly-
(R)-3-hydroxybutyrate with the explicit correction for the intermolecular interactions showed
superior accuracy to the one carried out in vacuo.97 Therefore, to correctly calculate LFR
spectrum for a crystalline material, information on their crystal structure is often required.
However, the quality of the available crystallographic data can significantly affect the accu-
racy of the predicted low-energy vibrational modes.98 There are also a myriad of methods
that can be chosen for simulations and further complicate the effectiveness of modeling the
LFR spectra.99 Fundamentally, the very shallow potential energy wells of such low-frequency
oscillators make it hard to calculate them with accuracy (Figure 1.12).
Figure 1.12: Illustration of potential energy wells of different harmonic and
anharmonic quantum oscillators.
Periodic density functional theory (DFT) is generally applied to perform this type of cal-
culation, and a number of different techniques and software solutions exist that mostly differ
on how electrostatic density is defined in relation to the basis set (a representation of the
electronic wave function). For instance, it may be described via localized basis sets such as
atomic-like/atomic-centered orbitals used in the DMol,100 SIESTA101 and FHI-aims,102 the
Gaussian wavefunctions exploited in CRYSTAL103 or plane-wave basis sets used in QUAN-
TUM ESPRESSO,104 CASTEP105 and VASP.106 Although all of the methodologies have
been successfully applied for LFR spectra simulations, CRYSTAL appears to be amongst the
most popular and widely used codes for this application,99,107–109 and was also used within
this thesis (Chapters 2 and 5). Furthermore, this software package allows for an easy utiliza-
tion of different long-range dispersion correction schemes to account for van der Waals forces
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that can often be underestimated during the energy minimization/lattice optimization step
and negatively affect the accuracy of the LFR spectra simulation.77 To address this, Grimme
three-body term parametrization (DFT-D3)110 was utilized, which currently is among the
most popular and widely used correction schemes for the type of analysis.49
Lastly, it must be noted that DFT calculations are typically performed at absolute zero
adapting the harmonic approximation to the lattice potential. While this approach is gener-
ally effective in predicting vibrational properties, the inclusion of anharmonic terms or the
use of more sophisticated quasi-harmonic approximation can improve the quality of the simu-
lation (especially the accuracy of the peak positions). For example, Raimbault et al. utilized
the FHI-aims package to predict and directly compare the harmonic and more resource-
intensive anharmonic LFR spectra of two generic drugs - aspirin and paracetamol. As antici-
pated, anharmonic approximation allowed for a more accurate characterization of low-energy
vibrations, but authors also emphasized that, realistically, due to associated much higher
computational cost, this approach currently may only be applied for very simple molecular
crystals,111 and, therefore, was not explored within this thesis.
1.2.2 Other analytical solid-state characterization techniques
Although LFR spectroscopy was primarily utilized for the studies described in this thesis,
several other analytical methods were also used that provided useful complimentary data,
and, hence, are briefly described here.
1.2.2.1 Powder X-ray diffractometry (PXRD)
PXRD is regarded as a “gold standard” in pharmaceutical analysis as it is fast, reliable and
versatile technique that allows for characterization of crystalline and amorphous solid-state
forms, where each phase produces a unique pattern based on the structure of its crystal lattice
(or lack thereof).7 Crystalline systems are characterized by the presence of sharp, individual
peaks, whereas disordered entities exhibit broad halo features, similar to those observed in
the LFR spectra. The diffraction phenomena itself results from a constructive interference,
if Bragg’s Law is satisfied:
nλ = 2dhklsinθhkl (1.18)
where λ is the wavelength of the radiation used, dhkl is the inter-planar spacing between
planes in the crystal lattice denoted via Miller indices (h,k,l), θhkl is the angle between the
incident X-ray beam and the relevant crystal planes (h,k,l), and n is an integer, referred to
as the order of diffraction, and is often unity.
Advanced uses of this technique in the field of pharmaceutics involve determination of
particle or grain sizes from the peak broadening in the diffraction patterns or characteristics
of Laue spots in the 2D-XRD patterns.112 Additionally, PXRD data can be used for powder
crystallography in order to determine the crystal structure of small molecules, if single crystals
of sufficient size/quality cannot be obtained.113
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1.2.2.2 Thermal methods
Thermal analysis methods, and especially differential scanning calorimetry (DSC) and ther-
mogravimetric analysis (TGA) are one of the most widely used methods within a typical
analysis framework of solid-state forms. In DSC, the instrument measures the heat flow
changes required to sustain identical temperature conditions between the sample and the
reference material. As the sample undergoes a thermal event, it is effectively changing the
total heat capacity of the system due to the latent heat associated with desolvation, melting
or crystallization. These events are then observed as peaks or, in the case of a Tg, a shift
in baseline. With the use of appropriate standards and calibration procedures, integration
of the area under the curve for specific thermal events can yield heats of fusion and heat
capacities for the respective processes (Figure 1.13).114
Figure 1.13: Illustration of the thermal transitions observed by DSC in
amorphous systems that retain their stability or undergo crystallization
and subsequent melting of the formed crystalline phase. Tc,onset and Tc,max
denote the onset and maximum temperature of the crystallization process,
respectively.
On the other hand, TGA allows us to monitor weight changes with temperature that can
be related to the intrinsic or sorbed solvent (water) content, and, thus, is frequently used
for characterization of solid-state forms (especially, solvates).114 Additionally, it can allow
one to further elucidate the nature of the thermal events observed by DSC. In fact, certain
commercial instruments are now available with combined capabilities of both DSC and TGA
that offer a simultaneous multimodal analysis of the samples.113
1.2.2.3 Dynamic vapor sorption (DVS)
DVS allows for the characterization of the material in relation to its interaction with solvent
at certain solvent vapor pressure (relative humidity for water). Intrinsically, this technique
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is based on the same principles as TGA with weight changes of the sample being monitored
over period of time, typically at isothermal conditions. Thus, it can help to characterize the
formation of solvated and desolvated phases as well as their transition point(s).113 Addition-
ally, for amorphous phases, the crystallization process at certain conditions can be revealed,
if it occurs with the weight loss of the respective solvent.115
1.3 Multivariate data analysis
Nowadays, many different approaches related to chemometrics can be utilized for the data
analysis ranging from more simplistic univariate and bivariate methods to more complex
multivariate solutions. While each of the aforementioned methodologies have certain advan-
tages for specific applications, multivariate methods, in particular, have received an increased
interest from the research community as highlighted by many recent studies that have also
emphasized the positive effect of the increased number of software solutions/tools now being
widely available for the purpose of qualitative and quantitative multivariate analysis.116,117
In general, these methods take advantage of all the available spectral information and probe
many variables, simultaneously, in order to understand the relationships that may exist be-
tween them. However, this aspect also governs the importance of appropriate collection and
treatment protocols of the data used for the chemometric analysis. In order to obtain phys-
ically meaningful results, a number of data quality attributes need to be considered such
as signal to noise ratio, presence of interfering or ambiguous signals (for example, various
baselines) and selected data range.118
1.3.1 Spectral pre-processing
Spectral pre-processing, arguably, is the most important step to ensure an optimal chemo-
metric analysis of the data.119 Herein, different pre-processing steps are discussed in detail,
including the practical aspects of their use.
1.3.1.1 Noise reduction and spectral feature subtraction
Smoothing (denoising) of the spectral data can be achieved using the well-known Norris-
Williams (NW) or Savitsky-Golay (SG) derivation or other custom algorithms,119,120 but
should always be secondary to enhancement of spectra using better data collection method-
ology or instrumentation. As these methods typically make use of a n-th order polynomial,
spectral information can be lost or altered, if inappropriately used. In an ideal scenario, the
effect of applied smoothing (or other pre-processing steps) needs to be carefully evaluated
by comparing the general trends and their potential deviations observed in the chemometric
analysis of the data.
In this context, real or artificial spectral feature subtraction and/or elimination is also
of high importance. Raman spectra, specifically, can be populated by previously described
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Figure 1.14: An example from Chapter 3 of spectral subtraction for a spec-
trum collected of transparent amorphous celecoxib tablet-shaped sample
positioned on a glass slide. The laser line (Rayleigh scattering) is omitted
for clarity.
cosmic spikes (see section 1.2.1.1). Additionally, there can be instances when collected Raman
spectra exhibit features from a known source (as shown in Figure 1.14) that can potentially
interfere with the analysis. For LFR data, these can also manifest as rotational sidebands of
atmospheric gases (mainly oxygen and nitrogen), if the analyte is a weaker Raman scatterer
and exhibits subpar signal intensity.121
1.3.1.2 Baseline correction
Baselines in data can manifest for multiple of reasons. For Raman spectra, for example,
fluorescence is a common source of interference, which occurs when the incident light has
enough energy to excite the molecule to the electronic state rather than a virtual intermediate
state of Raman scattering (Section 1.2.1; Figure 1.7). Although this is typically a lesser
problem for the LFR region due to intensity enhancement, signal can still be obscured at
times.71 However, baselines may not only be artificial, but also contain useful information,
for example, the aforementioned Boson peak in the LFR spectral range, characteristic of
amorphous systems. Thus, the initial processing method needs to be selected according to
the analytical end goal, where linear and rubberband baseline corrections are among the most
popular and widely used.122
A linear baseline is often considered as the simplest form of correction, which can be
approximated with the following expression:
ŷi = ayi + b (i ∈ Ω) (1.19)
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where a is a multiplicative constant, b is an additive baseline constant and Ω denotes the
selected wavenumber range for a Raman spectrum.123 For LFR data (especially for samples
with high disorder), this approach can be useful for correcting slight ambiguities without
losing valuable spectral information, if it is applied on the Stokes and anti-Stokes regions
simultaneously.124 Alternatively, besides the use of higher order polynomials, more complex
correction schemes can be utilized such as the aforementioned rubberband baseline correction
(a method that determines support points by finding the convex hull of each spectrum, which
are connected with linear or spline-like baselines125) or improved asymmetric least squares
method (IAsLS) that was specifically designed for the correction of baseline shifts in Raman
data.126
1.3.1.3 Scale and scatter correction
Multiplicative effects related to focusing and laser intensity fluctuations can also interfere
with the chemometric analysis and need to be accounted for through the means of data
normalization. Typically, standard normal variate (SNV) or multiplicative scatter correction
(MSC) methods are used,127 where the SNV procedure has been more widely applied to the
LFR data.61,65,67,84 In contrast to MSC, this method does not rely on a reference spectrum,





where xi,j is the experimental Raman intensity at ν̃j , x̄i is the mean Raman intensity, and Si
is the standard deviation of Raman intensities for spectrum i. It must be noted, however, that
for disordered crystalline and amorphous states, where relaxational motions also contribute
to the spectra, precaution with normalization should be taken according to the aim of the
analysis (for example, it should only be performed in the spectral range of phonon modes for
quantitative determination of such crystalline solid-state configurations).49
1.3.2 Principal component analysis (PCA)
PCA permits a reduction in the number of variables without the concomitant loss of informa-
tion. It is especially useful for the analysis of large datasets, where spectra can be simplified








xn1 · · · xnp
 (1.21)
D(n×p) = S(n×k) · LT(k×p) + E(n×p) (1.22)
where D is the initial dataset comprised of n samples and p variables, S is the scores matrix
of n samples by k parameters, LT is the transposed loadings matrix and E is the residuals
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matrix.128,129
The loadings matrix L(k×p) identifies the PCs along which data can be effectively projected
resulting into a reduced subspace or scores matrix S(n×k) that can be easily visualized via
2D or 3D scatter plots and allow for recognition of potential trends.116 Additionally, various
metadata can be utilized to enrich the analysis, and identify otherwise obscure tendencies.130
Nevertheless, improper selection of the number of components and/or presence of outliers
can severely compromise the PCA. Apart from the general scrutiny of the results, a proper
validation strategy needs to be employed to reduce this risk. Typically, this is achieved
through the use of external test set or cross-validation procedures.117 There are several cross-
validation methods that can be employed (for example, simple, double, segmented or full
cross-validation) that all share the basic concept of using different data sets for estimation and
validation of each PC model, but are differentiated on the basis of how these stages are divided
as well as on the “stopping rule”.131 Lastly, the actual algorithms such as singular value
decomposition (SVD) or non-linear iterative partial least squares (NIPALS) for obtaining
PCA and other chemometric models (see below) need to be also carefully evaluated.116
1.3.3 Partial least squares (PLS)
PLS can be used for both qualitative (classification) and quantitative analysis by using the
discriminant and regression analysis variations, respectively. It is an iterative procedure that
models relations between sets of observed variables by means of latent variables, and can be
expressed via the following generalized equation:132
y = D × b (1.23)
where y represent a specific property of interest and b denotes model coefficients.
Nowadays, linear PLS regression (PLSR) has become an especially popular tool for the
quantitative analysis of spectroscopic datasets, including ones collected using LFR spec-
troscopy. Number of studies have successfully built PLS models to quantify a specific com-
ponent by resolving a correlation between matrices of the LFR spectra and corresponding
concentration values.65–67,70,73,133 However, as with PCA, caution must be taken using the
otherwise empirical model by rationalizing the obtained model coefficients (effectively, the
loadings) and performing its thorough validation (ideally via independent test set), including






(ŷi − yi)2 (1.24)
where n denotes the number of samples in the data set, ŷi is the prediction of property y for
sample i and yi is the respective reference value.
132
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1.3.4 Multivariate curve resolution (MCR)
MCR can resolve initial data into pure constituent profiles and pure spectra by mathemati-
cally decomposing mixtures of signals into individual components resembling true chemical
entities, and follows similar bilinear additive model to PCA:134
D(n×p) = C(n×k) · ST(k×p) + E(n×p) (1.25)
where C is the concentration matrix of k components and ST is the transposed matrix of
their spectra.
However, the analysis towards a rational solution typically requires estimation of the num-
ber of involved components with initial guesses of their spectra or concentration profiles. For
iterative MCR methods such as MCR-alternating least squares (MCR-ALS), the determined
estimates are then used to start constrained optimization through iterative cycles. If spec-
tra are used as an input, the conjugated peak profile contributions can be calculated using
Equation 1.26 and subsequently, ST is then updated by using the Equation 1.27:
C = D · (ST )+ (1.26)
ST = (C)+ ·D (1.27)
where (ST )+ and (C)+ are the generalized inverses (pseudo-inverses) of ST and C, respec-
tively. Analogously, if peak profiles are used as an input, iterations start with the calculations
of the conjugated spectra. The ambiguities can be further resolved by using various con-
straints at every iteration, including non-negativity, unimodality and trilinearity (for three-
way data sets).134,135 Additionally, more advanced constraints such as kinetic constraints
with implied closure (mass balance) can be used with the application of so-called hybrid
hard- and soft MCR-ALS (HS-MCR-ALS), where each iteration are passed to a non-linear
kinetic fitting routine that constrains these profiles to obey a preselected kinetic model.136
1.4 Thesis aims
The primary aim of this thesis was to explore and advance the applications of LFR spec-
troscopy for the analysis of different pharmaceutical systems. As such, this thesis is comprised
of diverse set of projects, to each of which detailed introduction is given at the beginning of
the respective chapter. The specific projects included exploration of strategies for modeling
and assignment of low-energy vibrational modes of pharmaceutical crystals (Chapter 2), in-
vestigation of processing-induced destabilization in amorphous drugs and their formulations
(Chapters 3 and 4) as well as development of a completely new LFR spectroscopic subtech-
nique (Chapter 5). Each of the individual studies were also designed to intertwine certain
aspects between them to fully showcase the modern capabilities of LFR spectroscopy.
More specifically, Chapter 2 was aimed towards investigating rational pathways for LFR
CHAPTER 1. INTRODUCTION 26
spectra prediction and interpretation by combining theoretical density functional theory
(DFT) calculations and experimental variable-temperature data analysis for a set of model
compounds - a range of typically handled pharmaceuticals with increasing molecular com-
plexity. One of the main drugs explored in Chapter 2 (celecoxib; a popular non-steroidal
anti-inflammatory agent) was further used as a model compound in Chapter 3 that aimed to
elucidate the negative effect of compression-induced destabilization in the amorphous state via
LFR spectroscopic analysis of differently processed samples (uncompressed and compressed
samples with varied pressure and dwell time) exposed to different sets of conditions (tem-
perature and/or relative humidity) as well as in-situ monitoring during dissolution testing.
Chapter 4 further characterized this phenomena by exploring viable strategies to mitigate
compression-induced destabilization in multi-component amorphous formulations. Chapter 5
was focused on developing spatially/micro-spatially offset low-frequency Raman spectroscopy
(SOLFRS/micro-SOLFRS) to allow for a nondestructive spatial analysis of solid dosage forms.
Chapter 2
Theoretical and Experimental
Aspects of Low-Energy Vibrational
Mode Modeling and Assignment for
Pharmaceutical Crystals
Note: Parts of this thesis chapter have been published by the author in the following article:
K. Bērziņš, J.J. Sutton, S. J. Fraser-Miller, T. Rades, T. M. Korter, K. C. Gordon; Solving
the Computational Puzzle: Toward a Pragmatic Pathway for Modeling Low-Energy Vibra-
tional Modes of Pharmaceutical Crystals. Crystal Growth and Design 2020, 20(10), 6947-
6955.
The author would like to personally thank and acknowledge the contributions of Dr. Joshua
Sutton, who assembled the downward looking LFR experimental setup and Prof. Timothy
Korter, who helped to formulate the study, lent his expertise and carried out all the theoretical
simulations of vibrational modes for molecular crystals described within this chapter.
2.1 Introduction
A full characterization of low-energy vibrational modes is an important step for complete
LFR spectroscopic analysis of any analyte. However, there is an overall lack of information
related to the origin of LFR spectral features of many pharmaceuticals due the intrinsic
simulation complexity imposed by the nature of the phonon modes.61 The task is further
complicated by the fact that a large number of different theoretical solutions are readily
available that can prove the selection difficult and, thus, reduce the effectiveness of modeling
the low-wavenumber spectra. Ideally, the applied computational technique needs to inherit
a balance in providing sufficient simulation quality with the use of minimal computational
27
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resources.
This thesis chapter focused on exploring prudent approaches and devising a set of potential
guidelines to help researchers with particular analyses. For this purpose, five pharmaceuti-
cally relevant compounds with increasing molecular complexity were selected. Benzoic acid is
widely used as an antimicrobial preservative and antifungal agent.137 This simple, aromatic
carboxylic acid is also often selected as a coformer for preparation of cocrystals.1,138 Sim-
ilarly, diphenylacetic acid has been utilized for assembly of binary molecular crystals with
altered physicochemical properties.139 L-tyrosine, a non-essential amino acid has been com-
monly used as a dietary supplement and an important precursor for production of a number
of high-value compounds.140 Recently, its potential application as a co-former in amorphous
formulations has also been explored.19 Celecoxib and carvedilol are primarily used to treat
pain/inflammation caused by numerous conditions (most notably, arthritis) and hypertension
(a cardiovascular disease), respectively. These drugs have also been widely used as model
compounds in variety of different studies, and both exhibit relatively complex solid-state form
landscapes.141,142 At least four different anhydrous forms have been reported for celecoxib (I,
II, III and IV), where form III is considered to be the thermodynamically stable crystalline
configuration under ambient conditions (room temperature/atmospheric pressure).143 On the
other hand, carvedilol exhibits conformational polymorphism with at least three recognized
non-solvated forms (I, II and III) and a hemihydrate.141 It is worth noting that some studies
have reported the existence of other solid-state forms, including several solvates.144 For these
two systems, only their commercial polymorphs were investigated in detail (form III and II,
respectively) to avoid the co-occurrence of potential phase transformations while probing the
LFR spectral dynamics (especially at higher temperatures).
Herein, fully periodic density functional theory (DFT) simulations were complemented
by experimental LFR spectra collected over a broad temperature range (typically, from -
190 °C to ∼20-30 °C below the melting point of the particular solid-state form). Successful
validation of the computational results provided assurance in the used theoretical model and
parametrization (i.e., convergence criteria, k-point sampling, differentiation scheme etc.), and




Benzoic acid (MW = 122.12 g/mol), diphenylacetic acid (MW = 212.24 g/mol), L-tyrosine
(MW = 181.19 g/mol), celecoxib (MW = 381.37 g/mol; form III), and carvedilol (MW =
406.47 g/mol; form II) were purchased from BDH, Ltd. (Poole, UK), Sigma-Aldrich (St.
Louis, MI, USA), Sigma-Aldrich (St. Louis, MI, USA), AK Scientific, Inc. Union City, CA,
USA), and Cipla Ltd. (Mumbai, India), respectively.
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Figure 2.1: Molecular structures of the compounds used in this study: ben-
zoic acid, diphenylacetic acid, L-tyrosine, celecoxib, and carvedilol. Repro-
duced from Bērziņš et al. 77 with permission from the American Chemical
Society.
2.2.2 Variable temperature low-frequency Raman (VTLFR) spectroscopy
Raman spectra were collected using a home-built setup with an excitation source from a 785
nm laser module (Ondax Inc., Monrovia, CA, USA), which was filtered by BragGrate band-
pass filters (OptiGrate Corp., Oviedo, FL, USA) to remove amplified spontaneous emission
from the laser. A THMS600 variable temperature stage with LNP95 liquid nitrogen cooler
(Linkam Scientific Instruments Ltd., UK) was used to mount the sample (horizontally), which
was put inside a quartz sample holder. The temperature program for each specimen consisted
of two distinct steps. Initially, each sample was rapidly cooled to -190 °C and then gradually
heated to ∼20-30 °C below the melting and/or decomposition temperature with 10 °C incre-
ments. At each point, the temperature was allowed to stabilize for at least 2-3 min before the
Raman measurements, ensuring sufficient time to reach thermal equilibrium. Backscattered
light was collected and filtered through a set of volume Bragg gratings (Ondax Inc., Mon-
rovia, CA, USA) and focused into an LS 785 spectrograph (Princeton Instruments, Trenton,
NJ, USA) via a fiber-optic cable. The light was dispersed onto a CCD detector (PIXIS 100
BR CCD, Princeton Instruments, Trenton, NJ, USA), and the data were calibrated using
standards of sulfur, 1,4-bis(2-methylstyryl) benzene (BMB), and a toluene and acetonitrile
solvent (1:1) mixture. Spectra were collected over the spectral window -360 to 2030 cm-1 with
5-7 cm-1 resolution. Each spectrum was averaged from 60 scans with an integration time of
1 s, and the sample spot size was approximately 500 µm.
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2.2.3 Band analysis
The spectral range from 15 to 300 cm-1 was used for the band analysis, and fitted peak
positions were determined using the peak find function (default settings) in the SpectraGryph
1.2.14. software. This function measures the peak position by first finding the locally highest
pixel and fitting the nearby data range with a third order polynomial function. The absolute
peak position is obtained by calculating the polynomial’s analytical maximum.
2.2.4 PCA details
The spectra were converted from .spe to .spc file format using SpectraGryph 1.2.14 and PCA
was performed using The Unscrambler X 10.4 (CAMO, Oslo, Norway) software package.
Data analysis for low and mid frequency regions was carried out separately using the following
spectral ranges: 15-300 and 300-1800 cm-1, respectively.
2.2.5 Computational details
Theoretical solid-state density functional theory (DFT) calculations were performed using
the fully periodic CRYSTAL17103 software package to model low-energy vibrational modes.
The crystallographic data for all the studied solids are summarized in Table A.1 (Appendix
A).145–149 Normally, a generalized gradient approximation Perdew-Burke-Ernzerhof (PBE)150
functional with van der Waals interactions treated according to the Grimme D3110 method
was used, and all of the atoms were described with the Ahlrichs’ TZVP151 basis set. For
L-tyrosine, additional calculations were performed using a combination of PBE0152 hybrid
functional and the recently developed POB-rev2153 basis set. The crystal structures were fully
optimized with no implied restrictions on atom positions or lattice parameters. For carvedilol
form II, additional geometry optimization with implied restrictions on lattice parameters was
done, as an initially performed full relaxation caused ambiguities for the vibrational analysis
from the poor structural convergence. The dielectric tensor and Raman intensities were cal-
culated analytically using the coupled-perturbed Hartree-Fock/Kohn-Sham (CPHF/CPKS)
approach154 and the Anderson convergence accelerator.155 Energy convergence criteria was
set to ∆E ≤ 10−8 and 10−10 Hartree for the geometry optimization and vibrational calcula-
tions, respectively. Representative CRYSTAL input files for both geometry optimization and
frequency calculations are also available in the supporting information of the published ma-
terial. The calculated vibrational modes were visualized using the MOLDRAW 2.0 (version
H1) software.156 Intermolecular interaction energies and the resulting energy frameworks for
the studied compounds were calculated using CrystalExplorer 17.547 at the DFT/B3LYP/6-
31G(d,p) levels of theory.
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2.3 Results and discussion
2.3.1 Exploratory structural analysis
As stated previously, compounds for this study were selected with increasing molecular com-
plexity to represent a typical range of handled pharmaceuticals. Apart from the clear chem-
ical differences, all of the studied solids also exhibited varied hydrogen-bonding patterns,
which are visualized in Figure 2.2. For example, both carboxylic acids encompass very sim-
ple, head-to-tail dimers formed between the carboxyl groups with a R22(8) graph set. On
the other hand, L-tyrosine displays an intricate, three-dimensional hydrogen bond network,
where each of the entities is hydrogen bonded to six neighboring molecules. Besides the gen-
eral zwitterionic nature of the amino acids, these elaborate intermolecular interactions also
contribute to the exceptional physical stability of the L-tyrosine.157 Form III of celecoxib
has two distinct packing motifs: a head-to-tail dimer comprised of NH···N hydrogen bonds
between the sulfonamide and pyrazole moieties as well as sulfonamide chains, which propa-
gate along the crystallographic c-axis. Lastly, carvedilol form II shows two distinct patterns
involving NH···O and OH···N hydrogen bonds with interactions formed between alkyl aryl
ether and carbazole moieties, and hydroxyl and amino groups, respectively. For an additional
visual reference, energy frameworks based on a series of pairwise energy calculations are also
presented in the Appendix A (Figures A.1-A.5) to further showcase the relative magnitude
and topology of all of the described hydrogen-bonded networks.
Evidently, these intermolecular interactions were a contributing factor to the complexity of
the vibrational dynamics observed in the LFR experimental data. For each of the investigated
compounds, PCA was employed to more easily distinguish temperature-induced changes,
including ones in the mid-frequency region for completeness. In order to assign and analyze
LFR spectral features, the vibrational frequencies and corresponding Raman activities were
simulated using the CRYSTAL17 software. Initial calculations were carried out using the
same exact set of computational parameters and at a level that is routinely used for the type
of analysis. This resulted in large disparities of the required time/computational resources for
simulations to be completed with the following order of calculation intricacy: benzoic acid <
L-tyrosine < celecoxib form III < diphenylacetic acid  carvedilol form II. These differences
at least partially originate from the number of atoms in the asymmetric unit (see Table A.1)
as, in order to generate frequencies, triaxial displacements for each of the irreducible atoms
need to be calculated that ultimately prolong the simulations for larger molecules. In light
of this, L-tyrosine was selected to explore additional routes for the theoretical calculations to
evaluate the effect and rationale for using specific computational parameters.
2.3.2 Benzoic acid
The experimental and DFT-simulated LFR spectra of this carboxylic acid are presented
in Figure 2.3. As anticipated, this chemically simple compound exhibits only a few, well-
defined spectral features, making individual mode-assignments possible. While there was a
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Figure 2.2: Hydrogen bonding patterns in benzoic acid, diphenylacetic
acid, L-tyrosine, celecoxib (form III), and carvedilol (form II). Reproduced
from Bērziņš et al. 77 with permission from the American Chemical Society.
good agreement between the experimental and theoretical data, it is important to note that
our DFT-simulation had an even better match with previously published results of benzoic
acid single crystal Raman spectra recorded near absolute zero.158 This is not surprising as full
relaxation of atoms and lattice was carried out in the geometry optimization step, which better
represents a potential structure at 0 K temperature. The reference data158 were also used to
cross-check and validate the vibrational mode assignments in the studied temperature range
(full information available in the Appendix A; Table A.2). Interestingly, spectral features
at 116 and 195 cm-1 (-190 °C) demonstrated some anomalies in relation to Bose-Einstein
statistics of phonons. These bands became weaker with increasing temperature. Additionally,
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apart from intensity-based discrepancies, all of the peaks were redshifted when the sample
was gradually heated to 90 °C that is typically a consequence of increased bond lengths
and/or increased lattice strain. These spectral deviations ranged from ∼2 to 8 cm-1 and were
further highlighted by the PCA. Only two principal components (PCs) were necessary to fully
describe the dataset with PC1 accounting for most of the explained variance (97%). The PC1
versus PC2 scores plot revealed progressive, temperature-dependent separation (Figure A.6a)
with PC1 loadings (Figure A.6b) highlighting the global spectral differences at low and high
temperatures, represented in the negative and positive PC space, respectively. Furthermore,
PCA proved to be a very useful tool for discerning changes in the mid-frequency region,
which were less clear by eye (Figure A.7). Here, similar scores plots were obtained with the
respective loadings indicating some notable peak shifts (Figure A.8a). PC2 also revealed
some broadening for the peaks at 792, 1287, 1312 and 1600 cm-1 (Figure A.8b), which is
typically a consequence of mode anharmonicity.159
Figure 2.3: Experimental and DFT-simulated LFR spectra of benzoic acid.
Reproduced from Bērziņš et al. 77 with permission from the American
Chemical Society.
Further analysis of the LFR spectra revealed that all of the individual peaks had a non-
linear temperature dependence, which was in agreement with previously published results.160
Such phenomena can be described by the following semi-quantitative model:161
















where C andD are constants that include a volume expansion-induced contribution (Grüneisen
parameter)162 and the coefficient of thermal expansion; ν̃0 is the Raman shift at absolute
zero. The x and y correspond to h̄ω0/2kT and h̄ω0/3kT , respectively, where h̄ is the reduced
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Planck’s constant, k is the Boltzmann constant and ω0 is the fundamental angular frequency
of the Raman oscillator at absolute zero. The optimal ν̃0, C and D values were calculated
using a multi-parameter least-squares optimization with MS Excel 2016 Solver (Microsoft
Corp., Redmond, WA) software. The existence of a global optimization minimum was vali-
dated by varying input values over multiple calculations, and the results of this analysis are
presented in Figure A.9. Overall, all of the peaks exhibited similar behavior, which was well
described by the model. The highest intensity peak at ∼66 cm-1 (90 °C) varied the most
when compared to the other lattice modes. It has been previously associated with stretching
vibrations of O-H···O hydrogen bonds, and, in reality, consists of two, energetically close
bands related to R- and L-tautomeric forms of benzoic acid.158 The origin of the two appar-
ent breaks (between -110 and -100 °C, and 70 and 80 °C) in the temperature-wavenumber
continuum for the lowest energy band is not entirely clear. At the very least, they are related
to some intrinsic changes as visual inspection of the spectra revealed subtle shape/width
transformations of the particular peak at these temperatures.
2.3.3 Diphenylacetic acid
Similar to benzoic acid, this carboxylic compound displayed only a few, well-defined low-
energy vibrational bands in the studied temperature range (Figure 2.4), which were redshifted
with increasing temperature. Although there was a good match between the experimental
and theoretical results, the actual band assignment was more challenging as DFT-simulation
revealed an increased number of vibrational transitions (Table A.3), especially in the range of
70 to 100 cm-1. At this time, it is presumed that all of the particular modes are contributing
to the bulk of the experimentally observed spectral feature at 63-68.5 cm-1. Once again, PCA
allowed us to distinguish temperature-related differences in more detail. Both low- and mid-
frequency Raman PC scores plots (Figures A.10 and A.12) showed gradual separation of the
experimental data with exception of the spectra procured at 70 and 80 °C. It is important
to note that individual peak analysis (discussed below) revealed no anomalies related to
the spectra obtained at these temperatures. For the LFR region, PC1 (92%) separated the
bulk spectral shifts at low and high temperatures, depicted in the negative and positive PC
space, respectively. On the other hand, PC2 (8%) primarily distinguished intensity-based
differences, where some of the peaks were resolved with their average wavenumber position.
Similarly, mid-frequency PCA unveiled variation of spectral changes, some of which were
almost impossible to detect visually (for example, broadening of peak at 1032 cm-1; PC1
loadings plot, Figure A.12b).
The individual peak analysis of diphenylacetic acid is presented in Figure A.13, where the
same, non-linear temperature dependence can be observed, and similarly modeled. Interest-
ingly, the temperature-wavenumber continuum for the lowest energy vibrational mode was
once again interrupted at two temperatures. Furthermore, the optimized C and D values
were almost identical to the ones obtained for the equivalent mode of benzoic acid, which
was also associated with translational motions based on the DFT-simulations. While it is
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Figure 2.4: Experimental and DFT-simulated LFR spectra of dipheny-
lacetic acid. Reproduced from Bērziņš et al. 77 with permission from the
American Chemical Society.
plausible that this spectral feature/behavior is intrinsic to such simple aromatic carboxylic
acids, validation would require more specific research outside the scope of this study. Sim-
ilar to benzoic acid, the highest intensity peak (95 cm-1; -190 °C) was the most sensitive
to temperature and, based on the DFT calculations, embodies complex torsion vibrations,
including moderate stretching of O-H···O hydrogen bonds. It is important to note that the
peak at 129.5 cm-1 (-190 °C), which exhibited the second largest variation with the change
in temperature, was also revealed to encompass similar vibrational motions.
2.3.4 L-tyrosine
This amino acid showed the most complex spectral dynamics amongst all of the studied
compounds, partially due to a much broader experimental temperature range. Here, the
collected LFR data proved to be especially useful as few of the DFT-simulated bands (for
example, at 179 and 198.5 cm-1) only became discernible at low temperatures (Figure 2.5).
The overall intricacy of the LFR changes were also reflected by the PCA, where four PCs were
required to fully describe the resolved spectral variance (Figure A.14). PC1 (77%) displayed
main peak wavenumber changes, where redshifted features (at elevated temperatures) were
generally depicted in the negative PC space. Interestingly, based on the generated PC1 versus
PC2 scores plot (Figure A.14a), larger fluctuations for the majority of LFR signals only began
at ∼-150 °C. Later PCs appeared to resolve multimodal information, including appearance
of new peaks and intensity-based differences. For example, PC2 (20%) at least partially
accounted for the magnitude disparities of some of the Raman cross-sections, particularly in
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the range of 80-170 cm-1. On the other hand, PC3 (2%) discriminated the unique spectral
features of L-tyrosine at cold environment that were highlighted in the negative loadings plot
(Figure A.14d). As anticipated, the mid-frequency Raman region also exhibited significant
spectral changes upon the incremental heating of the amino acid, which mostly resulted
in shifting and severe broadening of the peaks (Figure A.15). Furthermore, there was an
inherent baseline curvature for the data recorded below 0 °C. This feature was resolved by
PC1 (99%) alongside the previously mentioned discrepancies related to peak characteristics
(Figure A.16).
Figure 2.5: Experimental and DFT-simulated LFR spectra of L-tyrosine.
Reproduced from Bērziņš et al. 77 with permission from the American
Chemical Society.
The results from the intrinsic peak shift analysis are shown in Figure A.17. Santos et al.
previously characterized the individual low-frequency spectral changes of L-tyrosine between
298 K and 453 K using a simplified linear model:163
ν̃(T ) = ν̃0 + αT (2.2)
where α is the first-order temperature coefficient and ν̃0 is the extrapolated peak position
at absolute zero. Therefore, extracted data were fitted with both, linear and non-linear
theoretical models to enable a direct comparison with the literature. Although the obtained
α values were largely similar, the linear model was found to be inadequate to thoroughly
describe the spectral changes, and could only be potentially used for specific vibrational modes
in a limited temperature range. On the other hand, the employed non-linear approximation
provided a much better fit to the experimental data, especially for the modes >100 cm-1.
Overall, LFR features related to the torsion of the intricate O-H···O and N-H···O hydrogen
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bonds were the most affected by the temperature. The large alteration (12-14 cm-1) of modes
at 128 and 162 cm-1 (-190 °C) suggests a higher contribution from the N-H···O bonds due to
their longer inherent distance. It is also important to mention that this amino acid embodies
an intricate yet sporadic hydrogen-bonded network (Figure A.3), which may attribute to the
increased temperature sensitivity for these vibrational modes.
As stated above, L-tryosine was also selected as a good candidate for more elaborate com-
putational analysis to evaluate the rationale for using specific parameters for such theoretical
simulations. We employed the recently revised version of pob-TZVP basis set that has been
derived from the same Gaussian-type Ahlrichs’ basis sets.153 The applicability of a hybrid
PBE0 functional was also tested. Figure 2.6 presents a direct comparison of the obtained
DFT-simulations with few key results worth pointing out. Each of the utilized approaches
appear to exhibit certain advantages in regard to the accuracy of specific peak wavenumber
and intensity modeling. For example, a clear difference between using the PBE or PBE0
functional can be observed for simulating the experimentally recorded peaks at 113 and 128
cm-1 (-190 °C). This aspect can become important for a correct assignment of vibrational
modes, which, while ultimately was not an issue here, could prove problematic elsewhere.
However, although the use of hybrid functionals may offer certain benefits, analysis of larger
systems (such as celecoxib or carvedilol; discussed below) can be compromised due to the
intricacy of the calculations (i.e., the higher number of irreducible atoms in the asymmet-
ric unit/presence of higher electron count chemical elements), and associated greater cost
of the required computational resources/time. Thus, realistically, it can only be applied for
relatively simple molecular crystals or in cases when an alternative approach is specifically
needed.
2.3.5 Celecoxib (form III)
This particular drug presented a challenging case for correlating theoretical and experimental
results. The low-temperature LFR spectra revealed a presence of an increased number of
vibrational bands in the range of 40-90 cm-1, which, to some extent, were reflected in the
DFT results. However, these calculated frequencies were difficult to reliably pair with the
experimental LFR features.
The global temperature-induced spectral changes were more straightforward than ob-
served for the other systems. The changes could be characterized with only two PCs (Fig-
ure A.18). Both PC1 (97%) and PC2 (3%) contained mixed information related to the peak
transformations - spectral and intensity-based shifts. Albeit PC1 versus PC2 scores plot
(Figure A.18a) was similar to ones shown for the other studied compounds (i.e., it displayed
gradual, temperature-based separation), there was an interesting “jump” in the score values
between the data collected at -30 and -20 °C. Visual analysis of the according experimental
spectra revealed a much greater change in LFR band intensities relative to other temperature
increments. A similar trend was also observed in the PCA of the mid-frequency Raman data,
where PC1 (80%) and PC2 (20%) largely discriminated peak shifts and intensity-based differ-
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Figure 2.6: Comparison of DFT-simulated L-tyrosine LFR spectra for com-
bination of different utilized functionals and basis sets. Reproduced from
Bērziņš et al. 77 with permission from the American Chemical Society.
Figure 2.7: Experimental and DFT-simulated LFR spectra of celecoxib
(form III). Reproduced from Bērziņš et al. 77 with permission from the
American Chemical Society.
ences, respectively (Figure A.20). The temperature-based characteristics of the sole spectral
features were once again described with the previously used non-linear model (Figure A.21).
Apart from the modes at ∼76 and 109 cm-1 (-190 °C), all of the peak positions were only
marginally affected; the increase in temperature manifested in a slight redshift (<5 cm-1).
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DFT-simulation results revealed that most of the modes are related to complex torsion mo-
tions. Considering the rigid, highly symmetrical three-dimensional hydrogen-bonded network
(Figure A.4), the energy threshold for inducing sizeable changes is likely to be very high.
2.3.6 Carvedilol (form II)
The experimental and DFT-simulated LFR spectra of carvedilol form II are presented in
Figure 2.8. This API exhibited the least temperature-induced changes amidst investigated
compounds that likely contributed to the excellent agreement between the theoretical and
experimental results. As stated before, only a restricted geometry optimization was carried
out for this solid-state form as full relaxation of the atom positions and lattice parameters
caused ambiguities for the vibrational analysis. The poor convergence of the full structural
optimization of carvedilol form II may be related to its higher energy as compared to the
more stable form III,164 with the full optimization attempting to converge to form III. Nev-
ertheless, it must be noted that particular theoretical simulation also inherited an imaginary
frequency with a very low relative intensity (∼-39 cm-1; primarily a translational motion
along the crystallographic a-axis), a likely artifact from the numerical derivative method
in the calculation which was considered to be negligible in light of the otherwise excellent
spectral reproduction. Ideally, to address this, more resource-intensive bidirectional triaxial
displacements for the generation of frequencies could be calculated, and, if further action is
necessary, a simulation cycle may need to be completely restarted using a tighter convergence
criteria in order to locate the true minimum at the potential energy surface. It also serves
to illustrate how difficult the analysis of such complex systems becomes. Similar to cele-
coxib, PCs from the chemometric analysis exemplified multiplex spectral information with
PC1 (>99%) containing more information related to the modest peak shifts (Figure A.22).
The PCA of mid-frequency Raman data illustrated comparable results (Figure A.24), which,
once again, would be hard to deduce from a simple visual analysis.
Individual, temperature-based peak position characteristics are presented in Figure A.25.
Unsurprisingly, in accordance to previously discussed results, none of the bands were red-
shifted more than 4-5 cm-1 when the drug was gradually heated up to 80 °C. Peaks in
the range of ∼75 to 100 cm-1 displayed an interesting behavior as their apparent intensity
ratio changed upon increase in temperature. While DFT calculations revealed that these
vibrational modes are mostly related to complex torsion motions, some of them displayed a
stronger character towards phenyl and carbazole moieties, which may exhibit different sensi-
tivity to temperature. Similarly to celecoxib, the overall robustness of this molecular system
can be directly related to the presence of intricate and robust intermolecular interactions
(Figure A.5).
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Figure 2.8: Experimental and DFT-simulated LFR spectra of carvedilol
(form II). Reproduced from Bērziņš et al. 77 with permission from the
American Chemical Society.
2.3.7 Significance
This chapter highlights some of the challenges associated with the modeling of low-energy
vibrational modes of typical pharmaceuticals, greatly linked to the molecular complexity
and intricacies of the crystal structure (including intermolecular interactions). The obtained
results show that even moderately demanding calculations can become a burden for more
sophisticated compounds. For example, the carvedilol form II structure optimization and
frequency analysis took approximately 28 days using 400 processor cores in parallel (ten,
40-core nodes with Intel Xeon Gold 6248 CPUs). Nevertheless, the utilized computational
parameters could serve as an adequate starting point for modeling LFR vibrational modes of
similar organic molecules as good results were obtained across all of the investigated solids.
It is also important to emphasize the necessity of high-quality, complementary experimental
data for these type of studies in order to correctly evaluate the quality of the DFT-simulations
as with the case of L-tyrosine, where some of the predicted low-frequency vibrational modes
could only be experimentally distinguished at very low temperatures. Furthermore, L-tyrosine
helped to showcase some of the advantages and caveats of using more sophisticated compu-
tational approaches. While these pathways can potentially help to provide alternative (if not
better) understanding of the chemical systems of interest, their rational use currently can be
limited due to the associated much higher computational cost.
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2.4 Conclusion
LFR spectral dynamics of several pharmaceutically relevant compounds were thoroughly in-
vestigated in a broad temperature range, and the chemometric analysis of the experimental
data was complemented with theoretical solid-state DFT simulations. The obtained infor-
mation on the origin of low-energy vibrational modes allowed to rationalize some of the
resolved temperature-induced changes of individual LFR bands in relation to the molecular
complexity and specific intermolecular interactions. Our generalized approach for solid-state
DFT simulations also provided considerably good results across all of the investigated solids
with adequate accuracy for both peak positions and Raman intensities, and could serve as
a basis for at least the preliminary modeling of the low-energy vibrational modes of simi-
lar pharmaceuticals. However, deficiencies of such general methodologies are still expected
to imply restrictions on the analysis of larger or highly complex drug molecules, where a
more individualized and resource-intensive approach may be necessary (for example, appli-
cation of hybrid functionals or specialized basis sets). Whilst continuous advancements in
the computing power will increase the rationale behind pursuing such avenues, future work
towards establishing more nuanced guidelines and developing alternative/specialized tools is
also needed to allow for a more robust understanding of the origin of low-energy vibrational
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3.1 Introduction
Approximately 40% of active pharmaceutical ingredients (APIs) with market approval and
90% of drug molecules under development are poorly water soluble.165 When administered
orally, the low aqueous solubility can significantly limit bioavailability. Typically, a range of
different single and multi-component crystalline solid forms (for example, salts and cocrys-
tals) are explored for solubility enhancement.1 In the last two decades, however, interest for
alternative approaches, such as amorphization has also risen significantly, reflected by the
increased number of approved amorphous formulations.18
Nevertheless, although amorphous forms have the potential to achieve higher solubil-
ity, higher dissolution rate, and, in some instances, better compression characteristics for
APIs than their crystalline counterparts, the physical instability can lead to crystallization
during manufacture or storage.17 Accordingly, many studies have focused on characterizing
the intrinsic stability of disordered pharmaceutical systems using a number of different tech-
niques.166 Comparatively less attention has been given to the analysis of processed amorphous
phases, especially to those originally derived from different preparation methods.167 From an
industry perspective, such knowledge can directly aid the development of robust amorphous
solid dosage forms.
It is important to note that the manufacture of such solid dosage forms (for exam-
ple, tablets) necessitates a number of steps, which can potentially induce destabilization.
For instance, grinding, a process for particle size reduction, is known to cause crystal-
lization.26 Several case studies have shown that compression can induce similar effects.
Thakral et al. reported that pharmaceutically relevant compression forces destabilized amor-
phous indomethacin causing hetero-spatial crystallization in tablets upon storage.27 Amor-
phous celecoxib has been shown to exhibit similar compression-sensitive characteristics.168
Compression-induced destabilization has also been documented in sucrose,4 griseofulvin,169
nimodipine,170 etoricoxib171 and bicalutamide.172 Thus, the manufacturing process may lead
to significant physicochemical changes of an API and ultimately may result in product failure.
Mechanistically, compression forces reduce the interatomic distances within the amor-
phous matrix. This can alter the dynamics and structural properties of the processed phase.
Accordingly, the network of intermolecular forces and chemical bonds can be vastly different
to those present in the neat amorphous material.173 Such disparities can directly affect both
thermodynamic and kinetic aspects of nucleation and crystal growth.
This thesis chapter focused on discerning the potential combined impact of compression
and preparation methodology on the physical stability and dissolution behavior of melt-
quenched amorphous drugs using LFR spectroscopy as the primary analytical technique. For
this purpose, celecoxib was selected as a model compound that, as stated above, has been
shown to be sensitive to compression-induced destabilization in the amorphous state.168 The
main hypothesis was centered towards the impact of compression parameters used during the
compaction where higher compression pressure and longer dwell times were expected to pro-
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gressively hamper the physical stability of the phases, including their dissolution performance
due to facilitated surface nucleation during compression (i.e., higher potential for faster crys-
tallization). Furthermore, stability studies at high relative humidity (RH) were regarded as
a potential pathway for correlating the crystallization tendencies in the glassy state (at room
temperature) to relevant dissolution characteristics.
3.2 Experimental
3.2.1 Materials
Celecoxib, form III (MW = 381.37 g/mol) was purchased from AK Scientific, Inc. (Union
City, CA, USA). Anhydrous monosodium phosphate (MW = 119.98 g/mol) and disodium
phosphate (MW = 141.96 g/mol) were purchased from Hopkin Williams Ltd (Chadwell
Heath, UK) and Thermo Fisher Scientific New Zealand Ltd (Albany, New Zealand), respec-
tively. Trisodium phosphate dodecahydrate (MW = 380.12 g/mol) was purchased from BDH
Laboratory Supplies Ltd (Poole, UK).
3.2.2 Preparation, compression and stability testing of amorphous cele-
coxib disks
Amorphous celecoxib disks (flat-faced; ∼8 mm diameter; ∼1 mm thick) were prepared by
melting 50 mg of the crystalline drug in a round silicone mold over a hot plate (approxi-
mately 170 °C) for about 30-45 s. Afterwards, the melted phase was cooled using either an
aluminium heat sink (immersed in ice) or benchtop surface (room temperature). This allowed
the preparation of amorphous phases with distinctly different cooling rates: >100 °C/min
and ∼25-30 °C/min (denoted fast and slow, respectively). These values were approximated
from the silicone mold surface temperature measurements using a Hei-Standard external tem-
perature probe (Heidolph Instruments GmbH Co., Schwabach, Germany), and expressed as
the average change in temperature between sequential time points (dT/dt) during the melt-
quench.
Compression of the disks was carried out using stainless steel die and punches (8 mm
diameter), in a hydraulic press (PerkinElmer Inc., Waltham, MA, USA), applying different
compression pressures (125, 250 and 500 MPa) and dwell times (0, 30 and 60 s). The
number of conducted experiments (Table B.1 and B.2) was optimized using a design of
experiments (DOE) approach in Design-Expert software (trial version 11.1.2.0, Stat-Ease,
Inc., Minneapolis, MN, USA). The effect of the three variables (cooling rate, compression
pressure and dwell time) on the crystallization behavior was studied using response surface
plots generated by the same software.
For the DSC and LFR high-temperature analysis, disks (uncompressed or compressed;
Figure 3.1) were cut in smaller pieces using a tablet splitter equipped with a stainless steel
blade, and were analysed immediately upon preparation. On the other hand, the samples
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Figure 3.1: Illustrative photographs of (a) freshly prepared and (b) com-
pressed amorphous celecoxib disks. Reproduced from Bērziņš et al. 84 with
permission from the American Chemical Society.
for long-term stability testing were securely positioned on a glass slide using double-sided
tape. The same sub-types of samples (for example, ones compressed using specific pressure
and dwell time) were placed on the same glass slide to equally limit exposure to the ambient
conditions during data collection. These slides were stored inside desiccators maintained
at room temperature (∼20 °C) under controlled relative humidity (RH) conditions. The
desired RH was achieved using either silica beads (<5%; samples kept under vacuum) or
saturated K2SO4 aqueous solution (∼97%).174 Samples were measured using low-frequency
Raman (LFR) spectroscopy (details below) at different time intervals. For each specimen,
three measurements (n = 3) per time-point were carried out across the surface of the disk
(edge to edge) to account for potential variability during the crystallization process.
3.2.3 Low-frequency Raman (LFR) spectroscopy
Raman spectra were collected using a home-built system utilizing an excitation source from
a 785 nm laser module (Ondax Inc., Monrovia, CA, USA) which was filtered by BragGrate
bandpass filters (OptiGrate Corp., Oviedo, FL, USA) to remove amplified spontaneous emis-
sion before irradiating the sample. For general analysis, samples (including glass slides) were
mounted sideways on an XYZ stage comprised of three UTS100CC linear motorized platforms
(Newport Corp. Irvine, CA, USA), whereas in-situ surface measurements during dissolution
were carried out by placing a custom-made, 3D printed flow-through cell175 with an organic
glass window under a downward looking lens. For both setup variations, the laser spot size
was approximately 500 µm. Backscattered light from the sample was collected and filtered
through a set of volume Bragg gratings (Ondax Inc., Monrovia, CA, USA) and focused into a
LS 785 spectrograph (Princeton Instruments, Trenton, NJ, USA) via a fiber-optic cable. The
light was dispersed onto a CCD detector (PIXIS 100 BR CCD, Princeton Instruments, Tren-
ton, NJ, USA) and the data were calibrated using a sulfur, 1,4 bis (2-methylstyryl) benzene
(BMB), and a toluene and acetonitrile solvent (1:1 v/v) standards. Spectra were collected
over the spectral window -360 to 2030 cm-1 with 5-7 cm-1 resolution. For a typical measure-
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ment, each spectrum was averaged from 60 scans with an integration time of 1 s. Raman
spectra for the surface dissolution analysis were obtained continuously and each spectrum
comprised of a single scan with an integration time of 1 s.
3.2.3.1 Isothermal kinetic studies of neat and compressed celecoxib disk samples
using LFR spectroscopy
Raman spectra for the isothermal measurements were collected using the same principal
setup as for the general LFR analysis (see above; 180° backscattering). A PE120 variable
temperature stage with T95 system controller (Linkam Scientific Instruments Ltd, UK) was
used for mounting the sample. An aluminium pan (TA Instruments, New Castle, DE, USA)
was used as a sample holder. A small amount of Artic Silver 5 thermal paste (Artic Silver Inc.,
Visalia, CA, USA) was applied to secure the position of the horizontally mounted sample, as
well as to ensure optimal thermal conductivity between the aluminium pan and the variable
temperature stage. The temperature program consisted of heating the sample from 20 to 90
°C using a 5 °C/min heating rate, holding the sample isothermally at 90 °C for 1 h and cooling
it back down to 20 °C (using 5 °C/min cooling rate). For the kinetic analysis, only the data
collected at the isothermal conditions (90 °C) was used. Each spectrum was comprised of 10
co-added scans with an integration time of 0.1 s for each scan, and accounting for readout
time, the measurement window for each spectrum was ∼1.2 s.
3.2.4 Data pre-processing
The spectra were converted to .spc from .spe file format using either SpectraGryph 1.2.7.
or 1.2.14. The pre-processing was carried out on the raw data to remove cosmic spikes
(≤3 pixel wide), as well as sources of variation associated with sample focus and incident
laser power. Due to the transparent nature of uncompressed samples, initial spectra (before
significant crystallization) were corrected by subtracting the contributions from the glass slide
(where necessary) using the scaled subtraction tool in the same software (an example of this
procedure has been presented in Chapter 1; Figure 1.14). For kinetic isothermal data, every 5
LFR spectra were averaged in the The Unscrambler X 10.4 (CAMO, Oslo, Norway) software,
and represented ∼6 s long time-frames. On the other hand, every 5 UV/Vis and LFR spectra
collected during the dissolution were averaged to represent ∼5 s long time frames. For the
selected spectral region (-300 to 2000 cm-1), scale and scattering variation were amended using
standard normal variate (SNV) transformation in the same software, where contribution from
Rayleigh scattering for LFR region was excluded (-15 to 15 cm-1). Baseline offset correction
was applied over the same spectral range.
3.2.5 Calibration data set and PLS analysis
In order to quantify solid-state transformations during the stability testing, a calibration data
set was prepared using amorphous celecoxib and its thermodynamically stable polymorph -
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form III. Here, an amorphous celecoxib sample was formed by heating ∼3 g of the crystalline
drug (in an aluminum foil pan) to about 170 °C (∼10 °C above its melting point) and holding it
at that temperature for 1-2 minutes (until a clear liquid with no observable opaque/crystalline
regions was observed). Afterwards, the melted phase was quickly transferred to an aluminium
heat sink immersed in an ice bath. This resulted in formation of a thin, glassy layer, which was
gently ground using mortar and pestle until a fine powder was obtained. Samples containing
1, 2.5, 5, 10, 25, 50 and 75% w/w of crystalline phase were prepared by a geometric mixing
or dilution (≤2.5% w/w) method. The PLS regression model was constructed using The
Unscrambler X 10.4 (CAMO, Oslo, Norway) software and a nonlinear iterative least squares
(NIPALS) algorithm with 10000 iterations. Raman data were collected and pre-processed
using the same procedures as described above. Five individual spectra were recorded for each
mixture type and systematic cross validation with systematically excluded segments (i.e.,
samples with a specific solid-state form ratio) was calculated.
3.2.6 Differential scanning calorimetry (DSC)
A differential scanning calorimeter (Q2000, TA Instruments, New Castle, DE, USA) equipped
with a refrigerated cooling accessory was used. The instrument was calibrated with indium.
In general, about 5-7 mg of sample was sealed in an aluminium pan (TA Instruments, New
Castle, DE, USA) and heated at 10 °C/min, from 0 to 200 °C under constant nitrogen purge
(50 mL/min). A specific (separate) set of samples (see Table B.3) was analysed using different
temperature range and heating rate (20-180 °C and 1 °C/min, respectively).
3.2.7 Water sorption
Amorphous celecoxib samples (n = 3) were prepared by melt-quenching ∼5.5 mg of crystalline
drug inside open aluminium pans using a Discovery DSC (TA Instruments-Waters LLC, New
Castle, DE, USA) differential scanning calorimeter. The temperature program consisted of
heating the sample from 20 to 175 °C using a 10 °C/min heating rate, holding the sample
isothermally at 175 °C for 30 s and cooling it back down to 20 °C using either the “fast
equilibration setting” (the fastest possible cooling rate) or 30 °C/min cooling rate under a
nitrogen flow of 50 mL/min. The samples were then quickly transferred to an automated
vapour sorption analyser (VTI-SA+; TA Instruments-Waters LLC, New Castle, DE, USA),
and equilibrated at 0% RH (20 °C) for 15 min under a nitrogen flow rate of 50 mL/min. The
RH was then increased to 97% and held for up to 24 h (equilibrium criteria: 0.0010% in 99
min).
3.2.8 Thermogravimetric analysis (TGA)
A TGA 55 thermogravimetric analyzer (TA Instruments, New Castle, DE) was used to
determine the water content of differently prepared melt-quenched amorphous celecoxib disks.
CHAPTER 3. COMP.-IND. DESTABILIZATION IN AMORPHOUS DRUGS 48
About 4-5 mg of gently ground powder was loaded into a platinum pan, and samples (n = 3)
were heated at 10 °C/min from 25 °C to 180 °C under constant nitrogen purge (40 mL/min).
3.2.9 PXRD
An X’Pert PANalytical PRO X-ray diffractometer (PANalytical, Almelo, The Netherlands)
was used for the analysis of samples. The measurements were performed at room temperature
using Cu Kα radiation (1.54187 Å, 45 kV and 40 mA) and data were collected over the range
of 5-35° 2Θ with a step size of 0.026° and dwell time of 0.0625 s.
3.2.10 Dissolution testing
A custom-made, 3D printed flow-through cell175 was used for the surface dissolution measure-
ments. Samples were inserted in the cavity (∼8.5 mm in diameter; inside a rubber O-ring)
in the middle of the cell such that only the top surface would be exposed to the dissolution
medium. It is important to note, however, that due to the fragile nature of the compacts,
only a partial (half-moon shaped) O-ring was used for these samples, where the disk was
gently pushed against the sidewall of the cavity. This approach ensured that the bottom
surface remained directly inaccessible to the dissolution medium during testing. Addition-
ally, an aluminum cylinder was placed beneath the samples inside the cavity to adjust their
vertical position and prevent acquisition of the Raman signal from the 3D printed poly-
meric material. The cell was connected to the Masterflex L/S peristaltic pump (Masterflex,
Gelsenkirchen, Germany), dissolution medium reservoir (10 mM pH ≈11.5 trisodium phos-
phate solution maintained at ∼37 °C using a temperature-controlled water bath) and quartz
UV flow-through cell using a silicone tubing in an open loop setup (Figure 3.2). Throughout
the experiment, the flow rate was maintained at 9 mL/min, which has been suggested to best
imitate the axial velocity of the intestine.176 UV measurements were conducted using a DH-
Mini UV-VIS-NIR fiber optic light source (Ocean Optics Inc., Dunedin, FL, USA) and Flame
fiber optic miniature spectrometer (Ocean Optics Inc., Dunedin, FL, USA). The data were
collected using the OceanView 2.0.7. software (Ocean Optics Inc., Dunedin, FL, USA) in the
range of 187 to 1031 nm with an optical resolution of ∼2 nm, and each spectrum comprised
of 10 scans with an integration time of 100 ms. For the quantitative analysis, a series of stan-
dard solutions of celecoxib in phosphate/acetonitrile (1:1 v/v) medium were prepared using
a previously described methodology.177 This approach allowed us to overcome the otherwise
limited celecoxib aqueous solubility and construct a linear calibration curve in a broad con-
centration range (1-25 µg/mL) from the recorded absorbance values at 255 nm (Figure B.1).
This particular wavelength was selected as it not only coincided with a peak maximum of
the celecoxib absorption profile, but also eliminated any potential interference from the sol-
vent matrix. Dissolution experiments were carried out in triplicate for differently prepared
amorphous celecoxib samples (uncompressed and compressed at 500 MPa pressure with a 60
s dwell time). For each sample, surface solid-state transformations (LFR spectroscopy) and
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the dissolution profile (UV/Vis) were continuously monitored for at least 30 min. The area
under the dissolution curve (AUC), the highest initial celecoxib concentration in solution
(Cmax) and time necessary to reach it (tmax) were determined by using numerical integration
tools in OriginPro 2018 (OriginLab Corp., Northampton, USA) and SpectraGryph 1.2.14.
For selected, differently prepared uncompressed and compressed samples, digital images of
selected areas were recorded using an Alpha 300R+ confocal Raman microscope controlled
with Project 5.1 software (WiTec, Ulm, Germany). Furthermore, the wetting behavior of
these samples was also studied by exposing the surface to 50 µL of aqueous red dye (food
color 124) solution for 3 min or 10 mM trisodium phosphate solution (dissolution medium)
for 0.5/15 min after which the samples were blotted using a soft tissue. Digital images of the
top and side surfaces of the samples were recorded before and after these experiments.
Figure 3.2: Schematic of the experimental design for the multimodal sur-
face dissolution data acquisition using two different analytical techniques:
LFR and UV/Vis spectroscopy. Reproduced from Bērziņš et al. 178 with
permission from the American Chemical Society.
3.2.11 MCR details
Separate MCR analysis was performed on the pre-processed isothermal and dissolution LFR
data using The Unscrambler X 10.4 (CAMO, Oslo, Norway) software with applied non-
negativity (non-negative spectra/concentration) and closure constraints, and using following
settings - sensitivity to pure components: 100; maximum number of alternating least squares
iterations: 10000.
3.2.12 PCA details
PCA was performed on the pre-processed data using The Unscrambler X 10.4 (CAMO, Oslo,
Norway) software. PCA was carried out on all the DOE samples prepared for DSC and
high-temperature LFR measurements using the initial LFR spectra recorded at the start of
the temperature program (see Section 3.2.3.1).
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3.2.13 Statistical analysis
Where applicable, one-way analysis of variance (ANOVA) and T-tests were performed using
the data analysis tool in MS Excel 2016 (Microsoft Corp., Redmond, WA, USA) software
with a confidence level of 95% (p<0.05).
3.3 Results and discussion
3.3.1 Exploratory analysis
In order to accurately evaluate the impact of compression-induced destabilization, it was nec-
essary to devise a specific method for preparing the amorphous phase. This was important as
the preliminary results showed significant batch-to-batch variability in supercooled recrystal-
lization dynamics when the amorphous phase was ground after the melt-quenching process.
Nevertheless, the initial Raman spectra for the ground celecoxib appeared to be identical to
the unground quench cooled glass (this aspect is discussed in more detail below), making the
pre-processed (powdered) amorphous drug appropriate for preparing mixtures for the PLS
model.
Melt-quenched amorphous celecoxib has also been shown to be highly sensitive to an-
nealing. Rapid nucleation (i.e., decrease in physical stability) was observed when samples
were stored even at a very low temperature (for example, at -50 °C) for a relatively short
period of time.179 Thus, it was impossible to prepare a larger batch of material, which could
be pre-processed at once and stored before use. Preparation of the melt-quenched phase
as individual amorphous celecoxib tablet-shaped disks circumvented these limitations. Also,
this approach allowed us to negate potential particle size effects for the kinetic analysis.
Figure 3.3 shows a typical Raman spectrum of crystalline (thermodynamically stable
form III) and amorphous celecoxib. Both phases are characterized by a number of unique
spectral features. Form III has multiple peaks in the LFR region (<300 cm-1) at around
27, 51, 61, 101, 177 and 249 cm-1, and the origin of these low-energy vibrations have been
discussed in detail in the previous chapter. In the same spectral range, amorphous phase
mostly exhibits a broad vibrational density of states (VDOS) feature with few individual
peaks at a slightly higher wavenumber region (150-300 cm-1). Furthermore, both solid-state
configurations have an array of unique spectral features in the mid-frequency region (300-
1700 cm-1). Thus, Raman spectroscopic data served as a good basis for developing a tool for
quantitative analysis of particular solid-state forms.
Calibration data and loadings plot of the PLS regression model are shown in Figure 3.4.
A single factor was used for constructing the model, and it accounted for 99% of the spectral
variance. Respective loadings plot revealed that crystalline and amorphous features are pre-
dominantly correlated with the positive and negative factor space, respectively (Figure 3.4b).
The existence of an outlier for form III (the lowest energy vibration; ∼27 cm-1) can be ratio-
nalized on the basis of relative abundances between this peak and the dominant amorphous
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Figure 3.3: Representative Raman spectra of (a) crystalline (form III) and
(b) amorphous celecoxib; full data and mid-frequency range (insets). The
laser line (Rayleigh scattering) is omitted for clarity. Reproduced from
Bērziņš et al. 84 with permission from the American Chemical Society.
phase VDOS contributions in the particular spectral domain. The accuracy of the model was
estimated based on multiple statistical parameters, including root mean square error (RMSE)
and correlation coefficient (R2). The performance was assessed on the basis of cross validation
results. Generally, for a satisfactory prediction capability, specific yet similar characteristics
for both models are required.132 In particular, the R2 and RMSE values are expected to
be close to 1 and 0, respectively. The obtained values of 0.993/0.994 and 2.95%/3.14% can
be evaluated as good when the range of experimental points (i.e., single components and
mixtures; 0-100% w/w) used for designing the PLS model is considered.
3.3.2 Kinetic analysis of uncompressed/compressed amorphous celecoxib
phases in the supercooled state
For our study, a range of different compression parameters were selected. It was important
to test both pharmaceutically relevant and extreme conditions, to evaluate the amplitude of
the destabilizing compression effect. Here, DSC served as a tool to identify potential changes,
while LFR spectroscopy was utilized to better discern these differences. All of the samples,
irrespective of applied compression conditions, were amorphous and there was no evidence of
celecoxib crystallization during compression based on the PCA (Figure B.2). The obtained
model showed random distribution of data points in the PC space without any attributable
features in the respective loadings plots apart from the signal noise or baseline discrepancies.
In general, the thermal behavior of the intact (control) amorphous phase was similar to
ones reported previously.142,180–182 Glass transition temperature (Tg) was observed at ∼52
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Figure 3.4: (a) Calibration data and (b) loadings plot of factor 1 of the PLS
regression model; spectral features attributed to form III and amorphous
phase are labeled with (C) and (A), respectively. Reproduced from Bērziņš
et al. 178 with permission from the American Chemical Society.
°C (midpoint), followed by crystallization (exotherm) at ∼103 °C and melting at ∼159, ∼161
and ∼162 °C. The three different melting endotherms were attributed to the form III, form
II and form I, respectively (see Figure 3.5). However, when compared to the literature,
the identified polymorphs exhibited slightly lower melting points (by ∼1-2 °C).143 This was
likely due to the fact that pieces of the disk and not powdered samples were analysed to avoid
inducing additional changes within the amorphous matrix. Particle morphology (among other
factors) is known to affect the thermal behavior of samples during the DSC measurements.183
Nevertheless, the used approach was justified on the basis of the consistency of the obtained
results across all individual sample types.
In the compressed phases, there was a significant decrease in the respective crystallization
onset temperature, while the Tg and enthalpy of recrystallization (∆Hc) remained largely sim-
ilar. Comparable changes in the thermal behavior have been reported for amorphous sucrose,
where range of different applied compression conditions decreased the crystallization onset
temperature.184 The authors attributed this observation to distortion of sucrose molecules,
and a possible increase in the free energy level, which may have facilitated the nucleation
of sucrose crystals. An analogous explanation can be provided for the analysed celecoxib
samples. Additionally, compression caused significant sample fracture (Figure 3.1b), which
can potentially lead to accelerated crystal growth due to increased number of free surfaces.185
It is also worth noting that ratio of recrystallized polymorphs (dominated by the unstable
forms) appeared to vary as indicated by the differences in the shape of the melting peaks. In
the temperature range of DSC cold crystallization (95-115 °C), forms I and III are reported to
exhibit diffusion-controlled mechanism with form I having faster growth rates.186 This may
explain the higher relative content of this polymorph in the recrystallized phases.
For the same samples, LFR spectroscopy provided an alternative approach to distinguish
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Figure 3.5: Representative DSC curves of amorphous celecoxib (control),
and compressed samples using a range of different compression pressures
and dwell times. Here, all of the represented samples have been procured
with fast melt-quenching. Reproduced from Bērziņš et al. 84 with permis-
sion from the American Chemical Society.
the observed differences via changes in the crystallization kinetics. The isothermal tempera-
ture conditions used were selected based on several factors. Our preliminary kinetic exper-
iments (for example, at 70 or 80 °C) were slow and yielded partially crystallized celecoxib
with unique Raman peaks (Figure B.3). However, we were unable to assign these spectral
features to a specific celecoxib polymorph. Accordingly, these observations prompted us to
increase the temperature (up to 90 °C), where crystallization occurred much faster (within a
rational time-scale), as well as procured only form III. At these conditions, multivariate curve
resolution (MCR) resolved the system to be comprised of two main components, and their
loadings plots (Figure B.4) paralleled Raman spectra shown previously (Figure 3.3). The
very slight differences (band shifts and changes in peak ratios) were attributed to the tem-
perature effect. The resolved minor distortions in the LFR spectral range for the amorphous
component could be related to the formation of a very small amount of other polymorphs
(form I and/or II) during the temperature ramp phase (from 20 to 90 °C) for some of the
samples. Nevertheless, for the sake of simplicity, the content of these potential crystalline
phases was assumed to be negligible. The obtained isothermal crystallization data was fit-
ted to the modified Johnson-Mehl-Avrami-Kolmogorov (JMAK) solid-state kinetic model34
describing nucleation and crystal growth:
α(t) = αmax − αmax exp [−(k(t− t0))n] (3.1)
where α(t) is the form III fraction crystallized at any time t, αmax is the fraction crystallized
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at t→∞, k is the rate constant, t0 is the crystallization onset and n is the reaction order. The
αmax parameter was introduced in the model due to incomplete crystallization resolved by the
MCR. It coincided with previously reported results, where partial celecoxib crystallization
was observed in the supercooled state using PXRD.180 The optimal αmax, k and n values
were calculated using multi-parameter least square optimization with MS Excel 2016 Solver
(Microsoft Corp., Redmond, WA, USA) software. The calculations were repeated until a
global minimum value was achieved, and the obtained optimization result was validated by
varying the input values for the optimizable parameters. Figure 3.6 contains representative
LFR spectra and kinetic curves showing progressive celecoxib crystallization in two extremely
different samples - uncompressed and one compressed at 500 MPa pressure with a 60 s dwell
time. It is important to note that the MCR model was built using the data from a broad
spectral range (-300 to 2000 cm-1), while the low frequency region was highlighted as it
displayed the most salient changes during the transformation. As expected, the crystallization
process was much slower for the control specimen inheriting longer induction time (t0) and
lower maximum extent of form III crystallization (αmax).
3.3.2.1 Effect of sample history on the compression-induced destabilization of
amorphous celecoxib in the supercooled state
It has recently been shown that the intrinsic state of an amorphous phase is an important
factor for limiting the destabilization induced by the tableting process. In general, plasticiza-
tion (i.e., higher water content) was found to amplify compression-induced destabilization
in amorphous sucrose and sucrose-polyvinylpyrrolidone solid dispersions.4 Therefore, it is
of interest to evaluate how different sample preparation methods can affect the extent of
compression-induced destabilization. The discussion so far has been restricted to character-
izing the destabilization process in amorphous celecoxib, which has been prepared by a fast
melt-quenching (>100 °C/min). Different critical cooling rates have been reported for cele-
coxib. For example, Blaabjerg et al. showed that experimentally (via DSC measurements)
glassy celecoxib can be repeatedly obtained with a cooling rate of 20 °C/min, while the pre-
dicted critical cooling rate value from the continuous-cooling-transformation (CCT) diagram
was 32 °C/min.16 Therefore, we adapted the “slow” cooling rate (∼25-30 °C) to be within the
temperature range. The response surface plots for the DSC crystallization onset data can be
seen in Figure 3.7. Overall, higher compression pressure and longer dwell time systematically
destabilized the two systems. Both uncompressed samples exhibited similar apparent phys-
ical stability, reflected by their almost identical thermal behavior. However, the amplitude
of destabilization was more distinct in samples prepared by a slow melt-quenching, where
the overall crystallization onset temperature range was higher. This result implies that sam-
ple history is a pivotal factor for limiting compression-induced destabilization. Furthermore,
mere intrinsic physical stability, although influential, cannot be used to identify the potential
for compression-induced destabilization.
Similar trends were observed in the LFR data, where the spectral information permitted
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Figure 3.6: Representative LFR spectral range of (a) uncompressed and
(b) compressed (500 MPa with 60 s dwell time) samples (procured via
fast melt-quenching) monitored at isothermal conditions (90 °C), and (c),
(d) experimental/theoretical (fitted) kinetic curves for the same respective
samples. Markings (1-5) denote the presented LFR spectra in respect to
the kinetic curves. Reproduced from Bērziņš et al. 84 with permission from
the American Chemical Society.
the probing of the compression-induced differences in more detail. The combination of highest
utilized compression pressure (500 MPa) and longest dwell time (60 s) yielded an amorphous
celecoxib with the lowest apparent physical stability. However, for samples prepared via
fast melt-quenching, the response plot showed distinct differences only at the utmost applied
compression conditions. It also resulted in reversed slope gradient profile with respect to the
dwell time effect at opposite ends of applied compression pressures. In contrast, the global
response surface plot for the other type of procured amorphous phase (Figure 3.8b; slow
melt-quenching) was very similar to the DSC results discussed previously (Figure 3.7b).
Equivalence between the results of isothermal and non-isothermal (dynamic) measure-
ments of the stability of amorphous phases has long been a subject of controversy. Kedward
et al. showed poor agreement between isothermal and non-isothermal DSC crystallization
kinetics for amorphous lactose, where different solid-state forms were obtained. In contrast,
sucrose showed a much better match between the experimental data, where the same crys-
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Figure 3.7: The DSC crystallization onset response surface plots for amor-
phous celecoxib phases procured via (a) fast or (b) slow melt-quenching
that were compressed using a combination of different compression parame-
ters. Reproduced from Bērziņš et al. 84 with permission from the American
Chemical Society.
Figure 3.8: The LFR crystallization onset response surface plots for amor-
phous celecoxib phases procured via (a) fast or (b) slow melt-quenching
that were compressed using a combination of different compression parame-
ters. Reproduced from Bērziņš et al. 84 with permission from the American
Chemical Society.
talline phase was procured.187 Using the LFR data we were able to highlight the kinetic
response at a set temperature. These data were modeled as a transformation from an amor-
phous form to a single polymorphic form (Figure 3.6). On the contrary, the DSC results
(Figure 3.5) showed a complex recrystallization behavior. A reduction in the dynamic na-
ture of the DSC measurements may enable more comprehensive comparison between DSC
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and LFR results. For this purpose, an independent set of samples (Table B.3) was anal-
ysed by DSC using a very slow heating rate (1 °C/min). The obtained results for these
experiments are presented in Figure 3.9. Once again, different applied tableting parameters
caused significant and reproducible changes in the cold crystallization dynamics. However,
the DSC thermogramms still displayed complex melting behavior and even encompassed mul-
tiple exothermic events, which were associated with a recrystallization from the melt. The
slow heating utilized appeared to produce a binary mixture of form III and form II with their
ratio being varied based on the compression parameters used. The obtained surface response
plot (Figure 3.9b) resembled a combination of ones presented earlier. As with the previous
DSC results (Figure 3.7), a pronounced dwell time effect was observed even at lower com-
pression pressures. In comparison, the compression pressure alone had a smaller effect on the
kinetics of crystallization. This highlights the importance of understanding the thermal and
temporal dynamics for a system able to crystallize in different forms. Nevertheless, a direct
correlation between the DSC and LFR data may be established, if the applied experimental
conditions would yield the same crystalline phase.
Figure 3.9: (a) Representative DSC curves for an independent sample
set (procured via fast melt-quenching), which was analysed using a slow
heating rate (1 °C/min), and (b) the respective DSC crystallization onset
response surface plot. Reproduced from Bērziņš et al. 84 with permission
from the American Chemical Society.
3.3.3 Stability testing of uncompressed/compressed amorphous celecoxib
phases in the glassy state
Considering the fact that susceptibility to compression-induced destabilization was altered
when amorphous celecoxib was prepared using different cooling rates during the melt-quench,
it was equally important to understand the behavior of such processed phases under practi-
cally relevant storage conditions. Recent studies have shown that pharmaceutical glasses can
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exhibit vastly different crystallization behavior in the glassy and supercooled states, which
is believed to be largely related to the changes in molecular mobility (i.e., local and global
motions).15,180 Thus, considering the complexity of the experimental design, it was also of
interest to determine if the previously observed trends would translate to the crystallization
tendencies under typical and stress storage conditions.
First, the physical stability of uncompressed/compressed samples was monitored at ∼20
°C (<5% RH); ∼30-35 °C below their Tg. The dry conditions enabled a direct evaluation of
the temperature effect, i.e., isothermal crystallization behavior in the glassy state. At spe-
cific time-points, samples were measured quasi-spatially across the surface of the disk using
LFR spectroscopy and slow transformation to form III was observed. The PLS model was
used to obtain quantitative information on solid-state form composition changes. Overall
results were in agreement with earlier findings, where the same crystalline phase formed for
melt-quenched amorphous celecoxib samples stored at similar conditions: ∼20 °C and ∼10%
RH.188 However, crystallization in our experiments proceeded much slower, even for some
of the compressed samples (Grzybowska et al. reported conversion to be complete within
200 h) possibly due to water uptake disparities,188 but this could also be related to the dif-
ferences in preparation method (for example, cooling rate during the melt-quench) and/or
processing steps taken (for example, grinding), which, unfortunately, were not specified by
the authors. Figure 3.10 shows recrystallization profiles for several uncompressed/compressed
samples procured via fast melt-quenching, where several interesting trends can be recognized.
First, more severe compression conditions (i.e., higher compression pressure and longer dwell
time) caused progressively faster crystallization of form III. It is important to note that even
compression conditions relevant to pharmaceutical manufacturing (for example, 125 MPa
pressure with minimal dwell time) significantly altered the crystallization behavior. Addi-
tionally, with the formation of a substantial amount of crystalline phase for the compressed
samples, there was a great variation in its content. More specifically, formation of the form III
was much more rapid towards the edges of the surface when compared to the central domain
(see Figure B.5). In contrast, uncompressed samples exhibited largely even surface crystal-
lization. Similar behavior has also been shown for amorphous indomethacin tablets stored
below the glass transition temperature (at 35 °C), where compression pressure as low as 10
MPa promoted significant radial surface crystallization while the core of the tablet remained
mostly amorphous.27 Huang et al. recently showed that edges and side surface regions gener-
ally experience the highest shear stress during unlubricated compaction. The finite element
analysis revealed that under 200 MPa compression pressure these areas are expected to be
up to 2-10 times more strained.189 Accordingly, this could explain the observed differences in
the compressed celecoxib samples as the shear stress can facilitate nucleation and even direct
solid-state transformations.190 It is also important to note that slow-melt quenched samples
exhibited similar tendencies as illustrated in Figure B.6.
For a more detailed comparison, response surface plots (Figure 3.11) were constructed us-
ing a characteristic crystallization time for a substantial mean amount of form III (10% w/w).
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Figure 3.10: Representative crystallization profiles of individual un-
compressed/compressed amorphous celecoxib samples (fast melt-quench)
stored at ∼20 °C; <5% RH (mean ± standard deviation; n = 3). The lines
are drawn to assist in visualizing the trends. Reproduced from Bērziņš
et al. 178 with permission from the American Chemical Society.
These values were calculated using the B-spline interpolation function in OriginPro 2018
(OriginLab Corp., Northampton, USA). The uncompressed samples exhibited similar physi-
cal stability regardless of the preparation method used. However, the affinity for compression-
induced destabilization was higher for the phases obtained via slow melt-quenching. This was
clearly evident from the differences in recrystallization behavior for samples compressed using
the longest dwell time (60 s). Interestingly, these general trends were very similar to the ones
observed at the supercooled state. Although limited to a single model compound, results
imply that kinetic information from the supercooled state may potentially be used to pre-
dict the compression-induced destabilizing effect for a broader temperature range, including
normal storage conditions. Such a tool is useful for improving the excipient selection/testing
process in multi-component amorphous formulations, and should be explored further.
For samples stored at elevated RH conditions (97%), near complete (>60%) form III
crystallization was observed within 7 days for all of the samples (Figure 3.12). Although
characterized as a nonhygroscopic compound as per the Callahan classification,191 amor-
phous celecoxib can still sorb significant amounts of water, which can then act as a plasticizer
and lower the physical stability of the disordered system.192 As before (i.e., dry conditions;
Figure 3.10), compressed samples crystallized more readily. However, the overall differences
were less distinct (both in crystallization behavior and form III spatial content; an example is
shown in Figure B.5). This is also pictured by the response surface plots (Figure 3.13), which
were constructed using the same approach as above to enable a direct comparison with previ-
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Figure 3.11: The LFR 10% crystallization response surface plots for amor-
phous celecoxib samples procured via (a) fast or (b) slow melt-quenching
that were compressed using a combination of different compression pa-
rameters and stored at ∼20 °C and <5% RH. Reproduced from Bērziņš
et al. 178 with permission from the American Chemical Society.
ous results. Surprisingly, while amorphous phases obtained via slow melt-quenching were still
more sensitive to compression-induced destabilization, their apparent physical stability was
slightly higher at these storage conditions. The resolved minor and occasionally irrational
differences amongst compressed phases (for example, ones subjected to 500 MPa pressure and
varied dwell time; Figure 3.13b) were assumed to be negligible due to the rapidness of the
crystallization process and associated uncertainty of the multi-step analysis. This presump-
tion was supported by the surface response plots of a crystallization time for higher form
III content (30%), where samples compressed at the utmost conditions (500 MPa pressure
and 60 s dwell time) clearly exhibited the lowest apparent physical stability (Figure B.7),
and still retained the same differentiating trends between phases obtained via fast and slow
melt-quenching.
It was hypothesized that the aforementioned discrepancies in the physical stability of
differently prepared phases are related to their intrinsic interactions with water vapor. Ini-
tially, water uptake kinetics were monitored ex-situ by placing uncompressed/compressed
disks into glass vials and weighing them at different time intervals. However, this approach
had limited accuracy due to a number of factors (namely, hydrophobic nature of the drug,
relatively small sample weight and additional water absorption/condensation by the sample
holders). Therefore, we opted to use an automated vapor sorption analyzer, which allowed
us to at least compare the water sorption profiles (Figure B.8) of in-situ differently prepared
uncompressed phases. The analysis revealed that both sample types sorbed similar average
maximum amount of water (∼1.9-2.2%) with slow melt-quenched samples exhibiting only
slightly faster water uptake. Nevertheless, in all cases, no crystallization was observed during
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Figure 3.12: Representative crystallization profiles of individual un-
compressed/compressed amorphous celecoxib samples (fast melt-quench)
stored at ∼20 °C and 97% RH (mean ± standard deviation; n = 3). The
lines are drawn to assist in visualizing the trends. Reproduced from Bērziņš
et al. 178 with permission from the American Chemical Society.
Figure 3.13: The LFR 10% crystallization response surface plots for amor-
phous celecoxib samples procured via (a) fast or (b) slow melt-quenching
that were compressed using a combination of different compression param-
eters and stored at ∼20 °C and 97% RH. Reproduced from Bērziņš et al. 178
with permission from the American Chemical Society.
the experiments, which was further confirmed by the PXRD analysis (Figure B.9). These
results may indicate a bigger influence of other factors on the LFR crystallization kinetics
such as initial water content or intrinsic surface area. Thermogravimetric analysis of amor-
CHAPTER 3. COMP.-IND. DESTABILIZATION IN AMORPHOUS DRUGS 62
phous celecoxib disks revealed that, on average, there is about 0.1-0.15% difference between
the two sample types with fast melt-quenched samples having higher outset water content.
As amorphous celecoxib is known to be sensitive to common plasticizers, including water,192
it is possible that even such small disparity could still affect the LFR crystallization kinetics,
especially considering the very short time-scales of these solid-state phase transformations
at high RH conditions (Figure 3.12). Additionally, it is important to note that it would be
complicated to rectify the water content differences (a likely consequence from using an ice
bath during the fast quench process) by drying the samples upon preparation. The charac-
teristic rapid annealing of glassy celecoxib179 would introduce an additional variable, which
may further affect its already complex nature to compression-induced destabilization.
3.3.4 Dissolution studies
The dissolution experiments were conducted on two differently processed samples (uncom-
pressed and compressed at 500 MPa with 60 s dwell time) to represent the two extremes
explored within this study. Irrespective of the specimen, preliminary results using, for ex-
ample, pH 6.8 phosphate buffer showed poor dissolution behavior, potentially due to the
coalesced nature of the amorphous disks. Thus, we elected to use 10 mM tribasic sodium
phosphate solution (pH ≈11.5) as the dissolution medium to enhance and accelerate the drug
release within rational timescales. Such approach (i.e., the use of an alkaline medium) has
also been approved by the U.S. Food and Drug Administration (FDA) in order to maintain
the sink conditions for dissolution of celecoxib capsules.193
Figure 3.14 shows representative multimodal dissolution data for a fast melt-quenched, un-
compressed sample. Herein, both spectroscopic techniques provided a direct insight into the
dissolution process - UV/Vis highlighted the initial solubility enhancement of the amorphous
phase (Figure 3.14a), whereas LFR spectroscopy characterized the solid-state transforma-
tions, which rationalize the subsequent decrease in the solubility due to the surface crystal-
lization (Figure 3.14b). More specifically, the recorded dissolution profile (Figure 3.14c; blue
curve) resembled a typical “spring” model, where the unstable form achieves a concentration
that far exceeds the equilibrium solubility, followed by its rapid decrease due to the forma-
tion of the stable solid form20 as concurrently shown by the chemometric analysis of the LFR
data (Figure 3.14c; orange curve). The MCR resolved the system to be comprised of two
main components (amorphous phase and form III), and their loadings (Figure 3.14d) once
again largely coincided with the Raman spectra presented previously (Figure 3.3). Some
of the observed minor differences are likely caused by the presence of dissolution medium
as well as interfering (overlapping) signals from the organic glass cover (Figure B.10). The
apparent secondary incline of the form III content toward the end of the experiment (here
and elsewhere; Figures B.11-B.12) could potentially be related to the proceeding subsurface
crystallization of the disk. As our custom-built LFR setup is non-confocal, the sampling
volume is not restricted to the surface of the specimen. This also coincided with the visual
observation that only a certain fraction of the disk crystallized as the bottom parts of the
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retrieved specimens after the dissolution test were still amorphous.
Figure 3.14: Representative (a) UV/Vis and (b) LFR dissolution data
of fast melt-quenched, uncompressed sample. (c) Respective dissolution
profile/MCR crystallization curve of component 2 and (d) MCR loadings
plots for component 1 and 2. Asterisks (*) denote spectral features related
to the organic glass cover of the dissolution cell. Reproduced from Bērziņš
et al. 178 with permission from the American Chemical Society.
Table 3.1 presents a summary of different dissolution parameters for the tested samples
(individual dissolution profiles and MCR curves for each specimen can be seen in the Ap-
pendix B; Figures B.11-B.12), including the area under the dissolution curve (AUC), the
highest initial celecoxib concentration in solution (Cmax) and time necessary to reach it
(tmax). Furthermore, extracted crystallization onset values from the MCR analysis of LFR
data are also included. These were determined as an intersection point between two lines (as
per Euclidian geometry) representing the induction time and the early stage crystallization.
A statistical comparison of all of the aforementioned parameters can be seen in Figure B.13.
Based on this data, several interesting observations were noted. First of all, irrespective
of the specimen, dissolution was found to be rapid, where the highest apparent celecoxib
concentration was reached within a time span of 1-1.5 min with no significant differences
between sample types. However, the extent and duration of supersaturation varied. Sur-
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Table 3.1: Summary of the dissolution results for the (processed) amor-
phous celecoxib samples.









1.19 ± 0.26b 4.4 ± 0.8 5.8 ± 2.9 2.0 ± 0.6
Fast melt-quench;
compressed with 500 MPa
and 60 s dwell time
1.17 ± 0.22 15 ± 6 49 ± 31 4.6 ± 0.7
Slow melt-quench;
uncompressed
1.13 ± 0.02 5.6 ± 1.6 8.1 ± 3.9 2.2 ± 0.8
Slow melt-quench;
compressed with 500 MPa
and 60 s dwell time
1.10 ± 0.23 9.5 ± 1.9 21 ± 6 3.5 ± 0.6
aAUC = area under the curve. bMean ± standard deviation; n = 3.
prisingly, the compressed samples exhibited better dissolution performance than their “as is”
counterparts (namely, proportionally higher Cmax and AUC values) while also showing some
intrinsic differences. The first phenomena could be explained by the disparities in the phys-
ical appearance of the samples. As stated before, compressed samples were fragile, mainly
due to biaxial fracture and resembled sheet-like assemblies. As such, it is likely that these
processed amorphous phases also inherent a higher accessible surface area that can influence






(CS − C) (3.2)
where C and CS represent the concentration of the dissolved chemical entity at a given time
t, and its solubility concentration, respectively; D is the diffusion coefficient, SA is the sur-
face area of exposed solid, V is the accessible volume of the dissolution medium and h is
the thickness of the diffusion layer. This assumption is supported by surface wetting ex-
periments using an aqueous red dye solution, where fast permeation was only observed in
the compressed compacts (Figure B.14). However, it was puzzling to see that both types
of compressed samples also exhibited prolonged crystallization onset times (Table 3.1) as
intuitively faster transformation to the stable solid-state form would be expected. Typically,
fracture leads to formation of free surfaces and induces fast crystal growth mechanism.186
In addition, densification is achieved during the compression that can promote contact be-
tween molecules and increase the probability of nucleation.196 A possible explanation for
this unusual phenomenon may lie in the particle/surface morphology and its observed di-
versity in compressed samples (Figure B.15). In an interface-driven crystallization, this can
potentially cause variability in surface energy and lead to changes in crystal growth rates
among other properties.197 Additionally, as opposed to uncompressed samples, the surface
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of the compacts notably changed upon contact with the dissolution medium (Figure B.15e).
This may have caused the observed differences in crystallization, where bigger needle-shape
crystals (characteristic to form III148) and their clusters formed on the unaltered surfaces
(Figure B.15c), potentially indicating their accelerated formation and/or increased growth
rates. Nevertheless, complete explanation of this unusual observation requires more research.
The intrinsic differences between similarly processed, but differently prepared (fast or slow
melt-quenched) samples appeared to be more straightforward and could be directly related
to the trends observed from the stability studies. More specifically, while ultimately sta-
tistically insignificant (Figure B.13), dissolution tendencies were not inconsistent with these
results as slow melt-quenched uncompressed phases displayed slightly better apparent disso-
lution characteristics when compared to the fast melt-quenched ones that also coincided with
the fact that fast melt-quenching preparation method yielded samples with a lower physi-
cal stability (Figure 3.13). On the other hand, compacts of slow melt-quenched amorphous
celecoxib phases exhibited more pronounced sensitivity to compression-induced destabiliza-
tion that likely manifested in reduced dissolution performance. This was directly illustrated
by the relatively shorter crystallization onset times observed from the LFR data (Table 3.1;
Figure B.13d).
Figure 3.15: Interplay between different (potential) factors affecting the
dissolution behavior of compressed melt-quenched amorphous celecoxib
phases. Reproduced from Bērziņš et al. 178 with permission from the Amer-
ican Chemical Society.
The resultant change in dissolution behavior of these samples was regarded as an interplay
between various factors that may affect the process differently and exhibit mixed significance
(Figure 3.15). While it is unlikely that the observed unusual positive effect of compression on
the dissolution characteristics is compatible with current pharmaceutical manufacturing due
to the unique nature of the studied samples, its adverse effect can potentially cause serious
ramifications. The obtained results imply that the preparation method of an amorphous API
can be influential in ensuring desired product performance, and, for example, could be of high
importance for procurement of extruded, spray-dried or freeze-dried amorphous particles that
are formulated into capsules or tablets.
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3.3.5 Significance
This work highlights the complex nature of compression-induced destabilization in pharma-
ceutical glasses. Both DSC and LFR spectroscopy allowed rapid evaluation of the destabi-
lizing effect in the supercooled state. Dynamic DSC measurements provided information on
overarching changes (encompassed a response linked to the formation of multiple crystalline
forms), while LFR spectroscopy granted an avenue to look at the impact of compression
in relation to a specific polymorph crystallization. Based on our results, both approaches
have a strong potential for broader utilization in the future. Additionally, similar trends to
compression-induced destabilization in the supercooled state were observed in both dry and
humid (stressed) storage conditions. This may be an indication that a quick screening can
be used as a basis for evaluating (and potentially predicting) the effect of compression for
a broader range of conditions that can also help in formulation development. Furthermore,
to the best of our knowledge, this is also the first application of LFR spectroscopy for a di-
rect analysis of coalescent API units during the dissolution process. The limited interference
from the dissolution media as well as the technique’s intrinsic high sensitivity for detecting
structural changes in the solid-state allowed elucidation of the (subtle) differences in the dis-
solution performance between different sample types, and could be further applied to similar
analyses of multi-component formulations, including commercial solid dosage forms. The
signal enhancement from the LFR region allows recording of high quality data in very short
time-scales (≤1 s), and, ultimately, grants access for monitoring fast processes otherwise
inaccessible via other analytical techniques.
3.4 Conclusion
The effect of compression, an important pharmaceutical processing step for the manufacture
of solid dosage forms was investigated in relation to the physical stability and dissolution
performance of melt-quenched amorphous celecoxib samples. Different applied compression
pressures (125-500 MPa) and dwell times (0-60 s) destabilized the amorphous celecoxib sam-
ples (i.e., reduced their physical stability) when monitored in the supercooled state or kept
under dry (∼20 °C; <5% RH) and humid (∼20 °C; 97% RH) storage conditions. This effect
propagated faster crystallization of the samples that was dependent on the severity of the
used compression parameters, where even pharmaceutically relevant tableting parameters
showed potential for lowering the physical stability of the disordered system. Furthermore,
the extent of this effect was also impacted by the utilized cooling rate during the procurement
of the amorphous phases, where slow melt-quenched samples generally exhibited higher sensi-
tivity to compression-induced destabilization. During the long-term stability studies, a high
variation in the surface crystallization behavior was also observed for individual compacts.
More specifically, solid-state transformations were found to be much more rapid toward the
edges/side surfaces when compared to the central domain. This phenomenon was rationalized
on the basis of other recent studies, which have attributed the aforementioned differences to
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the disparities in the shear stress experienced by these areas during compaction.
Preparation (melt-quenching) method and compression were also found to have a com-
bined effect on the dissolution behavior of these disordered systems. Overall, although com-
pression caused a surprising positive effect on the dissolution characteristics, which was at-
tributed to increased surface area due to biaxial fracture as well as potentially favorable
particle/surface morphology, the sensitivity to compression-induced destabilization still ap-
peared to govern the extent of this effect. In other words, slow melt-quenched samples
displayed hampered dissolution performance when compared to fast melt-quenched ones due
to the higher susceptibility to compression-induced destabilization. Nevertheless, future work
is necessary to elucidate this phenomena in more detail, especially in relation to performance
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Greg Walker who not only gave valuable feedback for the study, but also provided access to a
large number of excipients for us to explore, which were otherwise unattainable in a timely
manner due to the world-wide Covid-19 pandemic.
4.1 Introduction
This thesis chapter continued the investigation into compression-induced destabilization phe-
nomenon and explored some potential strategies for mitigating this negative effect by in-
corporating various polymer-type excipients within the melt-quenched amorphous celecoxib
formulations.
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It is well known that addition of polymer, especially with a high glass transition tem-
perature (Tg), has the potential of stabilizing the amorphous form of a drug via the an-
tiplastization effect.198 However, Tg can be an unreliable predictor of the physical stability
of amorphous solid dispersions (ASDs), and, instead, engineering of specific drug-coformer
intermolecular interactions such as hydrogen or ionic bonding can serve as a better formu-
lation strategy.18,23,46 This can also help to improve other aspects of the formulation, e.g.
by reducing the amount of co-former and other excipients necessary to ensure optimal per-
formance, such as lowering of the pill burden or enabling manufacturing of the amorphous
product using specific methods.199 The selection of model polymers for this study was based
on several factors. Most notably, potential candidates were narrowed down based on an exten-
sive literature survey with added scrutiny on their general use. Polyvinylpyrrolidone (PVP)
has been shown to hydrogen bond with celecoxib through the interaction of sulfonamide and
carbonyl moieties of the drug and the polymer, respectively.200,201 Xie and Taylor showed
that PVP/vinyl acetate copolymer (PVP/VA) also forms similar interactions with celecoxib,
however, while their strength appeared to be similar, the fraction of the drug involved in
hydrogen bonding with the polymer was decreased, and was attributed to a “diluting effect”
of the VA monomeric unit.201 In the same study, hydroxypropyl methylcellulose (HPMC)
was shown to exhibit no specific interactions with this particular drug, which made this poly-
mer an excellent “control” for comparison with PVP and PVP/VA.201 It was hypothesized
that a presence of more favorable intermolecular interactions within ASDs may decrease the
susceptibility of celecoxib to compression-induced destabilization.
Figure 4.1: Molecular structures of (a) polyvinylpyrrolidone (PVP), (b)
polyvinylpyrrolidone/vinyl acetate copolymer (PVP/VA), and (c) hydrox-
ypropyl methylcellulose (HPMC).
The hypothesis was tested by preparing celecoxib ASDs with different HPMC, PVP/VA
and PVP content (1, 5 and 10% w/w) using melt-quenching and compression of the melt-
quenched samples at two different conditions: 125 MPa with minimal dwell time and 500
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MPa with 60 s dwell time to represent pharmaceutically relevant and extreme conditions,
respectively. For the analysis, LFR spectroscopy and DSC were primarily employed, which
allowed to quickly identify potential changes by monitoring the behavior of the samples
in a broad temperature range, including the supercooled state. Additionally, the recorded
variable-temperature LFR data prior to the crystallization event allowed to probe the in-
trinsic molecular dynamics of the samples, including the secondary or local glass transition




Celecoxib, form III (MW = 381.37 g/mol) was purchased from AK Scientific, Inc. (Union City,
CA, USA). Hydroxypropyl methylcellulose (HPMC; MW ≈17000 g/mol), polyvinylpyrroli-
done/vinyl acetate copolymer (PVP/VA; Kollidon VA 64; MW ≈30000-45000 g/mol), and
polyvinylpyrrolidone (PVP; Plasdone K-25; MW ≈24000 g/mol) were purchased from Sigma
Aldrich (St. Louis, MO, USA), BASF (Ludwigshafen, Germany) and ISP Tech, Inc. (Wayne,
NJ, USA), respectively. The particular grades of the polymers were used to retain similar
or at least comparable molecular weight characteristics between them. Prior to preparing
amorphous solid dispersions or physical mixtures (see below), appropriate quantities of each
of the polymers were dried under vacuum (inside a desiccator containing fresh silica gel) at
room temperature (∼20 °C) for at least 72 h to minimize the sorbed water content.
4.2.2 Preparation and compression of amorphous celecoxib disks
Amorphous celecoxib or celecoxib-polymer disks (flat-faced; ∼8 mm diameter; ∼1 mm thick)
were procured using a similar approach as described in the Chapter 3. In short, 50 mg of
a pure celecoxib powder or a homogenous amorphous powder mixture containing a desired
ratio of celecoxib and polymer (HPMC, PVP/VA or PVP) was placed inside a silicone mold,
heated up to ∼170 °C, held at the temperature for about 30-45 s and quickly cooled using
the surface of an aluminum heat sink immersed in an ice bath. The homogeneity of the
amorphous celecoxib-polymer mixtures prior to melt-quenching was ensured by using a sol-
vent evaporation method, where 1.000 g of an appropriate ratio of celecoxib and polymer
was dissolved in 50 mL ethanol and dichloromethane solvent mixture (1:1 ratio) that was
subsequently removed at 40 °C under reduced pressure. The obtained powder was ground
using a mortar and pestle, and dried for at least 24 h under vacuum in a desiccator containing
silica beads.
The compression was carried out using stainless steel die and punches (8 mm diameter),
in a hydraulic press (PerkinElmer Inc., Waltham, MA, USA), applying two different com-
pression conditions (125 MPa minimal dwell time and 500 MPa 60 s dwell time), representing
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pharmaceutically relevant and extreme scenarios, respectively. For the DSC, ATR-FTIR and
LFR/VTLFR analysis, disks (uncompressed or compressed) were cut in smaller pieces using
a tablet splitter equipped with a stainless steel blade, and were analysed immediately upon
preparation.
4.2.3 Preparation of celecoxib-polymer physical mixtures
For comparison purposes, a series of amorphous celecoxib and the respective polymer (PVP,
PVP/VA or HPMC) physical mixtures were prepared by geometric dilution and analyzed
using LFR and ATR-FTIR spectroscopy. A larger amount of amorphous celecoxib powder
was obtained using a similar approach as described in Chapter 3. Briefly, approximately 2 g
of the crystalline drug was placed inside an aluminum foil pan, heated to about 170 °C and
held at that temperature for 1-2 min until a clear liquid with no observable opaque/crystalline
regions was observed. The melted phase was quickly transferred to an aluminium heat sink
immersed in an ice bath. This resulted in formation of a thin, glassy layer, which was gently
ground using mortar and pestle until a fine powder was obtained.
4.2.4 Low-frequency Raman (LFR) spectroscopy
Raman spectra were collected using a home-built setup with an excitation source from a 785
nm laser module (Ondax Inc., Monrovia, CA, USA), which was filtered by BragGrate band-
pass filters (OptiGrate Corp., Oviedo, FL, USA) to remove amplified spontaneous emission
from the laser. A THMS600 variable temperature stage with LNP95 liquid nitrogen cooler
(Linkam Scientific Instruments Ltd, UK) was used to mount the sample (horizontally), which
was placed inside an aluminum pan. Backscattered light was collected and filtered through
a set of volume Bragg gratings (Ondax Inc., Monrovia, CA, USA) and focused into a LS
785 spectrograph (Princeton Instruments, Trenton, NJ, USA) via a fiber-optic cable. The
light was dispersed onto a CCD detector (PIXIS 100 BR CCD, Princeton Instruments, Tren-
ton, NJ, USA) and the data were calibrated using sulfur, 1,4-bis-(2-methylstyryl) benzene
(BMB), and toluene and acetonitrile solvent (1:1) standards. Spectra were collected at room
temperature (∼20 °C) over the spectral window -360 to 2030 cm-1 with 5-7 cm-1 resolution.
Each spectrum was averaged from 60 scans with an integration time of 1 s, and the sample
spot size was approximately 500 µm.
4.2.4.1 Variable temperature low-frequency Raman (VTLFR) spectroscopy
Raman spectra for the VTLFR measurements were collected using the same principal setup
as for the general LFR analysis. The temperature program for each specimen consisted of two
distinct steps. Initially, each sample was rapidly cooled to -150 °C, held at that temperature
for 3 min to ensure sufficient time to reach thermal equilibrium and then gradually heated
to 140 °C with a heating rate of 10 °C/min. Afterwards, the sample was held at 140 °C for
additional 30 s and then cooled to 20 °C with a cooling rate of 20 °C/min. The data collection
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was carried during the both heating and cooling stages of the temperature program to fully
monitor the transformation process, and each spectrum was averaged from 10 scans with an
integration time of 0.1 s. The time-spatial linear correlation of a specific recorded spectrum
(frame) to a temperature condition was established by manually recording the readings across
multiple runs/samples.
4.2.5 Attenuated total reflectance-Fourier transform infrared (ATR-FTIR)
spectroscopy
ATR-FTIR spectra were recorded on a Bruker VERTEX 70 FTIR spectrometer (Bruker
Optics, Ettlingen, Germany) fitted with a GladiATR diamond ATR accessory (Pike Tech-
nologies, Madison, WI, USA). Each spectrum was the result of 128 coadded scans over 50-4000
cm-1 at a 1 cm-1 spectral resolution.
4.2.6 Differential scanning calorimetry (DSC)
A differential scanning calorimeter (Q2000, TA Instruments, New Castle, DE, USA) equipped
with a refrigerated cooling accessory was used. The instrument was calibrated with indium.
In general, about 5-7 mg of sample was sealed in an aluminium pan (TA Instruments, New
Castle, DE, USA) and heated at 10 °C/min, from -90 to 200 °C under constant nitrogen
purge (50 mL/min). The data analysis was carried out using TRIOS 5.1.1 software package
(TA Instruments, New Castle, DE, USA).
4.2.7 Data pre-processing
The LFR spectra were converted from .spe to .spc file format, whereas ATR-FTIR spectra
were converted from .0 (OPUS) to .csv file format using SpectraGryph 1.2.14. The pre-
processing was carried out on the raw Raman data to remove cosmic spikes (≤3 pixel wide),
whereas the ATR-FTIR spectra were denoised using the Savitsky-Golay (SG) derivation
tool (medium setting). Additionally, for LFR spectra, linear baseline correction was applied
in the range of -300 to 300 cm-1 using The Unscrambler X 10.4 (CAMO, Oslo, Norway).
Furthermore, for selected LFR non-isothermal kinetic data (>70 °C) used to elucidate the
crystallization behavior of the samples, scale and scattering variation were amended using
standard normal variate (SNV) transformation in the same software, where contribution
from Rayleigh scattering for the LFR region was excluded (-15 to 15 cm-1). Baseline offset
correction was also applied to these data using the same software to bring all variables above
zero for the chemometric analysis.
4.2.8 PCA details
PCA was performed on the pre-processed data using The Unscrambler X 10.4 (CAMO,
Oslo, Norway) software. Two different sets of VTLFR data were analyzed independently
(below and above 70 °C) to elucidate the molecular dynamics (including the determination of
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primary/global glass transition temperature; Tg or Tg,α and secondary/local glass transition
temperature; Tg,β) and crystallization behavior of the samples. In all instances, contributions
from the Rayleigh scattering (-15 to 15 cm-1) were excluded from the analysis whether or not
SNV correction was applied during the data pre-processing step.
4.2.9 Statistical analysis
Where applicable, one-way analysis of variance (ANOVA) and T-tests were performed using
the data analysis tool in MS Excel 2016 (Microsoft Corp., Redmond, WA, USA) software
with a confidence level of 95% (p<0.05).
4.3 Results and discussion
4.3.1 Exploratory analysis
The melt-quenched celecoxib and celecoxib-polymer dispersions were all found to be amor-
phous based on the Raman data exhibiting a broad low-energy vibrational density of states
(VDOS) feature characteristic to disordered moieties. A set of representative LFR data for
these samples are presented in Figure 4.2a alongside their DSC curves (Figure 4.2b), whereas
the respective MFR data are shown in Appendix C (Figure C.1).
Figure 4.2: Examples of (a) LFR spectra and (b) DSC curves for melt-
quenched amorphous celecoxib as well as celecoxib-HPMC, celecoxib-
PVP/VA and celecoxib-PVP ASDs with 10% w/w polymer loading (DSC
inset shows crystallization followed by melting in PVP ASD). The laserline
(Rayleigh scattering) is omitted for clarity.
In all instances, Raman data showed only subtle differences with the biggest change ob-
served <100 cm-1 manifesting as slight VDOS shifts and shape changes. The MFR region,
which was dominated by celecoxib spectral features (in contrast to the IR fingerprint data,
which showed significant changes and was therefore used to characterize intermolecular in-
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teractions within these samples; discussed below), likely resulting from the fact that all of
the used polymeric excipients exhibit very weak Raman scattering propensity in this spectral
range (Figure C.2). Additionally, all of the ASDs exhibited baseline shifts due to the pale yel-
low color characteristic of melt-quenched phases containing PVP or HPMC moieties.199 It is
important to note that these color disparities have been previously attributed to a trace (and
not substantial) levels of degradation below the limit of detection for exact or similar grades
of polymers, when celecoxib ASDs were prepared using similar melt-quenching methodology
as used within this study.199,202,203 DSC data further highlighted the disordered nature of all
of the samples. In amorphous celecoxib, similar to results described in the previous chap-
ter, the Tg (midpoint) was observed at ∼51 °C, followed by crystallization at ∼102 °C and
melting at ∼159, ∼161 and ∼162 °C. However, presence of various polymeric excipients (in
a concentration dependent manner following a rank order of PVP>HPMC≥PVP/VA) not
only improved the physical stability of the amorphous phases as evident by the increased
crystallization onset values (Figure 4.2b) and decreased enthalpies of crystallization (∆Hc;
Table 4.1), but also intrinsically altered the crystallization behavior. In these samples, forma-
tion of the elusive celecoxib form IV was observed with its characteristic lower melting point
(∼146-147 °C) that has previously only been obtained from celecoxib mixtures containing
different excipients, including HPMC and PVP.143 Additionally, all of the ASDs displayed
a single Tg value, indicating proper molecular mixing between both components. This pa-











where w1, w2 and T g,1, T g,2 are weight fractions and glass transition temperatures of com-
ponents 1 and 2, respectively. For the calculations, Tg values for each of the respective
polymer were determined experimentally (Figure C.3) and were in agreement with the liter-
ature.143,205,206
While statistically comparable, the most apparent deviation between calculated and ex-
perimental Tg values was observed in the PVP system (specifically with a polymer loading
of 10% w/w), which also appeared to be the most effective in inhibiting the crystallization
of celecoxib. A stronger drug-polymer interaction is one possible explanation for this obser-
vation. As stated above, PVP is known to strongly hydrogen bond with celecoxib through
the interaction between carbonyl and sulfonamide moieties.200,201 This was also observed in
our melt-quenched samples via the carbonyl band shift in the IR spectra from 1653 to 1659
cm-1 (Figure 4.3c), which also appeared to exhibit smaller overall width in the ASDs. Ad-
ditionally, there was an apparent upshift in the NH peak of celecoxib from 3258 to about
3262 cm-1. It is also important to note that such behavior was seen across all of the explored
PVP concentrations (1-10%). However, while the PVP loading of 1% inhibited some cele-
coxib crystallization based on the slightly reduced ∆Hc values, this particular ASD showed
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pred. exp. onset peak
Celecoxib 0 N/A 50.9 ± 0.1b 103.1 ± 1.9 109.9 ± 0.6 85 ± 2
Celecoxib-
HPMC
1 51.3 52.3 ± 0.2 101.4 ± 1.3 111.2 ± 0.4 71 ± 1
5 52.7 52.8 ± 0.3 109.8 ± 0.2 126.3 ± 0.9 50 ± 3
10 54.7 54.0 ± 0.5 112.0 ± 0.5 128.0 ± 0.1 16 ± 3
Celecoxib-
PVP/VA
1 51.2 50.2 ± 0.8 100.0 ± 0.7 107.9 ± 1.0 76 ± 1
5 52.2 52.0 ± 0.4 107.9 ± 0.5 118.9 ± 1.3 75.5 ± 0.1
10 53.6 54.3 ± 1.2 116.8 ± 0.1 131.3 ± 0.2 32 ± 5
Celecoxib-
PVP
1 51.3 49.9 ± 1.5 99.1 ± 0.3 106.7 ± 2.2 71 ± 2
5 52.7 52.7 ± 0.4 114.8 ± 0.2 128.6 ± 1.1 47 ± 12
10 54.6 56.8 ± 1.4 117.5 ± 0.2 128.1 ± 1.6 0.7 ± 0.3
aThe enthalpy value has been normalized for the celecoxib content in ASD.
bMean ± standard deviation; n = 2.
a generally inferior physical stability to amorphous celecoxib that could be rationalized on
the basis of increased hydrophilicity of the system. In other words, the hydrophilic nature of
the PVP likely amplified the water uptake during the melt-quenching process that could also
explain the slightly reduced Tg values with respect to the predicted ones, which, in return,
overshadowed the positive effect of molecular mixing between the celecoxib and PVP at this
component ratio. In fact, the same trend was also observed for other ASDs with the lowest
content of PVP/VA and HPMC.
Spectrally, the ASDs containing PVP/VA exhibited more subtle behavior (Figure 4.3b).
The PVP/VA moiety has two types of carbonyl groups originating from polyvinylpyrrolidone
and acetate, with characteristic peaks displayed here at 1657 and 1730.5 cm-1, respectively.
While the amplitude of changes was smaller, both carbonyl bands were upshifted by ∼3-4
cm-1 in the ASDs. Additionally, there was a formation of a new shoulder peak at ∼1718 cm-1,
which, considering the general molecular flexibility of PVP/VA, could be a result of formation
of some cross-linked moieties. Nevertheless, the higher frequency region still showed similar
behavior to the celecoxib-PVP system, with the NH peak exhibiting comparable wavenumber
shifts. These results indicate that while the nature of these intermolecular interactions was
similar to the ones observed in the ASDs containing just PVP, their characteristics were
different. Xie and Taylor 201 attributed similar observations to a decrease in the fraction
of drug molecules involved in the hydrogen bonding with their strength being unaltered.
However, without additional/more specific analysis, the change in strength of the interactions
should still be considered as plausible in this scenario due to the generally high difficulty in
distinguishing such discrepancies.23
Lastly, celecoxib-HPMC ASDs displayed the least pronounced spectral differences between
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Figure 4.3: IR spectra of (a) celecoxib-HPMC, (b) celecoxib-PVP/VA and
(c) celecoxib-PVP systems, including their physical mixtures (PMs) and
individual components in the amorphous state. The polymer concentra-
tions are expressed as % w/w.
individual components and their physical mixtures to the respective ASDs (Figure 4.3a),
indicating a much weaker interaction between both components in the melt-quenched phase.
This observation was in agreement with previous results where only subtle changes in the
IR spectra were noted for similar formulations.201 HPMC lacks carbonyl functional groups
(strong hydrogen bond acceptors) that are observed in PVP and PVP/VA polymers, but has
other, weaker acceptors such as hydroxyl or ether groups. Hence, if present, the strength of
such intermolecular interactions should be comparable to the ones in amorphous celecoxib
matrix between the drug moieties, and, thus, the stabilization effect of HPMC on celecoxib
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can be mainly attributed to its substantially high Tg value (∼160 °C).
4.3.2 Effect of compression on the physical stability of celecoxib ASDs
The procured samples offered a great variety of differently stabilized amorphous celecoxib
phases to be evaluated for their sensitivity to compression-induced destabilization. As with
previous results (Chapter 3), no evidence of direct crystallization was observed for the com-
pressed samples based on the analysis of LFR data. However, their thermal behavior was
significantly altered upon compression, an effect that was dependent not only on the ap-
plied compression parameters (i.e., pressure and dwell time), but also the composition of
the samples (i.e., polymer type and content). Here, DSC allowed for quick identification of
these changes, examples of which are illustrated in Figure 4.4, whereas a summary of the key
results is presented in Figure 4.5.
Although the Tg values of the amorphous celecoxib phases were largely unaffected by
the compression, there was an apparent change in the crystallization onset temperature and
enthalpy of crystallization for the majority of samples. This observation served as direct ev-
idence for compression-induced destabilization, a likely consequence of increased propensity
for surface nucleation.4,27 In amorphous celecoxib, these changes were practically identical
to the ones observed previously (Chapter 3), where the applied compression conditions re-
duced the onset of crystallization by 3-4 °C while the enthalpy of crystallization remained
constant (∼85 J/g representing a maximally crystallized celecoxib phase). Interestingly,
the amplitude of these changes varied within the ASDs. The formulations with the low-
est polymer concentration displayed similar behavior to the amorphous celecoxib, indicating
that such small polymer content was not capable of significantly changing the bulk prop-
erties of these amorphous samples. On the other hand, a higher polymer content in the
ASD introduced some substantial disparities. For example, 5% w/w polymer formulations
were sensitive to compression-induced destabilization regardless of the utilized compression
parameters, whereas all of the 10% w/w polymer formulations showed resistance against
pharmaceutically relevant compression conditions. However, this effect could not be corre-
lated to the strength or extent of drug-polymer interactions as initially hypothesized, but,
rather, appeared to be only dependent on the polymer concentration. Some studies have
suggested that in these instances the polymer acts as a physical barrier, which can reduce
the probability for contact between the drug molecules during the compression (i.e., potential
for nucleation).4,171 Our results further elucidated on this with an added caveat that higher
stabilization from a specific co-former may require higher concentrations to diminish suscep-
tibility to compression-induced destabilization. This was clearly evident by comparing data
of celecoxib-PVP ASDs to the other formulations, where compression caused a more sub-
stantial relative decrease in physical stability. Similarly, the sucrose-PVP system has been
shown to exhibit comparable characteristics in the literature, where a low polymer content
(1-4% w/w) significantly improved the physical stability of sucrose in the amorphous phase,
but was incapable of providing protection against compression-induced destabilization using
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Figure 4.4: Overlay of representative DSC curves for differently processed
(uncompressed or compressed) phases of amorphous celecoxib and cele-
coxib ASD samples. The arrows denote the change in the recrystallization
behavior of the samples with more severe applied compression conditions.
150 MPa pressure and 5 s dwell time. In this example, the relative extent of destabiliza-
tion (i.e., the change in the onset crystallization temperature from DSC measurements) was
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also far greater than in amorphous sucrose (∼10 vs ∼3 °C), and 15% w/w loading of PVP
was necessary to completely inhibit this negative effect (at least for the particular compres-
sion conditions used).4 This is an interesting interplay that warrants further investigation
for a larger variety of different drugs and co-formers as it can have direct implications for
formulating robust amorphous pharmaceutical drug products.
Figure 4.5: DSC results of (a) crystallization onset temperatures and (b)
normalized enthalpy of crystallization values for differently processed (un-
compressed or compressed) amorphous celecoxib and celecoxib ASD sam-
ples. Asterisks (*) denote a significant (p<0.05) difference between the
particular response of the compressed sample and the respective control
(i.e., uncompressed amorphous celecoxib or celecoxib ASD). Data repre-
sents the mean ± standard deviation; n = 2.
LFR spectroscopy was used to further elucidate this phenomenon. However, the large
disparities in the physical stability of these amorphous phases did not allow the selection of
common isothermal conditions (as used in Chapter 3) that could be employed for monitoring
the crystallization kinetics within rational timescales. Thus, dynamic, non-isothermal LFR
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measurements were carried out in a broad temperature range (-150 to 140 °C) using the
same heating rate as in the DSC analysis (10 °C/min). While this approach complicated
the data analysis due to a much more intricate signal responses (i.e., crystallization of solid-
state form mixtures as observed in the DSC), it enabled some additional information to be
extracted from the dataset. More specifically, as certain LFR domains (for example, quasi-
elastic scattering) also encompass information related to molecular mobility among other
properties (see section 1.2.1.1), it was possible to simultaneously probe molecular dynamics
within these samples.
Figure 4.6 shows representative VTLFR spectra for amorphous celecoxib and highly sta-
bilized celecoxib-PVP 10% ASD in a broad temperature range before any crystallization.
The subtle spectral changes warranted a careful analysis of the data. Although it is possible
to extract various components from the VDOS using certain manipulations and/or fitting
procedures (see section 1.2.1.1), we opted to use PCA to limit the pre-processing of the data,
largely due to the fact that many of the multi-component samples exhibited some fluorescent
background signature, which, as evident in Figure 4.6b, intertwined with the temperature-
dependent VDOS dynamics. Overall, this approach proved successful in providing the desired
information for at least part of the samples, when PCA was applied to each dataset individ-
ually (data normalization and subsequent combined analysis was not feasible here without
compromising data integrity). An example of this type of analysis is presented in Figure 4.6c,
where PC1 resolved the majority of the variance related to intensity-based differences (Fig-
ure C.4), but did not show any distinguishable trends, and, hence, was not used. On the
other hand, PC2 loadings (Figure C.4) showed more subtle discrepancies, especially in the
VDOS shape below 100-150 cm-1 and displayed a strong temperature dependance, especially
in the temperature range of -70 to -40 °C (midpoint around -57 °C) and above 40-50 °C.
These domains were attributed to the secondary/local glass transition temperature; Tg,β and
Tg or Tg,α, respectively. Here, the ability to detect Tg,β is particularity interesting as this
parameter has been shown to directly correlate with crystallization potency of amorphous
drugs, but is hard to be determined using conventional analytical techniques, including DSC
(Figure 4.2). Kissi et al. 15 used dynamic mechanical analysis (DMA) for analyzing this pa-
rameter in a range of neat amorphous drugs, including celecoxib, which showed a broad (∼50
°C) β-relaxation with its peak ranging from about -80 to -60 °C among triplicate measure-
ments. The disparities in the observed values between the LFR and DMA data is a likely
consequence of the different measuring techniques as in the same study, Tg,α for most of the
drugs showed a deviance for up to 15-20 °C when compared to “normally” observed values us-
ing, for example, DSC. Thus, considering that in our LFR data Tg,α was observed at the same
temperature as in DSC, the differently recognized Tg,β is not a surprising result. It is also
important to note that the examined ASDs showed similar Tg,β values, which was expected,
considering that Tg,β has been shown to correspond to the motions of a single component,
even in molecularly mixed systems, where the excess component (in this case, celecoxib) is
typically seen.207 Additionally, there was no apparent change in Tg,β values for compressed
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samples regardless of the composition and applied compression conditions. This could indi-
cate the lack of sensitivity for this parameter to detect an increase in nucleation propensity
within amorphous matrix that was assumed to be the cause for the reduced physical stability
of compressed samples.
Figure 4.6: Examples of raw VTLFR data in the range of -150 to 70 °C
for (a) amorphous celecoxib and (b) celecoxib-PVP 10% ASD, and (c)
subsequent PCA with PC2 scores versus the temperature illustrating the
molecular mobility changes within these samples (the respective loadings
plots are presented in Figure C.4). The highlighted region in the VTLFR
data of celecoxib-PVP 10% ASD sample denotes an isosbestic point re-
sulting from an interplay between the dynamic, temperature-dependent
VDOS changes and the intrinsic baseline originating from the pale yellow
color of the melt-quenched phase.
Interestingly, physical mechanisms governing the molecular mobility in the glassy and
deeply glassy states are still debated208 and the use of such LFR measurements could be of
great interest to elucidate these processes. However, while LFR can offer certain advantages
such as the generally high signal from the VDOS as well as limited interference from water
when compared to, for example, THz absorption spectroscopy that has also been successfully
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used to detect such subtle changes in the amorphous matrix,209 a more robust LFR data
analysis framework needs to be developed for this approach to become widely applicable.
For example, while interference from the fluorescence could potentially be diminished with a
better spectral data quality (here, the emphasis was put on fast data collection to achieve the
best temperature resolution for detecting the more pronounced crystallization event) and/or
the use of a longer wavelength laser, this may not always be possible. Additionally, this aspect
can not only limit analysis of multi-component systems, but also drugs themselves as some
compounds (for example, indomethacin) are known to exhibit certain color characteristics in
the amorphous state.27
Although the transformation to crystalline phases was spectrally more distinct among the
samples than the discrepancies in the lower temperature range, characterization of celecoxib
crystallization via VTLFR measurements still proved challenging due to the aforementioned
formation of a variety of solid-state forms and the presence of these forms as mixtures; a
process that was equally dependent on the polymer type and its content as observed in
DSC measurements (Figure 4.4). However, this aspect also allowed the characterization of
lesser understood celecoxib polymorphs such as form IV that predominantly crystallized from
celecoxib-HPMC ASDs with an increased polymer content (≥5% w/w). In fact, this could
potentially serve as an avenue to obtain a pure form IV and help complete its structural
characterization, which has not yet been achieved. A representative LFR spectrum of this
solid-state configuration (embedded in an amorphous matrix) at room temperature (20 °C)
is shown in Figure C.5, where distinct and unique features at 25.5, 38, 56, 69, 125, 148 and
165 cm-1 can be observed, some of which were vastly different from the ones characteristic
of, for example, the thermodynamically stable form III.
An example of the PCA for comparing the crystallization behavior among the various
formulations is shown in Figure 4.7, where the results for the same, differently stabilized
samples of amorphous celecoxib and celecoxib-PVP 10% ASD are highlighted. Here, even a
simple visual inspection revealed substantial disparities in the physical stability between the
samples that were further accentuated by the chemometric analysis. Similar to the analysis of
VTLFR data collected in the lower temperature range, PC1 appeared to explain the variance
related to overarching VDOS changes with increasing temperature. However, PC2 distin-
guished the signatures of crystalline and amorphous celecoxib moieties that were depicted in
the negative and positive PC space, respectively, and showed a clear trend of change with
increasing temperature for the majority of samples; a transition that was attributed to the
crystallization event (Figure 4.7c). As the particular PCA was carried out on all data sets
simultaneously, a direct, more quantitative comparison between all the samples was possible
(Figure 4.8). Specifically, the onset of crystallization was determined as an intersection point
between two lines as illustrated in the inset of Figure 4.7c. Although the general trends
were similar to the ones observed in the DSC data, some discrepancies were noted. Most im-
portantly, LFR data generally showed a higher crystallization onset values as illustrated in a
correlation plot (Figure C.6). This could indicate the inferior sensitivity of LFR spectroscopy
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Figure 4.7: Examples of raw VTLFR data in the range of 70 to 140 °C for
(a) amorphous celecoxib and (b) celecoxib-PVP 10% ASD, and subsequent
PCA with (c) PC2 scores versus the temperature illustrating the solid-
state changes (or lack thereof) within these samples, and (d) the respective
loadings plot of PC2. The grey colored data-points in the PC2 scores image
represent rest of the analyzed samples for a visual reference.
for detecting such changes, especially considering that, unlike DSC, LFR was unable to detect
solid-state form transformations in certain amorphous systems (for example, uncompressed
celecoxib-PVP 10% ASD samples).
4.3.3 Significance
Nowadays, a variety of amorphous formulations of drugs is being more frequently exploited to
improve the physicochemical characteristics of a pharmaceutical drug product. However, the
impact of processing-induced stresses such as compression on the physical stability of amor-
phous phases has not received adequate attention. In this closing chapter of a three-part
study, compression has been shown to have a pronounced effect on all of the investigated
celecoxib ASDs regardless of the intermolecular interactions present within the respective
amorphous phases. Although our initial hypothesis of more favorable intermolecular interac-
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Figure 4.8: LFR results of crystallization onset temperatures for differ-
ently processed (uncompressed or compressed) amorphous celecoxib and
celecoxib ASD samples. Asterisks (*) denote a significant (p<0.05) differ-
ence between the particular response of the compressed sample and the
respective control (i.e., uncompressed amorphous celecoxib or celecoxib
ASD). Data represents the mean ± standard deviation; n = 2.
tion mitigating the compression-induced destabilization was disproved, the results highlighted
an interesting aspect that warrants further investigation for a larger variety of amorphous
drug systems: finding the balance between the stabilization effect brought by the co-former
and its content necessary to prevent compression-induced destabilization could prove an in-
teresting challenge for formulation scientists. Additionally, to the best of our knowledge,
this is the first instance, where the capabilities of LFR spectroscopy for determining the
secondary/local glass transition temperature or Tg,β have been highlighted. Hopefully, these
findings will encourage even broader utilization of this spectroscopic technique within the
pharmaceutical research community, especially considering that further work towards estab-
lishing a more nuanced LFR data handling protocols for this type of analysis is necessary for
the method to become easily applicable.
4.4 Conclusion
This study investigated compression-induced destabilization in pharmaceutical ASDs using
celecoxib as the model drug, and HPMC, PVP/VA and PVP as the polymeric co-formers.
A detailed analysis of these systems containing varied polymer content (1-10 % w/w) was
carried out primarily using DSC and LFR spectroscopy. The effect of the applied pharma-
ceutically relevant (125 MPa pressure and minimal dwell time) and extreme (500 MPa pres-
sure and 60 s dwell time) compression conditions was evaluated by means of non-isothermal
kinetic analysis, primarily focused on the crystallization behavior of these samples in the
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supercooled state. From this data, clear differences in the intrinsic physical stability of the
samples were noted, where PVP offered the best stabilization of celecoxib, followed by HPMC
and PVP/VA. Each of the systems exhibited different intermolecular interactions between
the celecoxib and polymer moieties, however, these appeared to not play a major role for
inhibiting compression-induced destabilization. Instead, only the polymer content, in a con-
centration dependent manner, was found to negate this undesired destabilization effect. A
direct comparison between the DSC and LFR data further confirmed this finding as similar
trends were observed using both techniques. However, DSC exhibited superior sensitivity to
detect solid-state transformations and, thus, has a higher potential to reveal destabilization
immediately after product manufacture. Nevertheless, LFR spectroscopy could still provide
useful complimentary information within a framework of multi-modal characterization of
amorphous pharmaceutical systems, especially considering that this method showed poten-
tial for detecting subtle discrepancies related to molecular mobility, an aspect that could also
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5.1 Introduction
A non-intrusive multi-dimensional analysis can be useful in many pharmaceutical applica-
tions, especially for the analysis of solid dosage forms, where spatial information using con-
ventional analytical methods can typically only be obtained after destructive manipulations
with samples prior or during the measurements.210 Several recent studies have highlighted the
hetero-spatial nature of solid-state transformations on the surfaces of pharmaceutical tablets
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and its potential implications.27,210 The presence and severity of these changes (i.e., the
quantitative extent of transformations) can alter the appearance of the solid dosage form,
affect its physicochemical properties and ultimately result in product failure. Considering
that such solid-state transformations (propagated by different environmental factors) usually
proceed toward the core of the tablet, the information on the inner and outer layer structures
such as their thickness and composition can be especially valuable, for example, to assess
the process kinetics. Additionally, it can potentially allow for validation of the manufactures
specifications of multi-layer or coated solid dosage forms.
This project was focused on developing and exploring potential applications of a new
Raman subtechnique (spatially/micro-spatially offset low-frequency Raman spectroscopy;
SOLFRS/micro-SOLFRS) by combining LFR with already established spatially offset Raman
spectroscopy (SORS).211,212 In this technique, unlike the traditional Raman spectroscopy
approaches, spatial offset is created between the laser irradiation spot and collection point
of the scattered light, where the mean photon penetration depth increases with increasing
spatial offset. This phenomena enables nondestructive subsurface data collection from differ-
ent objects, including drug containers213 and various tissues (for example, bone).214 It has
also been explored for cancer diagnostics and assessment of blood quality in the transfusion
bags.215 However, application of SORS present certain challenges, one of which is the com-
promised Raman spectra quality upon large spatial offsets used to analyse deeper subsurface
zones, where the absolute signal propensity is typically very low. It was hypothesized that
the unique nature and generally higher scattering propensity of LFR regime could help to
address some of these shortcomings.
As a proof of concept study, a number of different tablet formulations were investigated
containing celecoxib as the primary model drug with lactose (the stable anhydrous and mono-
hydrate form) and polyvinylpyrrolidone (PVP) serving as the primary excipients. Addition-
ally, two different instrumental setups were assembled for the analysis of these tablets that
differed on how spatial offset between laser irradiation spot and collection point of the scat-
tered light was attained. This approach allowed for the exploration of both basic and ad-
vanced capabilities of SOLFRS ranging from a simple detection of the target subsurface layer




Celecoxib, form III (MW = 381.37 g/mol) was purchased from AK Scientific, Inc. (Union
City, CA, USA). α-Lactose monohydrate (MW = 360.31 g/mol) and polyvinylpyrrolidone
(Plasdone K-25; MW ≈24000 g/mol) were purchased from Ajax Finechem (Albany, New
Zealand) and ISP Tech, Inc. (Wayne, NJ, USA), respectively.
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5.2.2 Preparation of lactose anhydrous stable form
This solid-state configuration of lactose was prepared by adapting a previously described
methodology.216 In short, ∼50 mg of α-lactose monohydrate were thinly spread inside a
quartz sample holder and heated at 160 °C for 5 min using a THMS600 variable temperature
stage with LNP95 liquid nitrogen cooler (Linkam Scientific Instruments Ltd, UK) under
nitrogen atmosphere. The formation of the desired solid-state form was confirmed by mid-
frequency Raman data comparison with the literature.217
5.2.3 Tablet preparation and analysis
For the preparation of bilayer tablets (200 mg) for SOLFRS analysis, two components of
different proportion (either celecoxib form III and α-lactose monohydrate or PVP; see Ta-
ble D.1) were used to ensure varied, but comparable layer thicknesses. Additionally, reference
tablets (200 mg) of single components and their homogenous mixtures (1:1 ratio; mixed us-
ing a mortar and pestle) were prepared to verify the results procured from the chemometric
analysis (see below) of bilayer tablets. The compression was carried out using stainless steel
die and punches (8 mm diameter), in a hydraulic press (PerkinElmer Inc., Waltham, MA,
USA). The first layer (API) was compressed (pre-densified) with a ∼50-75 MPa compression
pressure and minimal dwell time, whereas the final compression was carried out by applying
500 MPa compression pressure and 60 s dwell time to ensure procurement of a robust (non-
fragile) tablet. The tablet thickness was measured using a micrometer. In order to determine
the thicknesses of individual layers, the top and bottom part of each tablet was gently twisted
in opposite directions or slid/pealed (after the Raman measurements), which resulted in at
least a partial break between the layers. For these phases, micrometer readings were recorded
for at least 5 different positions of each individual layer and its thickness (Table D.1) was
presented as an averaged value of these measurements.
The preparation of α-lactose monohydrate tablets for the SOLFRS kinetic analysis was
carried out in a similar manner. These tablets were dehydrated at 160 °C temperature using
a THMS600 variable temperature stage with LNP95 liquid nitrogen cooler (Linkam Scientific
Instruments Ltd, UK) for different time periods (2.5, 5.0, 7.5 and 10 min). After the SOLFRS
measurements, tablets were split using a tablet splitter equipped with a stainless steel blade,
and selected areas within the cross sections were analysed using Raman microscopy.
Bilayer, trilayer and multi-component tablets for micro-SOLFRS analysis (Table D.2)
were prepared using the same general approach. However, while the tablet thickness mea-
surements were recorded a micrometer, individual layer thicknesses for multilayer tablets were
determined from digital imaging data of their cross-sections using an Alpha 300R+ confocal
Raman microscope (10x magnification) controlled with Project 5.1 software (WiTec, Ulm,
Germany). For the exemplary analysis of solid-state form transformations, the homogenous
multi-component tablet was held at 140 °C temperature using a THMS600 variable tem-
perature stage with LNP95 liquid nitrogen cooler (Linkam Scientific Instruments Ltd, UK)
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for 20 min to induce at least partial dehydration of α-lactose monohydrate. Micro-SOLFRS
mapping measurements for this tablet was carried out at room temperature before and after
the experiment over the same areas to enable a direct comparison between the data.
5.2.4 Variable temperature low-frequency Raman (VTLFR) spectroscopy
In order to obtain the reference LFR spectra of the two α-lactose solid-state forms at low tem-
perature conditions for the computational simulations (described below), the same principal
LFR experimental setup was arranged in a downward looking, 180° geometry. A THMS600
variable temperature stage with LNP95 liquid nitrogen cooler (Linkam Scientific Instruments
Ltd, UK) was used to mount the sample (horizontally), which was put inside a quartz sample
holder and kept under nitrogen atmosphere. The desired temperature (-190 °C) was allowed
to stabilize for at least 2-3 min before the Raman measurements, ensuring sufficient time to
reach thermal equilibrium. Each spectrum was averaged from 300 scans with an integration
time of 1 s, and the sample spot size was approximately 500 µm.
5.2.5 Spatially/Micro-spatially offset low-frequency Raman spectroscopy
(SOLFRS/micro-SOLFRS)
Raman spectra were collected using a home-built system utilizing an excitation source from
a 785 nm laser module (Ondax Inc., Monrovia, CA, USA) which was filtered by BragGrate
bandpass filters (OptiGrate Corp., Oviedo, FL, USA) to remove amplified spontaneous emis-
sion before irradiating the sample. Samples were mounted sideways on an XYZ stage com-
prised of three UTS100CC linear motorized platforms (Newport Corp. Irvine, CA, USA).
For SOLFRS measurements, the laser light (∼70 mW) was focused on the sample (ellipsoid
laser spot with a “waist” of ∼500 µm and elongated axis of ∼700 µm) in ∼135° angle relative
to the collection lens - 20x microscope objective (MPLN20X, Olympus Australia Pty Ltd,
Notting Hill, Australia) ensuring ∼0.3 mm2 scattered light collection area of the analyte. To
achieve spatially offset discrimination between the laser irradiation spot and scattered light
collection point, a set of optics were mounted on an XYZ mount that allowed for control of
the vertical position of the laser line (see Figure 5.1a). In order to achieve a maximal spatial
offset range (∆S), data collection were initiated at the upper side of the tablet (∼2 mm from
the top edge) and laser position was gradually altered (i.e., moved downwards toward the
bottom edge of the tablet; ∼2 mm from the bottom edge) to create an increasing spatial offset
with 0.5 mm increments. Additionally, the relative position of optics and sample position
for each spatial measurement were retained the same across all of the analysed samples to
enable a direct comparison between them. However, regular surface measurements as well as
alignment adjustments were carried out by arranging the instrumental setup in a typical 180°
geometry as shown in Figure 5.1b (laser spot size ∼1-2 µm; ∼40-45 mW laser power). This
setup was also used for a low-frequency analogue of micro-SORS (denoted micro-SOLFRS),
where micro-scale spatial offset is achieved through defocusing (sample displacement, ∆Z).160
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Figure 5.1: Schematic of the instrumental setup for (a) spatially offset and
(b) micro-spatially offset low-frequency Raman measurements. Adapted
from Bērziņš et al. 218 with permission from the American Chemical Soci-
ety.
Backscattered light from the sample was collected and filtered through a set of volume
Bragg gratings (Ondax Inc., Monrovia, CA, USA) and focused into a LS 785 spectrograph
(Princeton Instruments, Trenton, NJ, USA) via a fiber-optic cable. The light was dispersed
onto a CCD detector (PIXIS 100 BR CCD, Princeton Instruments, Trenton, NJ, USA)
and the data were calibrated using a sulfur, 1,4-bis-(2-methylstyryl) benzene (BMB), and
a toluene:acetonitrile solvent (1:1 v/v) standards. Spectra were collected over the spectral
window -360 to 2030 cm-1 with 5-7 cm-1 resolution. For a typical measurement, each spec-
trum was averaged from 60 scans with an integration time of 1 s. However, each of the
micro-SOLFRS or SOLFRS measurements were averaged from 30 or 600 scans, respectively,
using the same integration time of 1 s. Additionally, for a typical micro-SOLFRS data col-
lection, 5 replicate measurements were carried out in a “cross-shaped” pattern (2 mm each
direction from the center point of the tablet). On the other hand, spectra for Raman maps
(15 scans with integration time of 0.1 s) were collected over the selected areas (central do-
mains; 2 x 2 mm) for the homogenous tablet in a point by point arrangement using a 50 µm
step size.
5.2.6 Raman microscopy
Selected areas of split α-lactose monohydrate tablets after dehydration experiments (see
above) were analyzed using an Alpha 300R+ confocal Raman microscope (WITec, Ulm,
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Germany). Measurements were carried out with the 532 nm laser and 10x objective (∼1.3
µm spotsize) in mapping arrangement (1500 x 500 µm; 5 µm step size) with a laser power
of 47 mW, spectral range from -56 to 3789 cm-1 and integration time of 0.1 s. Spectra were
obtained using Project 5.1 software (WITec, Ulm, Germany) and analyzed with TrueCom-
ponent analysis tool within the same software environment.
5.2.7 Data pre-processing
The SOLFRS and micro-SOLFRS spectra were converted from .spe to .spc file format using
SpectraGryph 1.2.14, and the data collected in a typical 180° geometry were corrected (where
necessary) by subtracting the small contributions from the microscope objective glass lens us-
ing the scaled subtraction tool. The pre-processing was carried out on the raw data to remove
cosmic spikes (≤3 pixel wide), as well as sources of variation associated with sample focus
and incident laser power. For an in-depth LFR data analysis, linear baseline correction was
applied in the range of -310 to 330 cm-1, and included both anti-Stokes and Stokes spectral
regions. However, for multivariate curve resolution and principal component analysis (see
below), rubberband baseline correction was applied on different spectral regions represent-
ing low-frequency (10-300 cm-1) and mid-frequency (300-1800 cm-1) domains using Orange
Canvas 3.24.1 spectroscopy module (University of Ljubljana, Ljubljana, Slovenia).125 Scale
and scattering variation were amended for the same spectral ranges using standard normal
variate (SNV) transformation in The Unscrambler X 10.4 (CAMO, Oslo, Norway). Baseline
offset correction was also applied to these data using the same software to bring all variables
above zero for the chemometric analysis.
Raman microscopy data (extended C-H stretching region; 2700-3150 cm-1) were pre-
processed using a similar framework, where cosmic spikes were first removed using the cosmic
ray removal (CRR; filter size of 6 and dynamic factor of 4), followed by a baseline correction
using the “shape” background subtraction method (filter size of 300) within Project 5.1
software (WITec, Ulm, Germany).
5.2.8 MCR details
This chemometric analysis was performed on the pre-processed Raman data using The Un-
scrambler X 10.4 (CAMO, Oslo, Norway) software. The MCR was carried out with applied
non-negativity (non-negative spectra/concentration) and closure constraints, and using fol-
lowing settings - sensitivity to pure components: 100; maximum number of alternating least
squares iterations: 10 000.
5.2.9 PLS details
Pre-processed LFR and MFR micro-spatially offset spectroscopic data from various celecoxib
form III and PVP bilayer tablets as well as celecoxib form III, α-lactose monohydrate and
PVP trilayer tablets were used to build calibration and test data sets for quantitative analysis
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of upper (PVP) layer or middle (α-lactose monohydrate) thickness, respectively. 2/3 of the
replicate data were allocated for building the calibration models, whereas the remaining 1/3
were used for building the test sets. The PLS regression models were constructed using The
Unscrambler X 10.4 (CAMO, Oslo, Norway) software and a nonlinear iterative least squares
(NIPALS) algorithm with 10 000 iterations that were validated using a full cross validation
procedure.
5.2.10 PCA details
This chemometric analysis was carried out on pre-processed LFR and MFR micro-spatially
offset spectroscopic data collected from multi-layer and multi-component tablets in The Un-
scrambler X 10.4 (CAMO, Oslo, Norway) software environment using full cross validation
procedure and NIPALS algorithm (10000 iterations).
5.2.11 Computational details
Theoretical solid-state DFT calculations were performed using the fully periodic CRYSTAL17
software adapting previously described generalized methodology for the vibrational analy-
sis of small pharmaceuticals (Chapter 2). In short, a generalized gradient approximation
PBE150 functional with van der Waals interactions treated according to the Grimme D3110
method was used, and all of the atoms were described with the Ahlrichs’ TZVP151 basis
set. The crystal structures of the two lactose solid-state forms (monohydrate219 and stable
anhydrous220) were fully optimized with no implied restrictions on atom positions or lattice
parameters. The dielectric tensor and Raman intensities were calculated analytically using
the coupled-perturbed Hartree-Fock/Kohn-Sham (CPHF/CPKS) approach154 and the An-
derson convergence accelerator.155 Energy convergence criteria was set to ∆E ≤ 10−8 and
10−10 Hartree for the geometry optimization and vibrational calculations, respectively.
5.3 Results and discussion
5.3.1 Exploratory analysis and technical details
As evident by the presented data in the previous thesis chapters, LFR spectral region can
provide unique information related to the structural properties, including solid-state form
characteristics. Additionally, the Raman cross-sections in this spectral regime usually exhibit
much higher intrinsic intensity compared to the ones in the more traditionally used MFR
region. In this protocol, particular phenomenon, arguably, helps to address one of the main
limitations of SORS with mid-frequency data - the compromised Raman spectra quality
upon large spatial offsets used to analyse deeper subsurface zones, where the absolute signal
propensity is typically very low.213 Thus, for a proof of principle study, an instrumental setup
primarily using free-space optics was assembled (Figure 5.1), which allowed for the exploration
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of at least the basic capabilities of SOLFRS. However, this approach, while functional, still
implied certain limitations, which are discussed below.
Figure 5.2: Representative (a) LFR and (b) MFR spectra of celecoxib
form III, α-lactose monohydrate (α-LM), anhydrous lactose (α-LS) and
polyvinylpyrrolidone (PVP). Reproduced from Bērziņš et al. 218 with per-
mission from the American Chemical Society.
Celecoxib (more specifically, its commercial polymorph - form III) was once again se-
lected as our primary model API. Additionally, several excipients were selected to explore
crystalline-crystalline and crystalline-amorphous subsurface interfaces, namely α-lactose an-
hydrous stable form (α-LS), α-lactose monohydrate (α-LM) and polyvinylpyrrolidone (PVP);
α-LM and PVP are used in commercial celecoxib solid dosage forms, the last of which is also
used for coatings.61 Figure 5.2a shows a representative LFR spectra of these chemical en-
tities, displaying a clear differentiation between them. More specifically, celecoxib form III,
α-LS and α-LM have a number of unique peaks (phonon modes) in the LFR spectral range,
whereas PVP exhibits broad vibrational density of states (VDOS) feature, characteristic to
amorphous moieties.
The origin of low-energy modes of celecoxib form III has been previously discussed in de-
tail in Chapter 2. However, thorough low-wavenumber vibrational analysis of the particular
α-lactose solid-state forms has not yet been reported in the literature. To address this, theo-
retical simulations for both α-LS and α-LM were carried out using the same generalized DFT
methodology described in Chapter 2. Overall, the calculated results (Figures 5.3 and 5.4)
were in good agreement with the experimental data (especially with the spectra obtained at
-190 °C because of the nature of the theoretical simulations; full relaxation of atom positions
and lattice parameters was carried out during the geometry optimization step, which better
represents the crystal structure near absolute zero). Information on the specific low-energy
vibrational mode assignments for the α-LS and α-LM solid-state forms is presented in Ta-
bles D.3 and D.4, respectively. It is also worth noting that there was an inherent baseline
curvature for the Raman data recorded at -190 °C for both lactose solid-state forms (more
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pronounced for α-LS). Although such spectral behavior has also been observed for other
small organic molecules, for example, L-tyrosine (Chapter 2) its origin is not clear at this
point.
Figure 5.3: Experimental and DFT-simulated (a) LFR and (b) MFR spec-
tra of α-lactose anhydrous stable form (α-LS).
Figure 5.4: Experimental and DFT-simulated (a) LFR and (b) MFR spec-
tra of α-lactose monohydrate (α-LM).
5.3.2 Case studies
5.3.2.1 SOLFRS
Herein, a series of bilayer tablets were first analyzed containing celecoxib form III and α-
LM or PVP that were prepared by using variety of different ratios between the components
(Table D.1). This approach allowed the procurement of tablets with different individual layer
thicknesses (Table D.1) and assessment of the limits of SOLFRS to probe them. The results
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were also compared to a typical SORS as Raman data from both the low and mid-frequency
spectral regions were collected simultaneously. Examples of these spectra for the celecoxib
form III/α-LM system are presented in Figure 5.5, whereas ones for celecoxib form III/PVP
are shown in Figure D.4.
Figure 5.5: Examples of (a) low and (b) mid-frequency spatially offset
Raman spectra for celecoxib form III and α-LM bilayer tablet (3:1 compo-
sition; ∼1.2 mm upper layer thickness). Reproduced from Bērziņš et al. 218
with permission from the American Chemical Society.
As anticipated, the mid-frequency spectral range presented a poorer quality data due to
inferior signal intensity in comparison to the LFR region. This was best reflected by the signal
to noise ratio (SNR), where, on average, LFR data was characterized by 10-15 times higher
SNR values when compared to the MFR data (Figure D.5). Additionally, upon increasing
spatial offset, a pronounced baseline appears that was only partially amended using the rub-
berband baseline correction. It is important to note that a more specific analysis of LFR data
(i.e., anti-Stokes/Stokes signal ratio comparison) also revealed a non-linear signal intensity
change with increasing spatial offset benefiting the use of anti-Stokes lines (Figure D.6); this
aspect needs to be explored in greater detail with subsequent studies. Multivariate curve
resolution (MCR) was used to model the signal ratio between the components that provided
an elegant way to further showcase and evaluate at least the qualitative aspects of SOLFRS.
Irrespective of the model system, all of the resolved loadings spectra (Figures D.7 and D.8)
matched the ones shown for each of the individual components (Figure 5.2), affirming the
general validity of the MCR models. Figure 5.6 shows a direct comparison between the ex-
tracted signal ratios between the celecoxib form III and the excipient (α-lactose monohydrate
or PVP) from the spatially offset low and mid-frequency Raman data collected for different
tablets at various relative spatial offset positions. Based on this comparison, several inter-
esting observations were noted. First of all, the larger variation of the predicted ratio values
(including an occasional inversion of the trend) at higher spatial offsets was likely influenced
by the increasing signal noise and corresponding MCR sample residuals (Figure D.9). Nev-
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ertheless, levels of Raman signal (including relative intensities) were expectedly dependent
on the layer thickness ratio,221 where LFR region was superior in distinguishing celecoxib
(i.e., its spectral signature) from the subsurface measurements for all of the bilayer tablets
that coincided with the visual observations of the Raman data. In some cases, for example
the celecoxib form III and α-lactose monohydrate bilayer tablet with the thickest individual
layers (1:1 ratio), it also provided the ability to detect the subsurface component at a smaller
spatial offset compared to the mid-frequency region. From a practical standpoint, this aspect
can potentially enable access to deeper subsurface zones, otherwise inaccessible by conven-
tional SORS, and/or shorten the necessary measurement time for the analysis. Additionally,
the intrinsic differences in representation of vibrational modes for amorphous and crystalline
compounds in the LFR range benefited the analysis of celecoxib form III/PVP bilayer tablets.
Another advantage here stems from the fact that celecoxib is a much better Raman scatter
(as typical for APIs)49 compared to the PVP that enhances the overall efficiency of both
techniques, but especially SOLFRS. In compressed state, PVP also forms a semi-translucent
phase that enhances the light penetration, which was directly reflected by the MCR results of
the data collected from 180° (surface oriented) measurements of these samples where celecoxib
sublayer signal could even be distinguished most of the time (Figure 5.6).
Additionally, SOLFRS provided a clear advantage for monitoring the subsurface dehy-
dration process of α-LM to α-LS within tablets, a transformation that is of high importance
in hot melt extruded drug products containing this excipient.222 Figure 5.7a shows a heat
map of α-LM/α-LS relative signal ratio obtained from MCR analysis (respective component
loadings are presented in Figure D.10) of isothermal LFR data collected at different dehy-
dration time-points and relative spatial offset positions (examples of spectra are shown in
Figure D.11). It is important to note that only SOLFRS data proved useful for the particu-
lar analysis as we were unable to procure a rational MCR model using MFR data, even when
initial guesses of the component spectral profiles were used. The high spectral similarity in
the MFR region between both solid-state forms (Figure 5.2b) as well as the relatively weaker
Raman scattering propensity (for example, when compared to celecoxib) likely contributed to
this result. On the other hand, SOLFRS, complemented by the Raman microscopic analysis
of split tablets (Figure 5.7b), provided an insight into this process. Overall, the dehydration
at particular conditions was found to be rapid and quickly progressed towards the core of the
tablet. In SOLFRS data, this was reflected by the sharp gradient of the dehydration front
(effectively, the kinetic boundary between the fully dehydrated layer and rest of the compo-
sition) that could be semi-quantitatively characterized by Raman microscopy measurements.
It was assumed that the observed small domains of α-LM in the largely dehydrated surface
layers had negligible contribution to the MCR analysis of SOLFRS data, implying a direct
correlation between the probed sample volumes with (almost) no traces of α-LM (blue to
dark blue areas in Figure 5.7a) to the visually approximated α-LS layer thicknesses from
Raman imaging (Figure 5.7b). Ultimately, such analysis could be expanded to a range of
temperatures (or other variable conditions, for example, relative humidity), where the gradi-
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Figure 5.6: MCR analysis of celecoxib form III and α-lactose monohydrate
(α-LM; upper panels) or polyvinylpyrrolidone (PVP; lower panels) bilayer
tablets of different composition (w/w) using (a,c) LFR or (b,d) MFR data
recorded at different relative spatial offsets from SOLFRS measurements.
The lines are drawn to assist in visualizing the trends. Reproduced from
Bērziņš et al. 218 with permission from the American Chemical Society.
ent changes may be used as a kinetic descriptor of the solid-state form transformations within
tablets, and, potentially, other solid dosage forms.
Nevertheless, despite the aforementioned potential advantages of SOLFRS, our instru-
mental setup still presented certain challenges and limitations that need to be addressed in
the future. Most importantly, a direct fiber optics coupling (as per typical SORS) to a volume
Bragg grating notch filter system (or its potential incorporation within the optic fiber) could
improve the procured data quality due to the reduced signal loss. For our setup, it would
also circumvent the current physical limitation implied by the microscope objective that dis-
allows conventional (surface oriented) Raman measurements due to laser geometry and focal
length restrictions (i.e., the current “zero” position has a small intrinsic spatial offset ≤0.5
mm). Additionally, the general levels of Raman signal could be increased by using a more
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Figure 5.7: (a) α-Lactose monohydrate (α-LM) / α-lactose anhydrous sta-
ble form (α-LS) relative signal ratio projection from SOLFRS data col-
lected at different time-points after isothermal dehydration of α-LM tablets
at 160 °C; (b) TrueComponent (MCR-like) analysis of Raman microscopy
data of the selected areas within the cross-sections of the same tablets (red
color denotes α-LM, whereas blue color - α-LS; resolved spectra for each
individual component are presented in Figure D.12). Reproduced from
Bērziņš et al. 218 with permission from the American Chemical Society.
powerful laser source, for example, similar to ones currently utilized in modern/commercial
SORS instruments223 and/or a better detector.
5.3.2.2 micro-SOLFRS
A similar approach was used for the exploration of micro-SOLFRS, where bilayer tablets
were first prepared for the analysis with varying individual layer thicknesses (Table D.2)
between the drug and excipient (in this case only the celecoxib form III and PVP). Figure 5.8
shows representative micro-SOLFRS spectra of a selected bilayer tablet over a broad sample
displacement range. From this data, it is evident that, as anticipated, the effectiveness of
micro-SOLFRS for achieving spatial distinction between spectral signatures is inferior to
that of SOLFRS. Nevertheless, significant changes could still be observed that were best
reflected by the MCR analysis (Figure 5.9) with loadings spectra presented in Figure D.13.
Here, LFR region once again proved superior in distinguishing the spectral signature of
celecoxib, that allowed to detect the drug in bilayer formulations with a considerably thick
upper layer (PVP) thickness (∼2.5-3.1 mm), whereas MFR failed to do so (red data points
in Figure 5.8b). Also, application of micro-SOLFRS allowed enhanced detection of celecoxib
even within these samples. This could be potentially further improved with even greater
displacements. Theoretically, the usable defocusing range in micro-SOLFRS is less confined
by the dimensions of the analyte (in contrast to SOLFRS) as the laser illumination and Raman
signal collection zones can be infinitely enlarged that could also allow spatial information from
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smaller objects to be obtained, if adequate quality data can be collected.
Figure 5.8: Examples of (a) low and (b) mid-frequency micro-spatially
offset Raman spectra (SNV corrected for a better visibility of trends) for
celecoxib form III and PVP bilayer tablet (7:3 composition; 140/60 mg
w/w). Reproduced from Bērziņš et al. 224 with permission from the Amer-
ican Chemical Society.
Figure 5.9: MCR analysis of celecoxib form III and PVP bilayer tablets
of different composition (w/w) using (a) LFR or (b) MFR data recorded
at different displacement positions from micro-SOLFRS “cross-pattern”
replicate measurements (n = 5). The lines are drawn to assist in visualizing
the trends. Reproduced from Bērziņš et al. 224 with permission from the
American Chemical Society.
In this instance, the SNR was used as data quality descriptor in order to select an op-
timal defocusing distance for quantitative modeling of the upper layer (PVP) thickness in
the bilayer tablets using partial least squares (PLS) regression analysis. However, as shown
in Figure D.14, the SNR gradually decreased for both LFR and MFR domains with only
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the tablet with the smallest upper layer exhibiting sustained SNR in a specific sample dis-
placement range (≤1 mm). Thus, all spatial positions were explored for the PLS analysis.
It is important to note, however, that due to the fragility of certain tablets (PVP content
<80 mg), it was impossible to obtain accurate layer thickness characteristics for all of the
samples, which limited their use for this analysis. Nevertheless, at least six samples from this
data set were still possible to be included in the PLS models, all of which also displayed a
direct correlation between the PVP layer thickness and layer weight (Figure D.15), indicating
comparable intrinsic layer properties such as their density.
Based on the rational inspection of the loadings plots as well as full cross-validation re-
sults, three factors were necessary to explain the majority of the spectral variance for LFR
micro-spatially offset data. The MFR data only required the use of a single factor. Repre-
sentative loadings spectra for subsequent factors of PLS analysis of MFR data are presented
in Figure D.16 for completeness. These loadings mainly contained information related to
baseline and signal noise discrepancies opposed to the ratio of celecoxib and PVP spectral
signatures expected to relate to the PVP layer thickness characteristics.225 Although the
loadings spectra for each of the respective series of PLS models were almost identical across
all of the defocusing distances, clear differences in their performance statistics were noted,
most notably by the variation in root mean square error (RMSE). These results (Table D.5)
allowed to identify the optimal sample displacement position that could be used for estimat-
ing the PVP layer thickness using each type of spectroscopic data. The best performing LFR
model was obtained for the 2.5 mm displacement with the test set data generating a RMSE of
71 µm and R2 of 0.98, whereas the best performing MFR model had a 4.0 mm displacement
and gave RMSE of 205 µm and R2 of 0.85. The overall fluctuation in the accuracy of all
of the PLS models (Table D.5) was assumed to be the result of an interplay between the
SNR and the ability to spectrally distinguish both components within the bilayer tablets.
Unsurprisingly, a much larger sample displacment for MFR data (4.0 mm as compared to 2.5
mm for LFR) was necessary to reach the lowest prediction RMSE, which is arguably related
to the fact that in certain bilayer tablets (for example, 80/120 w/w), it was only possible
to distinguish the celecoxib spectral signature at these micro-SOLFRS settings (Figure 5.9).
This aspect also influenced the general accuracy of the PLS models, where, regardless of the
defocusing distance, LFR data was superior in providing better accuracy for layer thickness
determination when compared to the MFR region.
Figure 5.10 shows a summary of the selected PLS models encompassing the calibration,
cross validation and test set data as well as the respective loadings plots that revealed that
celecoxib form III and PVP features are predominantly correlated with the negative and
positive factor space, respectively. The existence of some of the outliers for celecoxib form III
in the LFR data (for example, the lowest energy vibration at ∼27 cm-1; Figure 5.10b) can be
rationalized on the basis of relative abundancies between this peak and the dominant PVP
VDOS contributions in the particular spectral domain. These results also perfectly illustrate
the previously discussed shortcomings of MFR for modeling the PVP layer thickness above
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certain range (>2.1-2.5 mm). It is important to note, however, that below this threshold,
LFR and MFR appeared to exhibit similar potency for probing layer thickness characteristics
(at least for these samples).
Figure 5.10: (a,c) Calibration, cross validation and test set data, and (b,d)
loadings plots of respective factors of the selected PLS regression models
using LFR and MFR data (upper and lower panels, respectively) for PVP
layer thickness determination of 200 mg bilayer tablets containing celecoxib
form III and PVP. Reproduced from Bērziņš et al. 224 with permission from
the American Chemical Society.
In order to further elucidate this observation, PLS analysis was expanded to a new set of
bilayer tablets that contained a similar range of PVP content (80-180 mg), but a constant
celecoxib amount (100 mg). Analysis of these samples allowed to understand the impor-
tance of the probed celecoxib volume during the acquisition of micro-SOLFRS data for the
determination of upper layer thickness. The according PLS models were also constructed
using a mixed variety of the samples to test a feasibility of using a global model for different
types of samples. Figure 5.11 highlights the main characteristics of best performing models,
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whereas Tables D.6 and D.7 provide a more in-depth summary on all of them. Overall, a
significant decrease in accuracy was noted for all of these PLS models regardless of whether
LFR or MFR spectral data were used for building them. For example, the individual LFR
and MFR test set models for second set of bilayer tablets now displayed RMSE values of
158 and 211 µm, respectively. This was assumed to be mainly related to the fact that the
second set of tablets exhibited relatively thicker PVP layers (Figure D.15) when PVP content
was increased above 100 mg due to the higher total tablet weight (i.e., lesser compressibil-
ity). Nevertheless, the general loadings plots for all of the models were almost identical to
the ones shown in Figure 5.10, except for the factor-3 in the LFR data, which now largely
explained some discrepancies related to signal noise and, hence, was not used (also, as ex-
pected, the inclusion of this factor for the analysis did not much improve the performance
of the particular PLS models). This result highlights that even relatively small discrepancies
in sample composition/characteristics can have a pronounced effect in limiting the applica-
tion of micro-SOLFRS for quantitative or semi-quantitative measurements, and need to be
carefully tested.
Following the successful preliminary analysis of various bilayer tablets, more complex sys-
tems were attempted to be analysed with micro-SOLFRS. More specifically, multi-layer/multi-
component tablets comprised of celecoxib form III, PVP as well as different solid-state forms
of α-lactose (α-LM and α-LS). First, multi-layer tablets with constant total weight (200
mg, Table D.2) were analysed to understand the capabilities and potential advantages of
micro-SOLFRS to probe multiple subsurface components simultaneously. Figure 5.12 shows
a representative spectra for one of the analyzed trilayer tablets at different defocusing dis-
tances. In this instance, the spectral differences were more subtle when compared to the
previous results for celecoxib:PVP bilayer tablets (Figure 5.8), especially for the MFR spec-
tral range. This aspect complicated the MCR analysis, which failed to result in procurement
of rational models, even when initial guesses of the components were used. Thus, PCA was
instead used to allow for at least a qualitative comparison between the samples in the LFR
domain. Here, PC1 accounted for around half of the spectral variance within the analyzed
data set (53%) and mainly distinguished the changes in lactose spectral signature with vary-
ing defocusing distance, depicted in the positive PC1 space. On the other hand, PC2 (34%)
allowed to identify the phonon modes of celecoxib, and, hence, its changes over the recorded
displacement range (Figure 5.13).
Overall, the utilization of a higher defocusing distance allowed to better distinguish either
the presence of α-LM or celecoxib form III, the efficacy of which was based on several fac-
tors. Primarily, the relative amount (layer thickness) of each of the components appeared to
govern this effect as significant trend was only observed when the content of the subsurface
component exceeded 50 milligrams. Additionally, it was dependent on the PVP (top layer)
thickness as well as the composition ratio between the components, for example, as in the
case of 50/100/50 and 50/75/75 tablets that shared identical celecoxib content, but showed
significantly different characteristics for the drug via micro-SOLFRS measurements (orange
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Figure 5.11: Calibration, cross validation and test set data of the selected
PLS regression models using LFR and MFR data (left and right panels,
respectively) for PVP layer thickness determination of bilayer tablets con-
taining (a,b) constant celecoxib form III content (100 mg) and (c,d) both
constant and varied celecoxib form III content.
and green curves in Figure 5.13b, respectively).
These samples were also used to test the capability of micro-SOLFRS to determine the
subsurface layer thickness characteristics (in this case, α-LM) via the PLS analysis. In both
instances, a single factor was necessary to resolve meaningful spectral variance with α-LM
spectral features projected in the positive factor space. Figure D.17 shows the main char-
acteristics of best performing models (their calibration, cross validation and test set data as
well as the respective loadings plots), whereas Table D.8 provides a more in-depth summary
on all of the explored models for the analysis. The best performing LFR model was obtained
for the 4.0 mm displacement with the test set data generating a RMSE of 99 µm and R2
of 0.85, whereas the best performing MFR model had no displacement and gave RMSE of
160 µm and R2 of 0.61. Here, LFR proved far superior in providing the desired information
compared to the MFR region, an aspect that was also perfectly illustrated by the fact that
the use of an increased defocusing distance still marginally improved the prediction accuracy
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Figure 5.12: Examples of (a) low and (b) mid-frequency micro-spatially
offset Raman spectra (SNV corrected for a better visibility of trends)
for celecoxib form III, α-LM and PVP trilayer tablet (1:2:1 composition;
50/100/50 mg).
of the PLS models utilizing LFR data, whereas it vastly decreased for ones utilizing MFR
data (Table D.8). These results suggest that the use of micro-SOLFRS could be beneficial
for both qualitative and quantitative analysis of multi-core/multi-coated tablets that have
gained increased interest from the pharmaceutical industry as well as research community
due to their ability to modulate multiple properties simultaneously or in tandem such as drug
release, stability and even product taste.226
Lastly, applicability of micro-SOLFRS for multi-dimensional spatial analysis was tested
using a model multi-component tablet representative of an actual pharmaceutical product.
In order to imitate surface driven solid-state form changes, a mild dehydration was induced
to promote a transformation from α-LM to α-LS. However, similar to trilayer tablets, the
complexity of the system disallowed the use of MCR for the data analysis, and, hence, PCA
was used. It is important to note that this type of analysis was only feasible using the LFR
data due to the inferior signal quality in the MFR domain (Figure D.18) combined with the
intrinsic high spectral similarity of the α-lactose solid-state forms of interest (Figure 5.2).
While this deficiency could likely be diminished, if point measurements for the mapping
data would be collected with longer integration time/a higher number of co-accumulations,
it would also significantly prolong the time necessary for data acquisition. PC1 accounted
for 41% of spectral variance and largely distinguished the components of interest with α-LM
and α-LS spectral features depicted in the positive and negative PC space, respectively (Fig-
ure D.19). Figure 5.14 shows PC1 mapping data for the dehydrated tablet at different sample
displacement positions, where a number of interesting observations were noted. First, data
collected at no displacement position (focal point) revealed almost completely dehydrated
tablet surface exhibiting domains of varied α-LS content (light to dark orange/brown areas).
On the other hand, defocused mapping data exhibited areas with increased α-LM propensity
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Figure 5.13: PCA of the LFR spectra collected from 200 mg trilayer tablets
comprised of celecoxib/α-LM/PVP with (a) PC1 and (b) PC2 scores ver-
sus the sample displacement position (n = 5), and (c) associated loadings
spectra. The lines are drawn to assist in visualizing the trends. Repro-
duced from Bērziņš et al. 224 with permission from the American Chemical
Society.
(light to dark green areas), where a displacement of 5.0 mm showed almost no traces of α-LS.
These results indicate that only a very thin layer of α-LM had been dehydrated at the applied
conditions. Considering that even small changes on the tablet surface can affect its various
properties, including physical stability of individual components as well as the dissolution
performance (as shown in Chapter 3), this type of analysis could serve as a viable approach
for a nondestructive screening of solid dosage forms either during their manufacture or stor-
age. Additionally, PCA could also be used here semi-quantitatively if a relationship between
the PC score values (its gradient changes) and the probing depth were established.
5.3.3 Significance
The showcased capabilities of SOLFRS and micro-SOLFRS provide a new frontier for non-
destructive analysis of pharmaceutical dosage forms as well as other analytes. The generally
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Figure 5.14: Micro-SOLFRS maps based on the scores values of PC1 col-
lected for a multi-component tablet comprised of celecoxib, α-LM and
PVP after dehydration (α-LM to α-LS) at 140 °C temperature for 20 min.
Reproduced from Bērziņš et al. 224 with permission from the American
Chemical Society.
superior characteristics of LFR region when compared to the typically employed MFR do-
main can yield both unique and complementary information for spatial characterization of
the samples. For example, variable temperature (micro-)SOLFRS measurements could pro-
vide information on the surface and bulk molecular mobility of amorphous solid dosage forms
and their changes upon, for example, moisture uptake. Additionally, these techniques could
be employed for biomedical applications where the detection of structural changes is of high
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importance. Further advancements may also allow to convert SOLFRS into portable hand-
held devices (similar to SORS) that could aid the detection of illicit or dangerous substances
as well as facilitate unique data collection in various outdoor fields.
5.4 Conclusion
For the first time, a significant new combined method of low-frequency and (micro-)spatially
offset Raman spectroscopy (micro-SOLFRS or SOLFRS) is demonstrated via an exemplary
non-destructive spatial analysis of pharmaceutical solid dosage forms. Several scenarios were
explored to investigate the capabilities of this newly developed Raman subtechnique. First, a
range of bilayer tablets comprised of celecoxib form III and α-LM or PVP (at different ratios)
were analyzed to probe the effectiveness of SOLFRS for the subsurface layer detection. On the
other hand, homogenous α-LM tablets were exposed to elevated temperature conditions in
order to induce surface-driven formation of α-LS that allowed the exploration of the potential
of SOLFRS to monitor subsurface solid-state transformation kinetics. The use of chemomet-
rics enabled a direct comparison between the SOLFRS and the traditionally used SORS via
the signal ratio analysis of simultaneously acquired data from both spectral regions. Overall,
the application of SOLFRS yielded a higher subsurface Raman signal propensity, especially
at larger spatial offsets, where the SORS approach was sometimes unable to provide quality
data that, for example, hindered the kinetic analysis of α-LM tablets. This aspect could be
utilized to improve the general accuracy of non-intrusive subsurface Raman measurements,
for example, it could benefit the analysis of multi-layer solid dosage forms or other objects
with an increased surface layer thickness.
Micro-SOLFRS was tested within a similar experimental framework, where, in all of the
explored scenarios, LFR spectral domain enhanced or enabled the determination of different
layer (i.e., coating) thicknesses as well as the spatial analysis of solid-state form transfor-
mations. Considering the intrinsic simplicity of the micro-SOLFRS experimental setup, this
technique could potentially be adapted for in-line analysis of solid dosage forms during their
manufacture or storage and help to identify potential problems without irreversibly damaging
the product.
Chapter 6
Conclusions and Future Work
The presented work gives a comprehensive insight into the various capabilities of LFR spec-
troscopy that can be applied for the analysis of different pharmaceutical systems. As evident
by the case studies, LFR spectroscopy possesses certain attractive advantages over the more
commonly used MFR spectroscopy as well as other typically used analytical methods. Most
notably, the intrinsic high sensitivity to structural changes and typically superior scattering
(signal) propensity can help/enable in situ monitoring of fast processes such as phase trans-
formations, even in the presence of a dissolution medium (Chapters 3 and 4). Considering
the now available streamlined solutions for accessing the LFR spectral domain, these results
will hopefully encourage broader application of in-line LFR solutions to be utilized within
a framework of pharmaceutical manufacturing (i.e., process analytical technology, otherwise
known as PAT), where the LFR data could be used either separately or in combination with
other analytical techniques.
Here, this approach allowed the elucidation of the effect of compression-induced desta-
bilization in a popular amorphous model drug (celecoxib), an aspect that had received only
limited attention in the literature. A direct synergy between the preparation method and
compression was established for the model system analyzed and was found to negatively
impact both the physical stability and dissolution behavior of amorphous phases. The ef-
fect itself was largely attributed to the dynamic changes within the molecular arrangement as
well as the sheer stress experienced by the different surface domains that promoted nucleation
and, hence, faster crystallization. Accordingly, some formulation strategies were explored to
mitigate this effect. However, only the polymer loading (and not its type that could ensure
more favorable intermolecular interactions with the drug moiety) was found to significantly
mitigate it, the effectiveness of which was also concentration dependent.
Additionally, the investigation into experimental and theoretical aspects of low-energy
vibrational mode modeling and assignment allowed recognition of the importance of appro-
priate reference data for an accurate evaluation of computational LFR spectra simulations.
Additionally, the proposed generalized DFT methodology for understanding the nature of
the phonon modes not only showed a good prediction accuracy for the variety of pharmaceu-
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tically relevant compounds with different molecular complexity explored in Chapter 2, but
also was successful in providing good quality results for different α-lactose solid-state forms
utilized for constructing the model systems for micro-SOLFRS/SOLFRS analysis (Chapter
5).
Noteworthy, this newly developed Raman subtechnique served as the best example for
showcasing the superior qualities of LFR spectroscopy as, in all instances, the results were
directly compared to ones obtained using MFR data. The application of this technique
either enabled or enhanced the detection of the subsurface component in solid dosage forms,
quantitative analysis of layer (i.e., coating) thicknesses as well as monitoring the solid-state
form transformations spatially. The suggested improvements for our in-house built setup
could further elevate the capabilities of micro-SOLFRS/SOLFRS that could potentially lead
to its commercialization. Additionally, as LFR domain also encompasses information related
to molecular mobility (Chapter 4) among other properties, this technique has a potential for
very interesting and exciting applications in the near future, including within other research
fields.
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[65] Lipiäinen, T.; Fraser-Miller, S. J.; Gordon, K. C.; Strachan, C. J. Direct Comparison
of Low- and Mid-Frequency Raman Spectroscopy for Quantitative Solid-state Phar-
maceutical Analysis. Journal of Pharmaceutical and Biomedical Analysis 2018, 149,
343–350.
[66] Mah, P. T.; Fraser, S. J.; Reish, M. E.; Rades, T.; Gordon, K. C.; Strachan, C. J.
Use of Low-Frequency Raman Spectroscopy and Chemometrics for the Quantification
of Crystallinity in Amorphous Griseofulvin Tablets. Vibrational Spectroscopy 2015, 77,
10–16.
[67] Inoue, M.; Hisada, H.; Koide, T.; Fukami, T.; Roy, A.; Carriere, J.; Heyler, R. Transmis-
sion Low-Frequency Raman Spectroscopy for Quantification of Crystalline Polymorphs
in Pharmaceutical Tablets. Analytical Chemistry 2019, 91, 1997–2003.
[68] Shibata, T.; Igawa, H.; Kim, T. H.; Mori, T.; Kojima, S. Glass Transition Dynamics
of Anti-Inflammatory Ketoprofen Studied by Raman Scattering and Terahertz Time-
domain Spectroscopy. Journal of Molecular Structure 2014, 1062, 185–188.
[69] Latreche, M.; Willart, J.-F.; Paccou, L.; Guinet, Y.; Hédoux, A. Polymorphism ver-
sus Devitrification Mechanism: Low-Wavenumber Raman Investigations in Sulindac.
International Journal of Pharmaceutics 2019, 567, 118476.
[70] Inoue, M.; Osada, T.; Hisada, H.; Koide, T.; Fukami, T.; Roy, A.; Carriere, J.;
Heyler, R. Solid-State Quantification of Cocrystals in Pharmaceutical Tablets Using
Transmission Low-Frequency Raman Spectroscopy. Analytical Chemistry 2019, 91,
13427–13432.
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[136] Bērziņš, K.; Kons, A.; Grante, I.; Dzabijeva, D.; Nakurte, I.; Actiņš, A. Multi-Technique
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Appendix A
Additional data for Chapter 2
Table A.1: Crystal structure data summary of benzoic acid, diphenylacetic



















122.12 212.24 181.19 381.37 406.47
temper-
ature, K
20 125 295 293 173
crystal
system
monoclinic monoclinic orthorombic triclinic monoclinic
space group P21/c P21/n P212121 P 1̄ P21/c
a, Å 5.393(3) 11.979(3) 6.913(3) 10.136(5) 15.5414(14)
b, Å 5.003(2) 7.197(2) 21.118(10) 16.778(6) 15.2050(12)
c, Å 21.689(12) 12.650(3) 5.832(3) 5.066(6) 9.1174(8)
α, ◦ 90 90 90 97.62(7) 90
β, ◦ 98.51(3) 91.22(2) 90 100.65(6) 100.730
γ, ◦ 90 90 90 95.95(4) 90
V, Å3 578.75 1090.35 851.41 831.92 2116.83
ρcalc, gcm
-3 1.402 1.293 1.414 1.522 1.275





15 28 24 40 56
R1 (wR2), % 6.90 4.70 (12.0) 4.00 8.80 (9.60) 4.03 (9.86)
CSD identifier BENZAC07 TIDGAO03 LTYROS11 DIBBUL GIVJUQ01
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Figure A.1: Energy framework diagrams for a cluster of nearest-neighbor
molecules in benzoic acid. All diagrams use the same tube/cylinder scale
of 50, and energies with a magnitude smaller than 5 kJ/mol have been
omitted for clarity.
Figure A.2: Energy framework diagrams for a cluster of nearest-neighbor
molecules in diphenylacetic acid. All diagrams use the same tube/cylinder
scale of 50, and energies with a magnitude smaller than 5 kJ/mol have
been omitted for clarity.
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Figure A.3: Energy framework diagrams for a cluster of nearest-neighbor
molecules in L-tyrosine. All diagrams use the same tube/cylinder scale
of 50, and energies with a magnitude smaller than 5 kJ/mol have been
omitted for clarity. Destabilizing (positive) energies are depicted in yellow
color.
Figure A.4: Energy framework diagrams for a cluster of nearest-neighbor
molecules in celecoxib (form III). All diagrams use the same tube/cylinder
scale of 50, and energies with a magnitude smaller than 5 kJ/mol have
been omitted for clarity.
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Figure A.5: Energy framework diagrams for a cluster of nearest-neighbor
molecules in carvedilol (form II). All diagrams use the same tube/cylinder
scale of 50, and energies with a magnitude smaller than 5 kJ/mol have
been omitted for clarity.
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Table A.2: Vibrational mode assignment for the calculated LFR spectrum
of benzoic acid.
Wavenumber, cm-1 Symmetry Intensity Mode type Principal axis
31 Bg 745 Translation ca
49 Ag 312 Translation b
58 Ag 137 Translation cb
59 Bg 9 Translation cb
84 Ag 1000 Torsion a
85 Bg 365 Torsion a
98 Ag 686 Ring torsion bc
101 Bg 310 Ring torsion bc
121 Ag 273 Ring torsion a
125 Bg 56 Ring torsion a
126 Ag 842 Ring torsion a
128 Bg 4 Carboxylic torsion c
135 Ag 112 Carboxylic torsion c
136 Bg 56 Carboxylic torsion c
196 Ag 224 Complex torsion ab
196 Bg 3 Complex torsion ab
265 Bg 2 Complex torsion c
266 Bg 6 Complex torsion c
Figure A.6: (a) Scores plot of PC1 versus PC2 and (b) the first two loadings
plots from PCA of the variable temperature low-frequency Raman spectra
of benzoic acid.
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Figure A.7: Mid-frequency Raman spectra of benzoic acid in a broad tem-
perature range. The visual symbols denote either peak shift or peak broad-
ening.
Figure A.8: (a) Scores plot of PC1 versus PC2 and (b) the first two loadings
plots from PCA of the variable temperature mid-frequency Raman spectra
of benzoic acid.
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Figure A.9: The modeling of temperature dependence of individual LFR
peaks of benzoic acid as compared to the experimental results.
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Table A.3: Vibrational mode assignment for the calculated LFR spectrum
of diphenylacetic acid.
Wavenumber, cm-1 Symmetry Intensity Mode type Principal axis
34 Bg 158 Translation b
35 Ag 869 Translation a
40 Bg 583 Translation a
44 Ag 446 Translation a
56 Bg 13 Translation b
57 Ag 165 Torsion c
63 Bg 75 Ring torsion ab
69 Ag 126 Ring torsion ab
69 Bg 177 Complex torsion ca
76 Ag 747 Complex torsion ab
85 Ag 938 Complex torsion bc
86 Bg 239 Complex torsion abc
88 Ag 38 Complex torsion bc
92 Bg 847 Complex torsion abc
104 Ag 1000 Complex torsion acb
107 Ag 558 Complex torsion cba
108 Bg 336 Complex torsion cba











164 Ag 122 Complex torsion cab
166 Bg 1 Complex torsion cab
179 Bg 4 Complex torsion ab









255 Ag 14 Complex torsion ab
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Figure A.10: (a) Scores plot of PC1 versus PC2 and (b) the first two
loadings plots from PCA of the variable temperature low-frequency Raman
spectra of diphenylacetic acid.
Figure A.11: Mid-frequency Raman spectra of diphenylacetic acid in a
broad temperature range. The visual symbols denote either peak shift or
peak broadening.
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Figure A.12: (a) Scores plot of PC1 versus PC2 and (b) the first two
loadings plots from PCA of the variable temperature mid-frequency Raman
spectra of diphenylacetic acid.
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Figure A.13: The modeling of temperature dependence of individual LFR
peaks of diphenylacetic acid as compared to the experimental results.
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Table A.4: Vibrational mode assignment for the calculated LFR spectrum
of L-tyrosine.
Wavenumber, cm-1 Symmetry Intensity Mode type Principal axis
28 A 1000 Translation a
31 B3 5 Translation c
36 A 40 Translation c
55 B3 2 Translation a
57 B2 50 Translation c
66 B2 1 Translation b
75 A 165 Torsion ba
76 B1 63 Torsion ba
86 B2 79 Torsion a
87 B3 43 Torsion ac
91 B2 1 Torsion ac
95 B1 270 Torsion ba
102 B1 372 Torsion ab
116 B3 4 Torsion ba
117 A 679 Complex torsion abc
119 A 793 Torsion ab
122 B2 113 Complex torsion ba
123 B1 25 Complex torsion ac
124 A 44 Complex torsion ab
126 B1 215 Complex torsion abc
131 B1 116 Complex torsion ab
132 A 217 Complex torsion bc
135 B3 4 Complex torsion ab
142 B2 22 Complex torsion ab
143 A 17 Complex torsion bca
147 B1 62 Complex torsion ab
152 B3 30 Complex torsion ba
153 B2 1 Complex torsion ba
158 B1 39 Complex torsion ca
161 B3 677 Complex torsion ab
163 B2 38 Complex torsion ab
164 B3 448 Complex torsion ab
165 A 53 Complex torsion cb
173 A 156 Complex torsion ab
186 B3 105 Complex torsion ca
189 B1 5 Complex torsion ab
196 B2 1 Complex torsion bc
211 A 19 Complex torsion ba
219 B2 1 Complex torsion bc
225 B3 7 Complex torsion bc
238 B1 < 1 Complex torsion ba
249 B3 1 Complex torsion ba
260 A 53 Complex torsion ab
260 B1 31 Complex torsion ba
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Figure A.14: Scores plot of (a) PC1 versus PC2, (b) PC1 versus PC3,
(c) PC1 versus PC4 and (d) the first four loadings plots from PCA of the
variable temperature low-frequency Raman spectra of L-tyrosine.
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Figure A.15: Mid-frequency Raman spectra of L-tyrosine in a broad tem-
perature range. The visual symbols denote either peak shift or peak broad-
ening.
Figure A.16: (a) Scores plot of PC1 versus PC2 and (b) the first two
loadings plots from PCA of the variable temperature mid-frequency Raman
spectra of L-tyrosine.
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Figure A.17: The modeling of temperature dependence of individual LFR
peaks of L-tyrosine as compared to the experimental results.
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Table A.5: Vibrational mode assignment for the calculated LFR spectrum
of celecoxib (form III).




30 374 Translation b
46 128 Complex torsion cb
51 401 Complex torsion ab
52 226 Complex torsion ac
60 216 Complex torsion ac
66 103 Complex torsion bc
75 282 Complex torsion ba
81 266 Complex torsion bc
86 221 Complex torsion bc
93 183 Complex torsion ac
99 388 Complex torsion ab
114 233 Complex torsion b
126 1000 Complex torsion bc
132 90 Complex torsion b
141 431 Complex torsion bc
160 24 Complex torsion bc
178 74 Complex torsion ab
192 24 Complex torsion ab
201 82 Complex torsion a
219 22 Complex torsion abc
245 30 Complex torsion ab
253 48 Complex torsion b
Figure A.18: (a) Scores plot of PC1 versus PC2 and (b) the first two
loadings plots from PCA of the variable temperature low-frequency Raman
spectra of celecoxib (form III).
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Figure A.19: Mid-frequency Raman spectra of celecoxib (form III) in a
broad temperature range. The visual symbols denote either peak shift or
peak broadening.
Figure A.20: (a) Scores plot of PC1 versus PC2 and (b) the first two
loadings plots from PCA of the variable temperature mid-frequency Raman
spectra of celecoxib (form III).
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Figure A.21: The modeling of temperature dependence of individual LFR
peaks of celecoxib (form III) as compared to the experimental results.
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Table A.6: Vibrational mode assignment for the calculated LFR spectrum
of carvedilol (form II).
Wavenumber, cm-1 Symmetry Intensity Mode type Principal axis
21 Ag 842 Translation b
22 Bg 974 Translation a
28 Bg 21 Translation b
32 Bg 75 Translation a
36 Bg 462 Complex torsion bca
36 Ag 679 Complex torsion bc
43 Ag 1000 Complex torsion bc
44 Ag 408 Complex torsion bc
50 Ag 151 Complex torsion a
52 Bg 232 Complex torsion bc
55 Bg 13 Complex torsion ba
56 Ag 212 Complex torsion bc
57 Bg 41 Complex torsion bc
63 Ag 212 Complex torsion bc
69 Ag 216 Complex torsion bc
71 Bg 200 Complex torsion bc
80 Bg 556 Complex torsion acb
85 Ag 156 Complex torsion acb
87 Ag 135 Complex torsion a
88 Bg 75 Complex torsion b
91 Bg 23 Complex torsion ab
95 Ag 466 Complex torsion ab
97 Bg 284 Carbazole torsion a
111 Bg 83 Complex torsion ba
112 Ag 574 Complex torsion ac
115 Ag 304 Carbazole torsion ac
119 Ag 30 Complex torsion bc
120 Bg 185 Complex torsion bc
124 Bg 115 Complex torsion bc
128 Ag 62 Complex torsion bc
129 Bg 210 Complex torsion abc
143 Bg 51 Carbazole torsion ca
147 Ag 9 Complex torsion bac
150 Bg 93 Complex torsion bac
151 Ag 110 Carbazole torsion ca
154 Bg 73 Carbazole torsion a
161 Ag 64 Complex torsion a
178 Ag 51 Complex torsion ac
179 Bg 1 Complex torsion ba
184 Bg 16 Complex torsion bc
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Wavenumber, cm-1 Symmetry Intensity Mode type Principal axis
179 Bg < 1 Complex torsion ba
184 Bg 16 Complex torsion bc
191 Ag 82 Complex torsion bca
195 Ag 19 Complex torsion bac
198 Bg < 1 Complex torsion ba
209 Ag 24 Complex torsion ba
209 Bg 4 Complex torsion bc
231 Ag 13 Complex torsion bc
233 Bg 14 Complex torsion bac
240 Bg 26 Complex torsion bc
242 Ag 14 Complex torsion ac
250 Bg 10 Complex torsion cba
250 Ag 11 Complex torsion bca
261 Ag 3 Complex torsion bc
262 Bg 1 Complex torsion b
274 Ag 6 Complex torsion ba
275 Bg 17 Complex torsion bc
Figure A.22: (a) Scores plot of PC1 versus PC2 and (b) the first two
loadings plots from PCA of the variable temperature low-frequency Raman
spectra of carvedilol (form II).
APPENDIX A. ADDITIONAL DATA FOR CHAPTER 2 150
Figure A.23: Mid-frequency Raman spectra of carvedilol (form II) in a
broad temperature range. The visual symbols denote either peak shift or
peak broadening.
Figure A.24: (a) Scores plot of PC1 versus PC2 and (b) the first two
loadings plots from PCA of the variable temperature mid-frequency Raman
spectra of carvedilol (form II).
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Figure A.25: The modeling of temperature dependence of individual LFR
peaks of carvedilol (form II) as compared to the experimental results.
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Table B.1: Overview of the design of experiments (DOE) for the samples










2 125 60 2
3 250 30 3
4 500 0* 2




7 125 60 1
8 250 30 3
9 500 0* 1
10 500 60 1
*The dwell time was limited to the minimum.
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Table B.2: Overview of the design of experiments (DOE) for the samples










2 125 0* 2
3 125 60 2
4 250 30 3
5 500 0* 2




8 125 0* 2
9 125 60 2
10 250 30 3
11 500 0* 2
12 500 60 2
*The dwell time was limited to the minimum.
Table B.3: Summary of the independent set of samples, which was analysed















*The dwell time was limited to the minimum.
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Figure B.1: (a) Representative UV/Vis spectra of various celecoxib cali-
bration samples (1-25 µg/mL) and (b) the respective calibration curve at
255 nm (mean ± standard deviation; n = 5; error bars are smaller than
the used symbol size).
Figure B.2: (a) Scores plot of PC1 versus PC2 and (b) the first two load-
ings plots from PCA of the initial spectra of the respective DOE samples
(Table B.1).
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Figure B.3: Example of a Raman spectrum for amorphous celecoxib heated
at 80 °C for approximately one hour; full data and mid-frequency range
(inset). The highlighted peaks denote presence of formed crystalline cele-
coxib (assumed to be form I and/or form II), while rest of the spectral
features correspond to amorphous celecoxib.
Figure B.4: Resolved MCR loadings spectra of (a) component 2 (form III)
and (b) component 1 (amorphous celecoxib); full data and mid-frequency
range (insets). Blue labels denote peaks whose positions have been slightly
affected by the temperature effect. Highlighted area (marked with *) in
the LFR spectral range for the amorphous component is associated with
resolved negligible contributions from the form I and/or form II formed
during the temperature ramp phase (from 20 to 90 °C) for some of the
samples.
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Figure B.5: Combined crystallization profiles of all the fast melt-quenched
amorphous celecoxib samples (n = 3) compressed using 250 MPa pressure
and 30 s dwell time showing spatial crystallization tendencies when stored
at ∼20 °C and (a) <5% or (b) 97% RH (mean ± standard deviation;
naverage = 9, nedges = 6 and ncentral domain = 3).
Figure B.6: Representative crystallization profiles of individual un-
compressed/compressed amorphous celecoxib samples (slow melt-quench)
stored at ∼20 °C and (a) <5% or (b) 97% RH (mean ± standard deviation;
n = 3). The lines are drawn to assist in visualizing the trends.
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Figure B.7: The LFR 30% crystallization response surface plots for amor-
phous celecoxib samples procured via (a) fast or (b) slow melt-quenching
that were compressed using a combination of different compression param-
eters and stored at ∼20 °C and 97% RH.
Figure B.8: Water sorption profiles of in-situ differently melt-quenched
amorphous celecoxib samples kept under 20 °C and 97% RH (mean ±
standard deviation; n = 3). For clarity, only several common time-points
were chosen to draw the plots. The lines are drawn to assist in visualizing
the trends.
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Figure B.9: Representative PXRD patterns of celecoxib form III (from
Cambridge Structural Database) and amorphous celecoxib samples (pro-
cured either with fast or slow melt-quenching) after the water sorption
experiments. Asterisks (*) denote peaks attributed to the sample holder.
Figure B.10: Representative Raman spectrum of a glass cover for the dis-
solution flow-through cell. Asterisks (*) denote rotational sidebands of air
that are detected when analyte exhibits weak LFR signal.
APPENDIX B. ADDITIONAL DATA FOR CHAPTER 3 159
Figure B.11: Dissolution profiles and MCR crystallization curves of com-
ponent 2 (celecoxib form III) for fast melt-quenched (a-c) uncompressed
and (d-f) compressed samples. Arrows denote artifacts due to the occa-
sional air bubbles that were observed visually and distorted the LFR signal
as well as manifested as a baseline in the UV/Vis spectra. Data from these
regions were subtracted (not used) to determine the area under the disso-
lution curve.
APPENDIX B. ADDITIONAL DATA FOR CHAPTER 3 160
Figure B.12: Dissolution profiles and MCR crystallization curves of com-
ponent 2 (celecoxib form III) for slow melt-quenched (a-c) uncompressed
and (d-f) compressed samples. Arrows denote artifacts due to the occa-
sional air bubbles that were observed visually and distorted the LFR signal
as well as manifested as a baseline in the UV/Vis spectra. Data from these
regions were subtracted (not used) to determine the area under the disso-
lution curve.
APPENDIX B. ADDITIONAL DATA FOR CHAPTER 3 161
Figure B.13: Statistical analysis of determined dissolution parameters for
differently prepared and processed amorphous celecoxib samples (mean ±
standard deviation; n = 3). Asterisks (*) denote a significant (p<0.05)
difference between particular values.
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Figure B.14: Digital images of a fast melt-quenched sample compressed at
500 MPa with 60 s dwell time (a) before and (b) after the surface wetting
experiments using an aqueous red dye solution. Highlighted areas denote
the same regions, where fractures of different magnitude can be observed.
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Figure B.15: Digital images of fast melt-quenched samples: (a-c) uncom-
pressed and (d-f) compressed at 500 MPa with 60 s dwell time before and
after the surface wetting experiments using 10 mM trisodium phosphate
solution. Highlighted areas denote the same regions, where interaction
with the aqueous medium and progressive formation of celecoxib form III
needle-shaped crystals can be observed.
Appendix C
Additional data for Chapter 4
Figure C.1: Representative mid-frequency Raman spectra of melt-
quenched amorphous celecoxib as well as celecoxib-HPMC, celecoxib-
PVP/VA and celecoxib-PVP ASDs with 10% w/w polymer loading.
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Figure C.2: Representative Raman spectra of the utilized HPMC,
PVP/VA and PVP. The laserline (Rayleigh scattering) is omitted for clar-
ity.
Figure C.3: Representative DSC curves of HPMC, PVP/VA and PVP.
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Figure C.4: Examples of PCA loadings plots for VTLFR data collected in
the range of -150 °C to 70 °C for (a) amorphous celecoxib and (b) celecoxib-
PVP 10% ASD samples.
Figure C.5: Representative LFR spectrum (room temperature, ∼20 °C) of
celecoxib form IV embedded in an amorphous matrix after partial crystal-
lization from celecoxib-HPMC 5% ASD sample.
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Figure C.6: Comparison of the determined crystallization onset tempera-
tures (where applicable) from DSC and LFR measurements for amorphous
celecoxib and celecoxib ASD samples.
Appendix D
Additional data for Chapter 5
Table D.1: Information on the characteristics of the model pharmaceutical




















N/A 3.00 N/A N/A
α-LM N/A 2.95 N/A N/A
PVP N/A 3.25 N/A N/A
Celecoxib:
α-LM
1:1a 2.85 N/A N/A
1:1b 3.15 1.56±0.04c 1.66±0.04
5:3 3.15 1.71±0.02 1.47±0.03
3:1 3.10 1.99±0.08 1.17±0.06
7:1 3.00 2.55±0.06 ∼0.5d
Celecoxib:
PVP
1:1a 2.95 N/A N/A
1:3b 3.15 1.26±0.02 1.86±0.04
3:5 3.10 1.58±0.03 1.43±0.03
1:1 3.05 2.09±0.02 1.01±0.04
5:3 3.10 2.26±0.04 0.69±0.04
aHomogenous mixture.
bHeterogeneous (bilayer) mixture.
cMean ± standard deviation; n = 5.
dThe brittle nature of the thin upper layer limited the accuracy of the measurements.
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Table D.2: Information on the characteristics of the model pharmaceutical





















1:9 3.35 3110 N/A
1:4 3.25 2740 N/A
3:7 3.25 2508 N/A
2:3 3.20 2175 N/A
1:1 2.95 1785 N/A
3:2 3.05 1597 N/A
7:3 2.90 -a N/A
4:1 2.90 - N/A
9:1 2.85 - N/A
280 5:9 4.20 3301 N/A
260 5:8 4.10 3002 N/A
240 5:7 3.75 2553 N/A
220 5:6 3.45 2283 N/A





1:1:2 3.20 1902 528
2:3:3 3.00 1447 894
1:2:1 2.95 1301 899
3:3:2 2.95 857 947
2:1:1 2.90 941 720
1:6:1b 2.95 N/A N/A
aThe brittle nature of the thin upper layer disallowed (accurate) layer thickness measure-
ments.
bHomogenous mixture.
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Table D.3: Vibrational mode assignment for the calculated LFR spectrum
of α-lactose anhydrous stable form (α-LS).
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Figure D.1: Digital images of the cross-sections of 200 mg bilayer tablets
with varied celecoxib form III and polyvinylpyrrolidone (PVP) content
(w/w) for micro-SOLFRS analysis.
Figure D.2: Digital images of the cross-sections of bilayer tablets with
constant celecoxib form III, but varied polyvinylpyrrolidone (PVP) content
(w/w) for micro-SOLFRS analysis.
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Figure D.3: Digital images of the cross-sections of 200 mg trilayer
tablets with varied celecoxib form III, α-lactose monohydrate (α-LM) and
polyvinylpyrrolidone (PVP) content (w/w/w) for micro-SOLFRS analysis.
Figure D.4: Examples of (a) low and (b) mid-frequency spatially offset
Raman spectra for celecoxib form III and PVP bilayer tablet (1:1 compo-
sition).
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Table D.4: Vibrational mode assignment for the calculated LFR spectrum
of α-lactose monohydrate (α-LM).




35 A 170 cba
38 A 12 a
42 A 33 a
50 B 99 cb
61 B 10 b
67 B 28 ab
81 B 12 cab
88 A 28 cb
93 A 61 bc
94 B 36 bc
103 B 19 cb
103 A 10 cb
109 A 12 abc
110 B 1 bca
115 B 12 bc
116 A 41 bc
120 B 9 cba
128 A 12 bc
140 A 24 bc
144 B 4 bc
155 B 7 bc
159 A 22 a
162 B 19 ab
169 A 13 abc
174 A 53 bc
174 B 20 ac
182 A 26 bc
183 B 14 bc
188 B 6 bc
197 A 11 bc
202 A 73 ba
203 B 29 ba
217 A 15 bac
221 B 10 ba
227 B 6 bc
228 A 10 bc
241 B 7 a
243 A 16 a
261 A 44 ac
262 B 8 ac
278 A 20 a
279 B 5 a
290 A 25 a
295 B 18 a
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Figure D.5: Signal to noise ratio (SNR) analysis of celecoxib form III and α-
lactose monohydrate (α-LM; upper panels) or polyvinylpyrrolidone (PVP;
lower panels) bilayer tablets of different composition (w/w) using (a,c)
LFR or (b,d) MFR data recorded at different relative spatial offsets from
SOLFRS measurements. SNR (where applicable) was calculated using the
first standard deviation (FSD) approach by dividing the intensity difference
between the peak of interest (27 or 1612 cm-1) and selected background
(280 or 1800 cm-1) with the square root of the respective background signal
intensity. The lines are drawn to assist in visualizing the trends.
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Figure D.6: (a) Pre-processed (linear baseline corrected) LFR spectra of
homogenous tablet comprised of celecoxib form III and α-lactose mono-
hydrate (1:1 ratio) recorded at different relative spatial offsets and (b)
intensity ratio comparison of selected anti-Stokes/Stokes LFR bands. The
laser line (Rayleigh scattering) is omitted for clarity.
Figure D.7: Resolved MCR loadings spectra of the two components using
(a) LFR and (b) MFR spatially offset data that were recorded for celecoxib
form III and α-lactose monohydrate bilayer tablets. Dashed line spectra
denote the Raman signature of the corresponding chemical entity to the
MCR component for a visual reference.
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Figure D.8: Resolved MCR loadings spectra of the two components using
(a) LFR and (b) MFR spatially offset data that were recorded for celecoxib
form III and polyvinylpyrrolidone (PVP) bilayer tablets. Dashed line spec-
tra denote the Raman signature of the corresponding chemical entity to
the MCR component for a visual reference.
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Figure D.9: Sample residuals of MCR analysis of celecoxib form III and α-
lactose monohydrate (α-LM; upper panels) or polyvinylpyrrolidone (PVP;
lower panels) bilayer tablets of different composition (w/w) using (a,c)
LFR or (b,d) MFR data recorded at different relative spatial offsets from
SOLFRS measurements. The lines are drawn to assist in visualizing the
trends.
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Figure D.10: Resolved MCR loadings spectra of the two components using
LFR spatially offset data that were recorded for α-lactose monohydrate
tablets dehydrated at 160 °C for different time periods. Dashed line spectra
denote the Raman signature of the corresponding chemical entity to the
MCR component for a visual reference.
Figure D.11: Examples of (a) low and (b) mid-frequency spatially offset
Raman spectra for α-lactose monohydrate (α-LM) tablet dehydrated at
160 °C for 5 minutes.
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Figure D.12: Resolved TrueComponent analysis spectra of the two com-
ponents using Raman microscopy data collected from α-LM tablets (cross-
sections) after the dehydration experiments at 160 °C. Here, only the C-H
stretching spectral region of the data was used for the analysis as it pro-
vided better signal quality when compared to the MFR region while still ex-
hibiting clear differences between the respective solid-state forms. Dashed
line spectra denote the Raman signature of the corresponding chemical
entity to the component for a visual reference.
Figure D.13: Resolved MCR loadings spectra of the two components using
(a) LFR and (b) MFR micro-spatially offset data that were recorded for
celecoxib form III and polyvinylpyrrolidone (PVP) bilayer tablets. Dashed
line spectra denote the Raman signature of the corresponding chemical
entity to the MCR component for a visual reference.
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Figure D.14: Signal to noise ratio (SNR) analysis of celecoxib form III and
PVP bilayer tablets of different composition (w/w) using (a) LFR or (b)
MFR data recorded at different sample displacements from micro-SOLFRS
measurements (n = 5). SNR (where applicable) was calculated using the
first standard deviation (FSD) approach by dividing the intensity difference
between the peak of interest (27 or 1612 cm-1) and selected background
(280 or 1800 cm-1) with the square root of the respective background signal
intensity. The lines are drawn to assist in visualizing the trends.
Figure D.15: A comparison between the PVP layer thickness and layer
weight for different bilayer tablets containing celecoxib form III and PVP.
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Figure D.16: Representative loadings plots of factors 2 and 3 of PLS re-
gression model for PVP layer thickness determination within celecoxib and
PVP 200 mg bilayer tablets using MFR micro-spatially offset spectroscopic
data collected at 4.0 mm defocusing distance.
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Figure D.17: (a,c) Calibration, cross validation and test set data, and (b,d)
loadings plots of respective factors of the selected PLS regression models
using LFR and MFR data (upper and lower panels, respectively) for the
middle (α-LM) layer thickness determination of 200 mg trilayer tablets
containing celecoxib form III, α-LM and PVP.
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Figure D.18: Examples of raw spectra collected at different sample dis-
placements for the same areas of a multi-component homogenous tablet
containing celecoxib, α-LM and PVP dehydrated (α-LM to α-LS) at 140
°C for 20 minutes.
Figure D.19: PC1 loadings plot for PCA of micro-SOLFRS mapping data
collected from multi-component tablet containing celecoxib, α-LM and
PVP dehydrated (α-LM to α-LS) at 140 °C for 20 minutes. The red labels
denote unique peaks attributed to celecoxib form III.
